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Foreword
In response to its mandate to provide a safe and healthful workplace for working women andmen, the National Institute for Occupational Safety and Health (NIOSH) critically evaluates
the scientific data on potentially hazardous occupational exposures or work conditions and recom-
mends measures for minimizing the risk from the hazard. Millions of workers routinely handle
carbonless copy paper (CCP) forms each day. Reports of possible health effects from at least 12
countries have been published in the scientific literature. This document presents a review of the
health effects of CCP. When investigating the relationship between occupational exposures and ad-
verse health effects, NIOSH generally prefers to use the published literature; but some unpublished
sources were used in this review because the published literature was limited. Also considered as
part of this review were more than 14,000 pages of material submitted to NIOSH in response to
Federal Register notices requesting information about CCP. Such a comprehensive review should
help address issues of CCP exposure in the U.S. workforce.
Lawrence J. Fine, M.D., Dr.P.H.
Acting Director, National Institute for
Occupational Safety and Health
Centers for Disease Control and Prevention
iii
Executive Summary
In 1987, the Occupational Safety and HealthAdministration (OSHA) requested that the
National Institute for Occupational Safety and
Health (NIOSH) investigate the validity of re-
ported adverse health effects in workers occu-
pationally exposed to chemicals contained in
or released from carbonless copy paper (CCP).
Because of limited published information,
NIOSH issued a Federal Register notice solic-
iting information about possible adverse health
effects from CCP exposure [52 Fed. Reg.*
22534 (1987)]. On the basis of information
available at that time, no strong conclusion
could be reached concerning a consistent link
between CCP and major health effects. Be-
tween 1987 and 1997, additional reports in-
volving health problems potentially related to
CCP were identified. Therefore, in 1997
NIOSH issued a second Federal Register no-
tice soliciting new information [62 Fed. Reg.
8023 (1997)]. This report contains a review of
the published literature on CCP and the sub-
missions to the NIOSH docket from the two
Federal Register notices.
CCP was introduced in 1954 by the National
Cash Register Company as no-carbon-required
(NCR) paper—an alternative to separate
sheets of carbon paper [Sandberg 1955; Green
1955; Miller and Phillips 1972; Calnan 1979;
Buring and Hennekens 1991]. A given CCP
can vary greatly as to its constituents, weight
and types of paper coatings, paper color, dye
colors and combinations of dyes used on coat-
ings, solvents and solvent mixtures (including
*Federal Register. See Fed. Reg. in references.
variations from different suppliers), physical
form of the paper (rolls versus sheets), and fi-
nal form of the product (i.e., bound with adhe-
sives). Thus the product known as CCP is not a
single product but includes thousands of differ-
ent and often unique products [Mead Corpora-
tion 1997]. This fact needs to be considered
when interpreting the findings from the scien-
tific literature.
About 10 years after the introduction of CCP,
medical complaints began to be reported by
office workers [North Carolina Medical Jour-
nal 1982; Magnusson 1974; Göthe et al. 1981;
Buring and Hennekens 1991]. Since 1965,
various health effects associated with expo-
sure to CCP have been reported in the litera-
ture appearing from Denmark, Finland,
England, Sweden, Germany, the Netherlands,
France, Italy, Belgium, Japan, Norway, and the
United States.
NIOSH has reviewed the published and unpub-
lished literature on CCP. The following para-
graphs summarize the findings from this review
regarding the primary health effects associated
with CCP exposure.
Irritation of the Skin, Eyes, and
Upper Respiratory Tract
The most common findings from the human
studies are symptoms consistent with irrita-
tion of the skin, eyes, and upper respiratory
system following exposure to some types of
CCP. These symptoms have also been de-
scribed in numerous case reports and case se-
ries of persons exposed to CCP, and
associations between these symptoms and
iv
CCP exposure have been observed in several
cross-sectional epidemiologic studies. A posi-
tive exposure-response relationship between
these symptoms and CCP exposure has also
been observed in those studies that examined
this relationship.
The cross-sectional epidemiologic studies
have several major methodologic limitations
that make them difficult to interpret. One ma-
jor potential source of bias in these studies is
overreporting of symptoms by workers who
are already aware of a potential association be-
tween CCP exposure and irritative symptoms.
This form of bias is often referred to as “recall
bias” and is well recognized to be a potentially
important factor in epidemiologic studies in
which symptoms or exposures are identified by
questionnaires administered to the study sub-
jects. Selection bias is also a major con-
cern—particularly in studies with a low
participation rate, where subjects with symp-
toms may have been more likely to return the
questionnaires. These studies may also have
been biased toward observing no effects by
(1) analyzing a mix of workers with high and
low potential for CCP exposures and (2) in-
cluding only active workers and thus excluding
workers who may have left the workforce as a
result of adverse health effects related to CCP
exposure.
The strongest evidence for an association be-
tween symptoms and CCP exposure comes
from the studies of indoor air quality. These
studies report a positive (and in several cases
statistically significant) association between
CCP exposure and symptoms of skin, eye, and
upper respiratory tract irritation. Of the stud-
ies reviewed in this document, the indoor air
quality studies are the least susceptible to re-
call bias because they were not conducted in
workplaces where specific concerns about
CCP or other indoor pollutants were
heightened by previous complaints. None of
these indoor air studies were designed
primarily to address the CCP question, hence
investigator bias is also less likely.
Other information supports the plausibility of
the findings from the experimental studies in
humans. The plausibility of signs and symp-
toms of irritation associated with CCP expo-
sure is supported by the presence of several
known irritants and allergens (e.g., formalde-
hyde, kerosene, phthalates, acrylates,
glutaraldehyde, amines, and isocyanates) in
some types of CCP and by similar effects in
experimental studies of animals. For example,
in seven studies of CCP and formaldehyde,
nearly all exposure measurements exceeded
the NIOSH REL (but not the OSHA PEL) for
formaldehyde [Norbäck 1983b; Gockel et al.
1981; Hazelton Laboratories 1985; Apol and
Thoburn 1986; Chovil et al. 1986; Omland et
al. 1993; Zimmer and Hadwen 1993]. Finally,
laboratory experiments in humans support the
plausibility of the associations between irrita-
tive symptoms and exposure to CCP. Signs con-
sistent with irritation of the skin and/or the
upper respiratory tract have been noted in a
few of the experimental laboratory studies in
humans. However, most of these studies failed
to demonstrate any effects or showed extremely
mild reactions to CCP exposure. Inconsis-
tencies in the findings of these studies might
easily be explained by differences in study de-
sign and particularly by differences in the types
of CCP tested.
Allergic Contact Dermatitis
Several authors have reported cases of allergic
contact dermatitis that appear to have been as-
sociated with CCP or its components [Marks
1981; Kannerva et al. 1990a,b, 1993; Shehade
1987]. Development of sensitization to CCP or
its components was also reported in a few per-
sons in several industry-sponsored repeated in-
sult patch test (RIPT) studies (Report
77–512–70 and Supplemental Report
79–512b–70, Report 77–896–71, and Report
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79–0085–73, all from Hill Top Research, Inc.;
and Project SH–72–4, dated April 18, 1972,
performed by the Shelanski Holding Company,
Conshohocken, Pennsylvania, for Monsanto Co.,
St. Louis, Missouri). In 8 of 217 test materials,
study investigators indicated that skin sensiti-
zation occurred in some human subjects. How-
ever, these studies were mostly judged to be
negative for irritation by the investigators.
Thus in a small proportion of the population,
CCP or its components appear capable of in-
ducing cell-mediated (type IV) immune re-
sponse and allergic contact dermatitis,
particularly under the intensive exposures as-
sociated with RIPT protocols. Cases of allergic
contact dermatitis were reported only in RIPT
studies from the 1970s that were submitted to
the 1987 NIOSH docket; no cases were re-
ported in the studies submitted to the 1997
docket. This fact indicates that the CCP com-
ponent(s) responsible for the allergic contact
dermatitis observed in the early studies may
have been removed from current formulations
of CCP.
Systemic Reactions
Three patients with systemic reactions clini-
cally suggestive of mast cell and/or basophil
degranulation after cutaneous challenge with
CCP or its components have been reported in
two published case reports [Marks et al. 1984;
LaMarte 1988]. These reports suggest that some
CCPs or their components can induce reactions
clinically compatible with those caused by
mast cell and/or basophil mediator release. Im-
munologic sensitization was not adequately
evaluated in these studies, and thus it is unclear
whether an immunologic mechanism underlies
these reactions. However, no additional reports
were located in the peer-reviewed literature
over the last 12 years. Thus, even if the re-
ported reactions were referable to CCP expo-
sure, systemic reactions of this type appear to
be exceedingly rare. Furthermore, the rele-
vance of these reports to current CCP expo-
sures is uncertain.
Conclusions
On the basis of a NIOSH review of the scien-
tific literature and information submitted in re-
sponse to its 1987 and 1997 Federal Register
notices, NIOSH concludes the following:
 The weight of the evidence supports the
conclusion that exposure to certain types
of CCP or its components has, under
some conditions, resulted in symptoms
of irritation of the skin and of the
mucosal membranes of the eyes and up-
per respiratory tract.
This conclusion is based primarily on
interpretation of the evidence from the
epidemiologic studies. Although the mag-
nitude of the effects observed in these
studies was only weak to moderate, these
studies were reasonably consistent in re-
porting an association and evidence of an
exposure-response relationship between
CCP exposure and irritative symptoms
of the eyes, skin, and upper respiratory
tract. The plausibility of the epidem-
iologic evidence is supported by the
presence of known irritants in some
types of CCP, toxicologic studies that
demonstrate mild irritation in laboratory
animals exposed to CCP, and the evi-
dence for respiratory and skin irritation
in some of the experimental laboratory
studies in humans. Some of the epi-
demiologic studies may have been bi-
ased, particularly by overreporting from
study subjects who were already con-
cerned about the potential effects of
CCP exposure (i.e., recall bias). How-
ever, it is unlikely that recall bias could
explain the associations observed be-
tween CCP exposure and irritative symp-
toms of the eyes, skin, and upper
respiratory tract in the indoor air quality
studies, since these studies were not
conducted in an atmosphere of concern
regarding the health effects of CCP.
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 Exposure to CCP or its components may
rarely cause allergic contact dermatitis.
This conclusion is based on published
case reports of allergic contact sensitiza-
tion and results reported in several in-
dustry-sponsored RIPT studies. Cases of
allergic contact dermatitis were reported
only in RIPT studies from the 1970s that
were submitted to the 1987 NIOSH
docket; no cases were reported in the
studies submitted to the 1997 docket.
This fact may indicate that the CCP
component responsible for the allergic
contact dermatitis observed in the early
studies was removed from the more re-
cent formulations of CCP.
 Systemic reactions have occurred in a
few persons exposed to CCP.
This conclusion is based on the finding
that three such cases have been reported
in the peer-reviewed medical literature.
No cases have been reported in the last
7 years, and thus there is no evidence
that current exposures to CCP present a
risk for this health outcome.
 Data are insufficient to evaluate claims
of other adverse health effects (such as
neurologic effects and reports of multi-
ple chemical sensitivity [MCS]) that
have been suggested in some of the
clinical reports submitted to the NIOSH
docket.
In conclusion, although the weight of the evi-
dence indicates that exposure to CCP in the
past has resulted in adverse health effects, it is
uncertain whether current formulations of CCP
represent a significant risk to exposed work-
ers. Only a few cases of systemic reactions and
allergic contact dermatitis have been reported
in the United States or in Europe, which
suggests that the risk of these serious outcomes
is extremely low given the large number of
people who have been exposed to CCP over a
period of many years. Recently conducted ex-
perimental studies in humans (RIPT studies)
suggest that the potential for skin irritation
from exposure to current formulations of CCP
is nonexistent, or at most slight. However, it is
unclear how well these experimental studies
simulate the exposures and potential responses
of CCP users—particularly heavy users. Data
from industry reporting systems suggest no
widespread problem and in fact indicate a de-
crease in health-related complaints in recent
years despite an increase in CCP production.
However, these passive reporting systems are
unlikely to capture all or even most cases of
CCP-related health effects, and changes in
publicity about CCP may have caused fluctua-
tions in the reporting of cases. Since the 1980s,
no epidemiologic studies have been conducted
to determine irritative symptoms among U.S.
workers exposed to CCP [Mendell et al. 1991].
A positive epidemiologic study was conducted
in Finland in 1991 [Jaakkola and Jaakkola
1999]. However, the relevance of these find-
ings for U.S. workers may be limited because
of differences between the CCP products used
in Europe and the United States. Thus informa-
tion is lacking about the prevalence of irrita-
tion of the eyes, skin, and upper respiratory
tract among workers currently handling CCP
in the United States.
Recommendations
NIOSH recognizes that it may occasionally be
necessary to limit CCP exposure in certain
workers through administrative controls (such
as job rotation). But in most cases, implement-
ing normal precautions and recommendations
for maintaining acceptable indoor air quality
should be adequate to reduce or eliminate
symptoms. Good industrial hygiene and work
practices are likely to prevent symptoms from
potent irritants (such as formaldehyde) that
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may be emitted from CCP. These include ade-
quate ventilation, humidity, and temperature
controls; proper housekeeping; minimal
hand-to-mouth and hand-to-eye contact; and peri-
odic cleansing of hands.
In addition, NIOSH recommends the follow-
ing:
 CCP manufacturers and their suppliers
are encouraged to follow best practices,
such as the Product Stewardship Code
of Management Practices [American
Chemistry Council 2000]; they should
also consider enhancing their product
guidance to reflect that published studies
indicate that irritative symptoms appear
to increase with increasing exposure to
CCP.
 CCP manufacturers and their suppliers
should also consider how human test
procedures (e.g., RIPT) can be modified
by the use of standardized protocols
that include proper controls (e.g., bond
paper), tests that mimic high-use
situations, and meaningful criteria for
scoring and interpreting these tests to
assess safety from skin contact (e.g.,
ASTM D 6355–98) [ASTM 1999].
Current best practices in the field of
product testing may not be sensitive
enough to identify mild skin irritants.
 As part of ongoing surveillance, CCP
manufacturers and their suppliers may
want to evaluate the frequency and se-
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In 1987, the Occupational Safety and HealthAdministration (OSHA) requested the Na-
tional Institute for Occupational Safety and
Health (NIOSH) to investigate the validity of
reported adverse health effects in workers oc-
cupationally exposed to chemicals contained
in or released from carbonless copy paper
(CCP). OSHA also requested that NIOSH pub-
lish its findings if health effects were con-
firmed. The OSHA request was based on one
worker’s concern that skin, respiratory prob-
lems, and possible brain damage were due to
consistent exposure to CCP [52 Fed. Reg.*
22534 (1987)]. In addition, 10 to 12 of the ini-
tial complainant’s coworkers who were also
exposed to CCP were reported to have suffered
adverse health effects.
Thus in 1987, NIOSH issued a Federal Regis-
ter notice soliciting information about possible
adverse health effects from CCP exposure [52
Fed. Reg. 22534 (1987)]. On the basis of infor-
mation available at that time, no strong conclu-
sion could be reached concerning a consistent
link between CCP and major health effects.
Between 1987 and 1997, a number of addi-
tional incidents were identified as involving
health problems potentially related to CCP.
Therefore, in 1997 NIOSH issued a second
Federal Register notice soliciting new infor-
mation [62 Fed. Reg. 8023 (1997)].
*Federal Register. See Fed. Reg. in references.
This report contains a review of the published
literature on CCP and the submissions from the
two Federal Register notices. NIOSH prefers
to use the published literature when investigat-
ing the relationship between an occupational
exposure and adverse health effects, but some
unpublished sources were used in this case be-
cause the published literature was limited. The
unpublished information was found to be of
variable quality, validity, and utility.
1.2 Development and
Production of CCP
CCP was introduced in 1954 by the National
Cash Register Company as no-carbon-required
(NCR) paper—an alternative to separate sheets
of carbon paper [Sandberg 1955; Green 1955;
Miller and Phillips 1972; Calnan 1979; Buring
and Hennekens 1991]. NCR was a patented
name, but many of the patents have expired,
and several companies have licenses in other
countries.
The mechanism of CCP involves coating the
under surface of the top sheet of CCP with
an emulsion of a colorless dye in a solvent
(see Chapter 2). The emulsion is held in mi-
croscopic capsules (microcapsules) that are
ruptured by firm pressure from a writing in-
strument. The released dye reacts with a re-
agent on the surface of the paper and changes
the dye to a colored product (generally violet,
blue, or black). CCP may also be referred to as






CCP comprises an extremely complex group-
ing of products. A given CCP can vary greatly
as to its constituents, weight and types of paper
coatings, paper color, dye colors and combina-
tion of dyes used on coatings, solvents and sol-
vent mixtures (including variations from
different suppliers), physical form (rolls versus
sheets), and final form of the product
(i.e, bound with adhesives). To improve qual-
ity and performance, the “recipes” used in the
manufacture of CCP change frequently. No
single product can be identified as a typical
formulation of CCP since each product may
have its own distinct constituents and different
manufacturing processes. Thus the product
known as CCP is not a single product but
includes thousands of different and often
unique products [Mead Corporation 1997 (a
NIOSH docket submission)].
Production of CCP grew on an enormous scale
after its introduction in 1954. By the 1960s,
U.S. sales were about 16,000 tons, and pro-
duction had started in Europe. In 1962, a
Japanese company signed a license agree-
ment with the National Cash Register Com-
pany, and by 1970, worldwide production rose
to 100,000 tons. In 1991, about 1.8 million tons
of CCP (the equivalent of nearly 200 billion
8.5- × 11-in. sheets) [Fetters 1997 (a NIOSH
docket submission)] were produced and used
[Buring and Hennekens 1991; Murray 1991].
Consumption is divided into three principal
regions: North America—800,000 tons, Japan
and the Far East—300,000 tons, and Eu-
rope—600,000 tons [Murray 1991]. The Asso-
ciation of European Manufacturers of
Carbonless Papers [AEMCP 1985] indicated
that in 1985 there were more than 50 manufac-
turers of CCP throughout the world.
By 1979, four companies in Great Britain, four
in Japan, five in other European countries, and
five major companies in the United States were
manufacturing this paper [Calnan 1979]. Cur-
rently, 12 plants (5 manufacturers) in the
United States [Fetters 1997 (a NIOSH docket
submission)] and more than 50 plants around
the world [AEMCP 1985] manufacture CCP.
U.S. production averaged nearly 1 million
tons during the period 1987–1996 [Graves and
Tardiff 1999]. Annual global sales exceed
$5 billion [Finch 1990].
The production industry employs more than
10,000 workers [Fetters 1997 (a NIOSH
docket submission)]. Although the total num-
ber of workers potentially exposed to CCP in
workplaces other than manufacturing (such as
offices, laboratories, other businesses, schools,
banking, etc.) is unknown [Pedersen 1998], it
is likely to be in the millions. Also unknown is
the extent to which the general public is poten-
tially exposed to CCP during business transac-
tions, receipt checking, etc.
1.3 Reported Health Effects
About 10 years after the introduction of CCP,
medical complaints began to be reported by ex-
posed office workers [North Carolina Medical
Journal 1982; Magnusson 1974; Göthe et al.
1981; Buring and Hennekens 1991]. In 1975,
OSHA requested information from physicians
about any unusual frequency of eye, mucous
membrane, or skin irritation associated with
CCP similar to the information being reported
at that time in Sweden [North Carolina Medi-
cal Journal 1982].
Since 1965, various health effects associated
with exposure to CCP have been reported in
the literature appearing from Denmark, Fin-
land, England, Sweden, Germany, the Nether-
lands, France, Italy, Belgium, Japan, Norway,
and the United States. The National Swedish
Board of Occupational Safety and Health
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[1976] gathered information about the compo-
nents of CCP and came to the following con-
clusions:
 None of the substances present in CCP
at that time had known irritant or aller-
genic effects.
 The problems of skin and mucous mem-
brane irritation are most common in the
winter when the humidity is low.
 None of the substances gave rise to large
amounts of dust.
 None of the substances would lead one
to expect vapors to be generated at room
temperatures.
 The odor reported by some may origi-
nate from the solvents in the adhesives
or the inks.
Despite these negative conclusions, the Swed-
ish Board noted that further attention to the
question was warranted, “since problems with
the skin and mucous membranes are still being
reported by persons working with carbonless
paper.” Thus they also issued advice and in-
structions related to the handling of CCP [Na-
tional Swedish Board of Occupational Safety
and Health 1976].
In February 1980, the Swedish Trade Union
called for a ban on CCP [Göthe et al. 1981],
which was claimed to be the cause of numer-
ous conditions including the following [Göthe
et al. 1981; Kanerva et al. 1993]:
Itching Headache
Redness of the skin Joint pain
Breathing difficulty Rapid heart beat
Hoarseness and
airway obstruction
Burning of the nose,










Government and public concerns have waxed
and waned in response to various reports in the
literature as well as anecdotal information. The
Danish, French, Swedish, and German govern-
ments have offered recommendations for re-
ducing exposure to CCP (summarized in
Chapter 6) that rely on simple work practices,
personal hygiene, substitution, administrative
controls, and increased ventilation as preven-
tive measures. The Danish, French, and Ger-
man governments have also recognized
alleged health effects from CCP exposure as
compensable according to the seriousness of
the worker’s reaction [Norbäck et al. 1983b].
At the first symposium on CCP (which was
held in Stockholm and attended by producers,
labor, government, and representatives from
nine nations), Göthe et al. [1981] commented
that strong forces had been mobilized in Swe-
den 2 years before the meeting to ban CCP or
find a substitute for it. They noted that support
for such resolutions has “often been anxious-
ness enhanced by unverified rumors or alarm-
ing mass-media reports about dramatic and
serious diseases caused by work with
carbonless copy papers.” On the basis of their
field investigations, Göthe et al. [1981] indi-
cated that handling large amounts of CCP
might induce dose-related but benign and
nonallergic irritative symptoms, particularly in
the mucous membranes of the nose and mouth.
These authors did not consider these symptoms
to be specific for CCP: they could also be elic-
ited by handling large amounts of ordinary pa-
per. But it appeared that a higher percentage of
CCP workers might develop these symptoms
than workers exposed to ordinary paper. These
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investigators did not consider the phenomenon
to indicate any large health risk, but they noted
that CCP seems to be somewhat more irritating
than ordinary paper in equivalent amounts.
In Canada, Harris [1983] reported that the
symptoms directly associated with use of CCP
(and shown to decrease outside of work or at
other tasks) develop primarily in office work-
ers who use CCP and less in those who make it.
He stated that the symptoms (1) appear to be
quickly reversible when exposure ceases,
(2) are rarely caused by allergic reactions, and
(3) vary greatly from office to office (which
may depend on combinations of factors includ-
ing the brand of CCP, the intensity of use, and
office conditions such as ventilation and hu-
midity). He further stated that no individual
chemicals such as formaldehyde, oils, or paper
dust had been identified as causing the related
symptoms and that measurements in the office
air were generally too low to account for the
symptoms. Harris [1983] concluded that the
reported health problems were due to the mix-
ture of chemicals used in CCP and to mechani-
cal irritation by the clay coatings on the paper.
To provide a comparison with the information
available on CCP, Brissette and Paquette
[1987] summarized the known information
about the prevalence of health problems asso-
ciated with carbon paper in Quebec, Canada.
They reported that 34 of 390 cases of industrial
dermatitis reported in 1929 and 5 of 5,000
cases reported between 1932 and 1936 were re-
lated to carbon paper, but the observations
were not based on patch testing. They further
reported that at the Finsen Institute in Copen-
hagen, cutaneous toxicity to carbon paper was
evaluated in 40,000 people. Only four cases of
allergic contact dermatitis were recorded, and
the agents responsible were triorthocresyl
phosphate, oleic alcohol, nigrosine, and violet
methyl. None of these agents are reported to be
used in CCP.
On February 13, 1986, the National Swedish
Board of Occupational Safety and Health de-
creed that the CCP Announcement No. 1976:2
[National Swedish Board of Occupational
Safety and Health 1976] (which recommended
actions to be taken when CCP-exposed
workers showed symptoms of irritation) was
no longer valid: “The problems which were
previously considered to be caused by carbon-
less paper are now regarded as being of an ex-
tremely complex nature and have been linked
directly to the paper only in a small number of
cases (see Arbete Och Hälsa [Work and
Health] 1983:2, Report on Problems Caused
by Carbonless Paper).
1.4 Information Sources and
Types
This NIOSH report is based on published and
unpublished information. The published infor-
mation includes case studies and case series,
cross-sectional epidemiological studies, patent
literature, and some reports of human and ani-
mal experimental studies. The unpublished
materials were submitted to the NIOSH
Docket in response to the Federal Register no-
tices in 1987 and 1997 [52 Fed. Reg. 22534
(1987) and 62 Fed. Reg. 8023 (1997)]. These
unpublished materials generally include hu-
man repeat insult patch test (RIPT) studies, an-
imal exposure studies, and medical records of
workers who indicated that they had exposure
to CCP.
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2 The Technology of CCP
2.1 How CCP Works
Athree-part business form (Figure 2–1) il-lustrates the concept of how CCP works.
The first sheet in this three-part example is a
coated-back (CB) sheet, the second is a
coated-front and -back (CFB) sheet, and the
third is a coated-front (CF) sheet. The bottom
surfaces of the top and the second sheet are
coated with a layer of microcapsules that have
a diameter of 3 to 6 m. The coating includes
inert spacer particles (“stilts,” such as floc, un-
cooked arrowroot, and/or wheat starch parti-
cles) that are larger than the microcapsules and
are added to protect the microcapsules from
premature rupture. The microcapsules (filled
with a colorless solution of 2% to 6% dye
dissolved in a high-boiling-point-organic sol-
vent) rupture under pressures encountered in
normal handwriting or impact printing. For
example, in a three-part form, the released dye
solution is transferred from the bottom surfaces
of the first and second sheets to the top surfaces
of the second and third sheets, respectively,
where it reacts with the clay or resin coating to
form an image. The capsules and reactive coat-
ing can be coated onto the same paper surface.
In this case, the product is called self-contained
CCP.
2.2 CCP Production
The principles of the CCP production process
are similar throughout the industry, but many
components are variable and complex. During
CCP production, an acid-sensitive dye precur-
sor such as crystal violet lactone (CVL) or
N-benzoylleucomethylene blue (N-BLMB) is
microencapsulated with a high-boiling-point
solvent or oil within a cross-linked gelatin or in
synthetic mononuclear microcapsules, includ-
ing polyamides, polyesters, or polyurethanes.
From the origination of NCR paper until 1970,
the main solvent for the dyes was poly-
chlorinated biphenyls (PCBs [Arochlor]). Ex-
amples of solvents that have replaced PCBs are
hydrogenated terphenyls, diarylethanes, alkyl-
naphthalenes, cyclohexane, and dibutyl-
phthalate (more detailed information about
solvent composition, technical requirements,
and admixtures is given later in this section).
These materials are often diluted with odorless
kerosene [Calnan 1979].
CCP production consumes thousands of tons
of microcapsules annually. During CCP man-
ufacturing, microcapsules are coated onto the
back of the top sheet (referred to as a CB
sheet) at a density of several million per cm2
with a binder or suitable adhesive [Certin
and Zissu 1983]. Since paper is the usual sup-
port, the binders or adhesives are principally
paper-coating agents such as the following






 Starch or starch derivatives (wheat or
corn) or polymer lattices (e.g.,
butadiene/styrene copolymers or acrylic
homopolymers or copolymers)
 Vinyl acetate and water soluble







The paper employed comprises not only nor-
mal paper made from cellulose fibers, but also
paper in which cellulose fibers are replaced
(partially or completely) by synthetic polymers
[Bedekovic and Fletcher 1986]. (Please refer
to Section 2.8 for a listing of brand names and
trademarks of CCP.)
The sheet intended to receive the image, the CF
sheet, is treated on the front with a clay or resin
that is alkaline on the surface but acidic inside,
or with an alternative reactive coating [Calnan
1979]. In Europe, the color developer system is
typically based on clays, whereas phenolic
resins are most commonly used in the United
States and Japan [Murray 1991]. The coating is
spread in a mixture, dried, and adhered with a
styrene-butadiene-latex or one of the binders
listed above. When the top sheet is
mechanically impacted, the dye capsules rup-
ture and the dye solution is transferred to the
receiving sheet, where the acid developer acti-
vates the dye as a result of a change in pH or
oxidation.
2.3 Microcapsule Production
Three processes can be used to micro-
encapsulize the dyes for the size requirements
of CCP: complex coacervation, interfacial
polymerization, or in situ polymerization
[Kroschwitz and Howe-Grant 1979, 1995;
Sliwka 1975]. The complex coacervation pro-
cess produces a shell material of gelatin and
gum arabic (treated with glutaraldehyde); the
chemical class is a protein-polysaccharide
complex. Interfacial polymerization produces
a shell of polyurea or polyamide and is chemi-
cally classed as a cross-linked polymer. The
in situ process results in a shell material of
aminoplasts and is also considered to be in the
cross-linked polymer chemical class. Micro-
capsules have a wide range of geometries and
structures. These range from a continuous core
shell that surrounds the core material to a
multinuclear capsule in which a number of
cells of core material are distributed uni-
formly throughout the matrix of shell material
and a continuous core capsule with two differ-
ent shells. Examples of other synthetic resins
used for the microencapsulation process are
6 Carbonless Copy Paper
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Figure 2–1. Three-part carbonless copy paper system.
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listed above. When the top sh et is m chani
cally impacted, the dye capsule rupture and
the dye solution is transf rred to th receiving
she t, where the acid developer activates the












polyamide, and polyurethane resins [Asano et
al. 1983]. Maggio et al. [1978] stated that
urea-formaldehyde capsules are more resistant
to pressure than those made of gelatin.
2.4 CCP Production Process
Apol and Thoburn [1986] described the pro-
cess of CCP manufacturing. The plant they in-
vestigated made paper from pulp and then
applied the appropriate coatings to the paper
to make CCP. The paper itself is usually pro-
duced in a continuous sheet from a pulp slurry
to form a wet web of paper as it exits on a
screen, such as in a Fourdrinier paper machine.
Apol and Thoburn [1986] describe a process
in which the CF and CB coatings are applied
to the wet web. The CF coating can also be
applied as the paper exits from the paper ma-
chine. As the coating is applied, the paper
passes through a dryer and is wound on a roll.
The CB coating may be applied in a separate
plant area to the paper as it passes through a
series of dryers and is rewound on a roll.
The CF and CB coatings are prepared in the
coater preparation area. The phenolic resins
(1- to 10-m or 1- to 3-m size range is preferred
[Mathiaparanam 1992]) may be prepared
by grinding the resins to specific-size particles,
or they may be purchased already prepared.
The already prepared resin reduces exposure to
phenol among workers who handle the coating
preparation and is the preferred option for to-
day’s technology.
A typical coating composition for the CF
component is shown in Table 2–1. The CF is
dried in a high-velocity air oven at 93 °C
[Kroschwitz and Howe-Grant 1995]. Miller
and Phillips [1972] stated that suitable
amounts of the various materials per unit of pa-
per are as follows: chromogenic dyes, 0.03 to
0.075 lb/ream (one ream is 500 sheets of
25- × 38-in. paper totaling 3,300 ft2), with the
preferred amount being 0.05 lb/ream; solvent,
1 to 3 lb/ream; polymer, 0.5 to 3 lb/ream.
CF, CB, and CFB coated papers are produced
in large rolls weighing up to several tons.
These are subsequently cut down by machines
to a variety of smaller reel and sheet sizes.
This cutting means that the contents of the
microcapsules will be ruptured and released.
Although many of the sheeting, reeling, and
packing operations are automated, some of the
paper still needs to be hand-sorted. The workers
who hand sort these papers are potentially
exposed to the components, particularly the
contents of the ruptured capsules that have
been cut in previous mechanical operations.
Some of these workers sort paper at the rate
of 90 kg/hr (or more than 2 tons/week [600,000
sheets]) [AEMCP 1985].
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CCP is converted into forms for a variety of
applications—for example, business forms,
invoices, computer paper, and Telex rolls. This
process is normally performed by printers with
appropriate forms design using conventional
printing inks as well as specialized desensitiz-
ing inks. The latter are applied to the CF
surface to prevent the color former from de-
veloping into an image on certain areas of the
paper [AEMCP 1985].
CCP may be collated into business form sets
that are glued along one edge. The glues
(called edge-padding, edge-tipping, or
“fanapart” glues) are similar to those used for
ordinary paper writing pads. Manifold forms
using pressure-sensitive CCP are produced us-
ing conventional printing press techniques. For
some applications, the production of the
multipart form by photocopying or laser
printer operations is preferred—especially in
short-run for production, emergencies, and
experimental or individualized forms. The
manifold forms are bound with an adhesive
containing gum resins such as abietic acid.
More recently, Moore Business Forms, Inc.,
was granted a patent [McIntyre and Greig
1989] for the use of a repositionable adhesive
pad on the CF (such as is found on money
wrappers). Bodmer and Peters [1984] and
Bodmer and Miller [1985, 1986] noted that CF
coating components can accumulate on the
heated fuser roll of the copier or the laser
printer, which becomes tacky and can lead to
poor copy quality. A phenolic polymeric film
material, diolefinic alkylated or alkenylated
cyclic hydrocarbons (cyclic terpene deriva-
tives such as limonene), and/or an oil-soluble
metallic salt (primarily zinc) of a phe-
nol-formaldehyde novolak resin can be used to
overcome the fuser roll contamination prob-
lem, which may or may not result in slower
print speeds.
2.6 Other Forms and Variations
of CCP Technology
Forms sometimes combine CCP with carbon
paper to become a “two-write” system [Mead
Corporation 1992]. The Branch Safety Coun-
cil for Offices and Administrations [1988]
also reported on another type of CCP that is
pressure sensitive and is called “mechanical”
paper. The CB sheet is coated with zinc chlo-
ride and covered by a thin layer of wax. Pres-
sure created on the top side of the form causes
the zinc chloride to break through the wax and
adhere to the sheet below that is coated with
an absorbing layer of color generators, polyvi-
nyl acetate, and clay. The Mead Corporation
was granted a patent that incorporated a micro-
encapsulated, photosensitive material that cured
to a stable image when heat-activated in the
presence of a developer such as an organic
peroxide [Sanders 1984]. The Mead Corpor-
ation was also granted a patent on a novel
system that uses a self-contained imaging sheet
to produce images on plain paper using a pho-
tosensitive*, photocurable, image-forming
agent and a developer material on the surface
of the paper support [Feldman et al. 1994].
The NCR Corporation (formerly the National
Cash Register Company) was granted a patent
[Marinelli 1985] for the addition of an aqueous
wax emulsion to the CB coating to act as a bar-
rier between the reactants in the CB coating
and in the CF coating in multiple-copy printing
operations. The technology prevents precolor
formation caused by reactants seeping into the
CF and can withstand on-press CF coating
(presumably with desensitizing inks). Formu-
lations included the use of Jonwax™ 120 (an
emulsion of polyethylene and paraffin wax),
Jonwax 26 (a wax emulsion of polythene wax),
and Jonwax 22 (a water-based wax compound).
*“Actinic radiation,” including the entire electromag-
netic spectrum.
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The wax emulsion also replaces some of the
microcapsules on the substrate. (Jonwax™ is a
registered trademark of S.C. Johnson and Son,
Inc., of Racine, Wisconsin.) According to
Graves and Tardiff [1999], this process was
never commercialized.
2.7 Desensitizing Inks
Frequently, information entered on the top
form must be unreadable on certain sections of
the form or forms beneath. If the areas on the
forms beneath are not needed for other data,
two types of obscuring methods can be used.
The most common is the “masking” blockout,
which entails the printing of a solid block of
blue ink over the appropriate areas. The second
type of blockout method calls for printing a
dense pattern of random lines and blotches
suggestive of Chinese characters (“Chinese
blockout”). Both methods use the same color
ink as the carbonless image color. When the
blocked-out areas must remain clear to allow
data entry on lower plies, the manufacturer
must print a special clear “desensitizing” ink
on that area. This desensitizing ink deactivates
the carbonless imaging system by not allowing
the CF side to react with the color former en-
capsulated on the CB surface [Mead Corpora-
tion 1993]. Desensitizing inks may contain a
variety of solvents such as white spirits, kero-
sene, toluene, alcohols, glycols, ketones, and
plasticizers such as dibutyl phthalate, etc.
[AEMCP 1985]. Desensitizing inks are sold to
industrial printers much like other printing inks
[Graves and Tardiff 1999].
Chang [1978] described a patented method
of desensitizing CCP when the color devel-
oper is a combination of acid clay, phenolic
novolac resin, and metal salt of an organic
carboxylic acid coated with 10 to 35 parts
N-vinylpyrrolidone and about 65 to 90 parts of
a free-radical, co-polymerizable compound of
a photoinitiator having at least one terminal
ethylenic group per molecule. The paper is
then subjected to ultraviolet radiation.
Some CCP originates from printing shops that
may use different manufacturing sources of
CCP in the same manifold. Thus it is extremely
difficult to trace the origin of a particular pa-
per. For example, the CF sheet could come
from one manufacturer and the remainder of
the form from another supplier or manufac-
turer. In addition, the printer can apply the de-
sensitizing inks to the form [Danish Branch
Safety Council for Offices and Administration
1988].
2.8 Summary of Chemical
Components of CCP
This section lists the known components of
CCP classified as to the microcapsule, color
developer, CF coating, etc. The compilation
was taken from the scientific literature, patent
applications, and manufacturers’ submissions.
ADHESIVES FOR BINDING THE






polymer lattices (e.g., butadiene/styrene copolymers or
acrylic homopolymers or copolymers)
starch or starch derivatives (wheat or corn)
styrene-butadiene-latex
vinyl acetate
water-soluble polymers (e.g., carboxymethyl
cellulose, polyvinyl acetate and polyvinyl
alcohol)
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COLOR DEVELOPERS FOR DYE-FORMERS ON






aluminum sulfate and phosphate
attapulgite
bentonite
calcium stearate activated kaolin
halloysite
silica or silica gel
zeolite




bis-Phenol A as an admixture
para-phenylphenol resin
polyphenylphenol as a trace contaminant
para-tertiary phenol resin
Aromatic carboxylic acids (examples)
benzoic acid
diphenic acid and metal salt compounds









Addition product with phenol for color
developers on the CF
olefins (e.g., limonene, alpha-terpinene, divinylbenzene,
various isomers of diisopropenylbenzene, terpenes, and
4-vinyl-1-cyclohexene)
Polyvalent metal salt (magnesium, aluminum,
and zinc) of carboxylated terpenephenol
resin
Inorganic dispersing agents (examples)
organic dispersing agents such as carboxylic
acid types (polyacrylic acid), polymaleic
acid types (styrene-maleic anhydride
copolymer), di-tertiary acetylene glycol,
and sulfonic acid types (naphthalene-
sulphonic acid salts) used in conjunction






2-(2-hydroxyphenyl) benzotriazoles used in
the active clay formulation








Organic pigment on the CF
melamine/formaldehyde condensates
urea/formaldehyde condensates
Defoamer used to augment coating (example)
sulfonated castor oil
AGENTS CONNECTED WITH THE COATINGS ON THE CB
Dyes or color formers (examples)
acyl auramines
acylleucophenothiazines
alpha- and beta-unsaturated aryl ketones
azaphthalides
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para-toluene sulfonate of Michler’s hydrol
triarylmethane
triphenylmethanes (gentian violet and
malachite green)
xanthine structure types
Solvents for solubilizing the color






aromatic ethers (e.g., benzylphenyl ether)
benzyl butyl phthlate
benzylated ethylbenzene
benzylated xylene and other chlorinated or
hydrogenated condensed aromatic
hydrocarbons, paraffin oils or kerosene
and diisopropylnaphthalene
benzyl benzoate
butyl diphenyl (butyl biphenyl)









diethylated, di-propylated, or di-butylated













linear alkyl benzenes (C10 to C13-LABs)
Magnaflux oil
mixtures of solvents (e.g., MIPB and
hydrogenated terphenyl)
monochlorobenzene
mono-ethylated, mono-propylated or mono-
butylated biphenyl, biphenyl oxide, or
biphenyl methane
naphthalene or terphenyl (e.g., isopropyl,








(e.g., monochlorodiphenyl or trichloro-
diphenyl)
Santosol 100 (consists of ethyl-DPMs, benzyl-
ethyl-DPMs, and dibenzyl-ethyl-DPMs)














alcohols (e.g., partially hydrolyzed polyvinyl
alcohol or lignosulfonate)
aliphatic diisocyanates dissolved in diiso-
propylnaphthalene, hydrogenated terphenyl,
alkylated biphenyl, or diphenyl-alkanes
(such as chloroparaffin) or a mixture of these solvents
and diamines
amines (e.g., ethylenediamine, hexamethyl-
enediamine, or triethylenetetramine) and
alcohols (e.g., partially hydrolyzed




Japan wax, beeswax, paraffin wax,
candelilla wax, rice wax, carnauba wax or





polyamide and polyurethane resins
polyisocyanates and cross-linking agents
(amines)
solvent such as n-tridecane
urea-formaldehyde







aid on CB in reducing premature microcapsule breakage (e.g.,
floc, uncooked arrowroot, wheat starch particles, starch, talc)
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2.9 Brand Names or
Trademarks for CCP
Brand names or trademarks for CCP were ob-
tained from the following sources: Calnan
[1979], CHIP [1988], Levy and Hanoa [1982],
Olsen and Mørck [1985], Paper Europe [1993],
and Dady [1998]. The brand names or trade-
marks are listed as follows:
A-copy Korofax
Action Lijnco
Baron Self Copy Mitsubishi
Biplura Moore Clean Print (MCP)
Carbonless Copy Paper Nashua
Carr’s Treform Nashua Carbonless Paper
CCP NCR Paper
CCP Carbonless NCR Xero/form
Copymate Novo-script Paper
Crosley Transcript Presstype







Idem Recycled Sheets Signal
Idem Superior CB60 NTC SM 70
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3 Exposure
3.1 Introduction
Workers may be exposed to CCP or itscomponents during handling or manu-
facturing. This chapter summarizes exposures
from CCP handling reported in the literature
(Table 3–1). Little consistency exists among
these reports: they vary depending on the
chemical composition of the CCP, the method
of manufacturing during the study period, and
the number of forms handled during the
industrial hygiene survey. For workers who
handle CCP, the most common exposures
are to formaldehyde and kerosene or its com-
ponents. Formaldehyde is used in some micro-
capsule manufacturing processes as part of the
mixture that forms the shell for the micro-
capsules; it is also used in the manufacture of
other paper products such as plain bond paper.
Kerosene is one of the principal solvents used




Some studies listed in this section are de-
scribed in another section of this review.
Jujo Paper Company, Ltd. 1979. One of the
earliest reports with CCP exposure data came
from the Jujo Paper Company, Ltd. [1979].
They reported that the maximum concentration
of CCP solvent (unspecified) in a finishing
room where 100 tons of CCP were handled
each day was 0.3 mg/m3. The company also
reported an average CCP solvent retention of
180 g on the fingers of women who handle,
sort, and count 50,000 to 70,000 sheets each
day. Blood samples obtained 15 to 16 hr after
work revealed no detectable concentrations of
the solvent. Further biochemical tests of the
blood and urine, skin tests (types unspeci-
fied), examinations, and interviews of 135
exposed workers and 84 comparison workers
revealed no differences between the two
groups. The company indicated that no skin
disorders had been reported by any worker
since the CCP mill came into operation. No in-
dependent survey of worker complaints was
performed.
Mølhave and Grunnet 1981. In an addendum
to the telephone company report by Menné
et al. [1981], Mølhave and Grunnet [1981]
reported on a headspace analysis (sampling
of the gaseous phase of a sample heated to
50 NC) of the CCP in use at the time of the
study. They used one paper sample received
from the factory where the problem was inves-
tigated and one sample from the manufacturer
of the paper. The authors reported that more
than 42 chemicals degassed from the paper
samples, and concentrations were seven times
greater in the paper from the facility than in
those of the manufacturer’s sample. About 90%
of the emission was alkanes or alkenes
(C5–C14). Another analysis was performed on
the Santosol oil content of both CCP samples.
The CCP that (according to the authors) caused
the original skin problems contained up to 150
times the amount of Santosol oil contained by
the manufacturer’s sample of CCP. According
to the authors, the Santosol oil consists
Carbonless Copy Paper 13
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Table 3–1. Exposures from CCP handling
Reference and country
Occupation or
exposure scenario Sample type
Airborne
concentration
Jujo Paper Company, Ltd.
   [1979], Japan
Paper finishing CCP solvent (unspecified) 0.3 mg/m3
Mølhave and Grunnet
   [1981], Denmark
Experimental
   laboratory conditions
Alkanes or alkenes (C5–C14)
Santosol Levels not reported
Göthe et al. [1981] and
   Norbäck et al. [1983b],



















Gockel et al. [1981],
   United States
Office workers Formaldehyde <0.51 ppm
Chrostek and Moshell
   [1982], United States
Telephone workers Total dust
Formaldehyde
Glove analyses:
   Dibutyl phthalate
   Diethyl phthalate







   Sweden
Experimental





   per hr
0.33–0.54 mg/m2
   per hr
0.1–0.3 mg/m3
Norbäck and Göthe
   [1983], Sweden











   United States
Purchasing office Formaldehyde ND—0.04 ppm
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 tnotes at end  of table. (Conti
Table 3–1 (Continued). Exposures from CCP handling
Reference and country
Occupation or




   [1985], United States
Experimental
   laboratory conditions
Formaldehyde 0.033 ppm for
   marking and   
separating 30
   4-ply forms/hr
   for 8 hr
Olsen and Mørck [1985],
   Denmark
























Chovil et al. [1986],
   United States
University office Formaldehyde 0.015–0.022 ppm
Burton and Malkin












Omland et al. [1993],














   (REL)
0.023–0.034 mg/m3
Thompson [1996],















*Abbreviations: DETA=diethylene diamine tetraacetic acid; HMDI=hexamethylene diisocyanate; MIPB=monoisopropyl biphenyl;
ND=none detected; REL=NIOSH recommended exposure limit.
     
†Attributed to cigarette smoking.
‡Limits of detection varied from 0.04 to 0.08 ppm.
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mainly of hydrogenated terphenyl,* which
is known to produce eye, skin, and respiratory
irritation and possibly sensitization in experi-
mental animals [Haley et al. 1959]. At the
telephone company that reported the problem,
workers exposed to CCP dust and vapors emit-
ted from the paper experienced marked irrita-
tion at air concentrations exceeding 10 mg/m3
(data not given). Mølhave and Grunnet [1981]
believe that the terphenyls act as primary irri-
tants, particularly when workers are wearing
protective gloves that trap moisture and expo-
sures next to the skin.
Göthe et al. 1981 and Norbäck et al. 1983b.
Göthe et al. [1981] and Norbäck et al. [1983b]
reported on an investigation of climatic and
airborne concentrations of microcapsule sol-
vents found in printing offices and ordinary of-
fices that used the same type of CCP. The
authors noted that very few complaints were
related to CCP in the printing offices compared
with ordinary offices. Temperature and rela-
tive humidity were, on the average, about the
same in the two environments. The highest
concentrations of microcapsule solvents were
observed in the printing offices (Table 3–1).
This finding suggests that no simple correla-
tion exists between solvent vapor concentra-
tions and the occurrence of complaints; or it
may indicate that skin contact is the important
factor.
Gockel et al. 1981. Gockel et al. [1981] re-
ported on formaldehyde released to the air
from CCP forms that were suspected of caus-
ing eye, skin, and respiratory irritation among
office workers. Water extraction of CB white
sheets of CCP yielded 0.18 to 1.89 mg formal-
dehyde per 8.5-×11-in. top sheet of CCP. The
authors felt that water extraction might have
enhanced the formaldehyde concentrations, so
*This description differs from other descriptions of
Santosol components, which do not refer to terphenyls
but to diphenylmethanes.
they adopted a sampling procedure that col-
lected the formaldehyde released into 15 L of
air (1 L/min for 15 min). Formaldehyde con-
centrations ranged from 33.6 to 858 g/kg of
forms sampled and from 0.02 to 0.96 ppm
in the 15-L air samples using 8 different CCP
forms. A modification of the procedure en-
sured adequate air flow past all parts of each
form in the sampling apparatus. Standardized
testing of four sheets of equivalent area for
each type of five different forms resulted in
formaldehyde concentrations ranging from 0.45
to 16.8 µg/kg, demonstrating a 37-fold differ-
ence in formaldehyde emissions. The authors
demonstrated that these air sample analyses
using a standardized testing area produced re-
sults that varied by a factor of 0.83 to 1.42
compared with sampling of a full form. The
authors also provided evidence that the resid-
ual formaldehyde is dissipated into the air as a
result of handling and storage. Air concentra-
tions of formaldehyde were as high as
0.51 ppm in filing cabinet drawers where the
forms had been separated and stored for more
than 6 months.
Chrostek and Moshell 1982. See Section 4.2.1
for a description of this study.
Norbäck 1983b. Norbäck [1983b] studied the
chemical emissions from entirely unused pa-
per and from paper in which approximately 1%
of the microcapsules had been crushed by stan-
dard writing. Most of the CCPs studied were
handled by workers who had experienced
work-related respiratory irritation symptoms
when handling CCP. In light of the observed
emissions of formaldehyde from CCP over
time [Gockel et al. 1981], the 1- to 2-year-old
paper was replaced with fresh CCPs of vari-
ous types collected from three different print-
ing shops. Most measurements were
performed at an ambient temperature of
22 NC and 20% to 30% relative humidity. Sev-
eral tests were also performed at 27 NC. CCP
was cut, weighed, and measured for surface
16 Carbonless Copy Paper
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area. It was then placed into wash bottles
(0.25-L), and air was passed through them at
the rate of 0.1 L/min. Charcoal (for solvent
analysis) or Amberlite XAD (coated with
2,4-dinitrophenyl hydrazine for aldehyde
analyses) was used to collect the emissions for
30 to 60 min. Solvent concentrations were
measured using gas chromatography (GC),
and aldehyde analyses were performed with
liquid chromatography. The relative solvent
emissions calculated were based on mea-
surement times, surface area, and amounts of
solvent/aldehyde released. Mann-Whitney’s
rank sum test was used for testing the statisti-
cal significance of paired t-values. Norbäck
[1983b] found small but measurable amounts
of formaldehyde (0.1 to 0.3 mg/m3; detection
level=0.3 mg/kg per hr) in 3 of 4 fresh CCP
samples. No glutaraldehyde was detected
(detection level=0.1 mg/kg per hr). No alde-
hyde emissions were detected from any of the
papers that were 1 to 2 years old. One week
after the microcapsules had been crushed, four
of the five solvents studied were still being
released in measurable quantities, including
monoisopropyl biphenyl (MIPB), kerosene,
phenylxylylethane, and diisopropylbiphenyl—
but not hydrogenated terphenyl. The kerosene
emissions ranged from 5 to 60 mg/m3, with the
two CCP samples not linked to work-related
respiratory tract symptoms yielding the lowest
kerosene emissions. On the basis of this obser-
vation, the author tested three different groups
of kerosene-containing CCP, some of which
had observed links with work-related respira-
tory tract symptoms. He demonstrated in this
study that no links existed between mucous
membrane symptoms and kerosene emissions.
He also showed that there were no statistically
demonstrable trends toward a link between
work-related respiratory tract symptoms and
high kerosene emissions—even where all CCPs
associated with respiratory symptoms were
combined, and regardless of the solvent content.
This difference was attributed to the difference
in encapsulation processes (MIPB used “poly-
mer,” and hydrogenated terphenyl used gela-
tin). The author noted that the kerosene
concentrations in the wash bottles were 10 to
100 times higher than those measured in the
breathing zones of workers involved in inten-
sive manual handling of CCP. The author also
concluded that aldehyde emissions from CCP
were not likely to explain the irritative mucous
membrane symptoms among workers who han-
dle such paper. Table 3–2 demonstrates how
writing on CCP (and thereby crushing the
microcapsules) affects the solvent emissions
from the paper.
Norbäck and Göthe 1983. In a Swedish study,
Norbäck and Göthe [1983] collected personal
and area samples in Stockholm at 11 offices
where large quantities of CCP were handled
and at five printing shops where form (mani-
fold) sets of CCP were produced. The mea-
surements were made from January 1980 to
November 1981, mainly during the winter half
of the year (the period in which problems
Table 3–2. Solvent emissions from CCP with intact microcapules
and 1% crushed microcapsules (mg/m
2
per hour)
CCP form treatment Kerosene emissions MIPB emissions
Unused 0.35 0.33
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were reported). Workers from 10 of the offices
studied had been referred to the clinic of Occu-
pational Medicine at Southern Hospital be-
cause of health problems associated with
handling CCP. The authors measured ambient
temperatures, relative humidities, and ventila-
tion efficiencies. As a measure of the chemical
emissions from CCP, airborne concentrations
of the solvents from microcapsules were
analyzed using activated charcoal tubes. The
carbon-disulfide-desorbed solvents were ana-
lyzed by GC, and detection limits varied be-
tween 0.001 and 0.02 mg/m3.
Airborne concentrations of total dust,
dust-bound solvent, solvent in the vapor phase,
and formaldehyde were also determined in a
laboratory situation using a 34-m3 room with
an air-exchange rate of 0.8 times/hr. Thirty
sheets of each type of paper were handled in
a standardized procedure for 60 min. Table 3–3
shows that airborne solvent concentrations
are generally low, and they are considerably
lower in the office environment than in
the printing shop. Area samples were also
consistently lower than personal samples,
suggesting that manual handling generates
airborne solvent. For example, kerosene (which
is relatively volatile) had the highest airborne
concentrations, whereas the hydrogenated
terphenyls (whose volatility is low) produced
unmeasurable concentrations. The data
indicate that various paper types generated
similar concentrations of dust during stan-
dardized paper handling in the laboratory.
The airborne formaldehyde concentrations were
below the limit of detection (<0.05 mg/m3). This
finding does not support formaldehyde as the
cause of the health effects. The particle-bound
solvents were also consistently below the
detection limit (<0.0002 mg/m3), which corre-
sponds to a dust solvent content of less than
1% by weight. Norbäck and Göthe [1983] con-
cluded that no obvious climatic differences
were evident between the two environments,
even though health problems occurred in the
offices and not in the printing shops. The au-
thor observed that these health problems occur
in offices with both high and low levels of
Table 3–3. Airborne concentrations of total dust and solvents









0.05 0.81 0.06 —* —
Paper containing
diarylethane




0.05 0.70 — — <0.01
Ordinary paper 0.05 — — — —
Control—without paper 0.02 — — — —
Source: Norbck and Gthe [1983].
*Dash indicates that no measurement was performed.
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ventilation. The solvent concentrations were
relatively higher in printing shops than in
offices, but the number of health problems
in the printing shops was low. The authors
cited a study by Hasegawa et al. [1973] that
found a diisopropylnaphthalene concentration
of 0.3 mg/m3 in the air at a sorting department
in which each worker daily handled 50,000 to
70,000 CCP sheets containing the solvent.
They also cited an unpublished report by
Dodds [1980] who found hydrated terphenyl
concentrations in the ppb range during the pro-
duction of microcapsules containing color for-
mer dissolved in hydrogenated terphenyls.
Norbäck and Göthe [1983] conclude that the
measured dust concentrations did not contain
solvents in sufficient quantity to be associated
with primary irritation. This study is unclear as
to whether encapsulated CCP solvent attached
to airborne fibers is extractable by carbon
disulfide and is thus included in measurements
of dust-bound solvent. This study did not con-
sider the effect of high local concentrations of
solvent on the epidermis when a microcapsule
fractures. Also unresolved are the relative skin
exposures for workers in offices and printing
plants. Although printing plant workers pro-
cess a far greater tonnage of paper than office
workers, its not clear whether printing plant
workers have more or even as much skin con-
tact as CCP users in offices.
Olsen and Mørck 1985. Olsen and Mørck
[1985] extensively studied a brand of CCP that
was dominant in the Scandinavian countries at
that time. They performed gas chromatogra-
phy/mass spectrometry (GC/MS) analysis,
finger analysis of the residual CCP components
on the skin, analysis of keyboard surfaces of
computers and typewriters, microbiological
analysis of the microcapsules, analysis of the
mucous membranes of the nose, electron mi-
croscope studies of the skin using tape before
and after handling CCP, dust measurements,
and headspace analysis of CCP emissions. The
authors found that hydrogenated terphenyls are
transferred to the skin (120 g per sorting
finger) along with their impurities of bi-,
tetra-, and pentaphenyls, but they did not find
kerosene in detectable amounts owing to its
volatile nature. The ratio of hydrogenated ter-
phenyls to kerosene in the microcapsules was
1:3; but after rupture, analysis of the CF
layer revealed that more than half of the ker-
osene had evaporated. Analysis of exposed
workers’ mucous membrane secretions
failed to reveal any CCP components. Head-
space analysis demonstrated that kerosene
evaporated from the CCP without mechani-
cal rupture of the microcapsules (value not
given). The amount evaporating increased
after rupture (the highest concentration found
in room air was 1.9 mg/m3 [0.3 ppm]), but hy-
drogenated terphenyls were not released into
the air as vapor. Analysis of keyboards re-
vealed concentrations of hydrogenated ter-
phenyls and transfer of this compound to
telephones, table tops, etc. in the office. Mea-
surements of total dust ranged from 0.11 to
0.21 mg/m3, and no chemical components of
the CCP were associated with it. No growth of
fungi or bacteria resulted from the incubation
of microcapsules, but one base paper sample
(not CCP) supported the growth of actino-
mycetes at 50 NC. Electron microscopy did not
show transfer of the clay/kaolin components to
the hands after 3 hr of handling CCP.
Apol and Thoburn 1986, Chovil et al. 1986,
and Burton and Malkin 1993. See Section
4.2.1 for a discussion of these studies.
Omland et al. 1993. See Section 4.2.3.2 for a
discussion of this study.
Zimmer and Hadwen 1993. In response to a
request from the management of the Federal
Records Center in Dayton, Ohio, Zimmer and
Hadwen [1993] investigated six worker com-
plaints of an overpowering, irritating odor in
the archives area where Federal tax records and
X-ray films were stored. Acetic acid was the
apparent source. Concentrations of acetic acid
and cyclohexane were below the NIOSH RELs
of 25 and 1,050 mg/m3, respectively. Formal-
dehyde concentrations were 0.023, 0.024, and
exceeding the NIOSH REL of 0.02 mg/m3. The
most likely source of the formaldehyde was the
CCP records located throughout the center.
Thompson 1996. Thompson [1996] reported
measurements of indoor air quality in an un-
published U.S. study of 75 workers who con-
tinuously handled CCP in the finance and
accounting building of a university. This build-
ing had a history of indoor air quality problems
and medical complaints from workers dating
from 1992. The relative humidity, temperature,
and mold and fungus counts were within the
American Society of Heating, Refrigerating,
and Air-Conditioning (ASHRAE) limits of
40% to 60% relative humidity, 74 to 78 F
temperature, and low indoor spore counts (rel-
ative to outside counts for mold and fungus)
[ASHRAE 1981]. The carbon dioxide concen-
tration was 1,000 ppm, which exceeded the
ASHRAE standard [ASHRAE 1989]. Correc-
tive actions to the ventilation system included
repair of the heating, ventilating, and
air-conditioning system, increased outside
fresh air supply, earlier air-handling startup
times, and increased air circulation (which de-
creased carbon dioxide concentrations to 400
to 700 ppm).
Area air samples were collected in two loca-
tions of the CCP building and compared with
an air sample from another building that had
60 occupants, no history of medical com-
plaints, and minimal use of CCP. GC/MS
standards were prepared from the CCP forms
(all three sheets, top sheets alone, and bottom
sheets alone) and a sample of SurSol 290 (a
solvent carrier for dyes used in the production
of the microcapsules). Table 3–4 lists the con-
centrations of chemicals found in these sam-
ples. The sample from the comparison building
showed concentrations that were about three
orders of magnitude less than those found in
the CCP building. Of the chemicals for which
3 EXPOSURE
20 Carbonless Copy Paper
Table 3–4. GC/MS analysis of CCP samples, SurSol 290 solvent,
and area air samples (ppb)
Area air samples










solvent Sample 1 Sample 2
Comparison
building
Decane 13.2 0.001 7.9 — 1.0 1.1 0
Undecane 0.02 <0.001 12.7 — 0.3 0.3 0.004
Dodecane 2.6 <0.001 4.8 0.027 0.6 0.6 0.006
meta-, para-
Xylene
0.1 0 0 6.2 1.2 0.6 0
ortho-Xylene 0.0 0 0 — 0.4 0.2 0
Toluene 2.9 0.3 0.1 — 1.3 0.5 <0.001
Ethyl benzene 0.4 0 0 8.9 0.5 0.3 0
Adapted from Thompson [1996].
occupational safety and health standards exist,
the concentrations were four to six orders of
magnitude lower than the standards.
3.2.2 NIOSH Docket Submissions
3.2.2.1 Winfield 1983
Winfield [1983] performed an industrial hy-
giene survey in a purchasing office at the Uni-
versity of Texas in response to worker
complaints of headaches, skin eruptions, upper
airways irritation, and other symptoms. The
number of workers who reported symptoms was
not given, but the report stated that the incidence
of symptoms was higher among the 22 em-
ployed in the purchasing section than in the 16
employed in the vouchers section. Several for-
mer employees reported that their symptoms
ceased when they terminated employment.
Formaldehyde was measured inside a closed
cabinet containing CCP forms, and the level
was found to be just above the limit of detec-
tion. Other measurements were obtained for
hydrocarbons linked to toner solvent from a
copy machine and for chlorinated solvents
linked with correction fluid, waxes, glues, etc.
Interviews were conducted at four other offices
where workers handled CCP forms. Workers
reported no symptoms in the press office, where
forms were handled for printing and gluing.
In the personnel office, where forms were
handled but not typed on, one worker reported
transient skin irritation. Two of four workers
in the mail and supply office reported skin ir-
ritation. In the central receiving office, two
workers complained of odor and headaches
when using continuous-roll copy paper; how-
ever, the report did not note whether this paper
was CCP. Alterations in the air-handling
system (which were engineered to exceed the
minimum rate for office spaces) did not reduce
the reported symptoms. The author stated that
the reported symptoms were probably caused
by CCP based on the available scientific
literature, but she offered no definitive scien-
tific evidence in support of this conclusion.
Recommendations from the available litera-
ture were suggested to improve the comfort
and health of the workers, but no followup
survey was reported.
3.2.2.2 Hazelton Laboratories 1985
A NIOSH docket submission by Hazelton
Laboratories [1985] (Final Report, March 11,
1985: A Study to Determine the Potential Ema-
nation of Formaldehyde Vapor from Carbon-
less Copy Paper) describes an investigation
performed for a member of the U.S. CCP in-
dustry to determine the potential emanation of
formaldehyde vapor from CCP.
The experiments were performed in a glove
box to measure the following: (1) the maximum
formaldehyde air concentration (collected with
impinger and measured using NIOSH Method
125 [NIOSH 1994]) produced by a set number
of sheets of CCP and (2) the effects of mark-
ing and separating four-ply CCP forms on the
emission of formaldehyde. The experiments
also evaluated the effects of ventilation on the
formaldehyde concentrations from various types
of CCP. The formaldehyde concentration in
the glove box ranged from 0 to 0.7 ppm for the
CF and the “self-contained black” paper, re-
spectively. Those products containing black
ink produced substantially higher formalde-
hyde concentrations than those containing blue
ink. A model was developed from the kinetic
experiments to predict air concentrations of
formaldehyde attributable to handling CCP in
the office environment.
Product test methods. An aluminum pouch
containing the papers was placed in the 285-L
chamber for testing. Table 3–5 presents the
data for turning 2 or 6 sheets/min using a vary-
ing number of total sheets turned. Chamber
concentration of formaldehyde increased as
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the number of exposed sheets increased. An-
other test (Table 3–6) was performed to deter-
mine whether the rate of turning would affect
the final concentration of formaldehyde in
the test chamber immediately after turning
and 60 and 90 min after turning. When mea-
sured immediately after turning, concentra-
tions decreased as the turning rate increased.
But concentrations varied little when measured
60 and 90 min after the tests. This result indi-
cates that the rate-limiting factor for total form-
aldehyde released from CCP is the amount of
time spent equilibrating with the environment.
The final test method evaluated was an emission
rate study. In this study, 120 sheets of paper
were placed in the chamber and turned at a rate
of 4 sheets/min. Short-interval sampling began
with the initiation of the page turning and con-
tinued for 90 min (Table 3–7). The chamber air
achieved a constant formaldehyde concentra-
tion in less than 30 min. The initial rate of
formaldehyde release was 0.098 g/sheet per
min. This rate was calculated from the first
sample by considering the 0.310-g/L concen-
tration as the midpoint concentration between
0 g/L and equilibrium, and by assuming an
approximately linear increase in the airborne
concentration of formaldehyde over the
15-min sampling period.
Product testing. Three replicate sets of eight
types of CCP were tested by placing 60 sheets
of CCP in the chamber and turning them at
a rate of 4 sheets/min. They remained stacked
in the chamber for 15 min and were then re-
turned to the foil packages for the duration of
the air sampling, which was conducted for
20 min at a rate of approximately 0.5 L/min.
The airborne concentrations of formaldehyde
in the test chamber averaged from 0.009 to
0.693 ppm (Table 3–8). Little formaldehyde
would be expected from the CF since it
contains no microcapsules. All types of the
CB and CFB with black ink produced higher
average formaldehyde concentrations than did
the blue ink counterpart. The self-contained
samples yielded the highest formaldehyde
22 Carbonless Copy Paper
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Table 3–5. Formaldehyde concentration after repeated
turning of CCP sheets in a test chamber
*
Rate of turning and total number



















Adapted from Hazelton Laboratories [1985].
*The indicated number of sheets placed in the chamber, turned at the stated rate, and repackaged. Air samples were then collected from the
chamber.
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Table 3–6. Formaldehyde concentrations in the test chamber at
various points after turning (total of 60 sheets for each condition)













6 0.150 0.307 0.456
5 0.184 0.318 —
4 0.210 0.308 0.387
3 0.316 0.318 0.386
2 0.334 0.367 0.429
0 — 0.260 0.427
Adapted from Hazelton Laboratories [1985].
*Sixty sheets were placed in the chamber and turned at the indicated rate.
†After turning was completed, the sheets were repackaged in the foil pouch and an air sample was collected.
‡Sixty minutes from the start of the turning, the sheets were repackaged in the foil pouch and an air sample was collected.
§Ninety minutes from the start of the turning, the sheets were repackaged in the foil pouch and an air sample was collected.
Table 3–7. Formaldehyde concentrations in
















Adapted from Hazelton Laboratories [1985].
*One hundred twenty sheets were placed in the chamber and turned at 4 sheets/min. Air sampling began when turning began and continued for
60 min after turning was completed.
concentrations. The study director stated that
the total formaldehyde release for the four-part
form could be predicted from the sum of its
parts.
Office activities. Experiments were performed
to examine the effects of office activities on
formaldehyde emissions from CCP. Four-ply
CCP forms were manipulated by marking, sep-
arating marked forms, and separating un-
marked forms.
 Marking forms: Four-ply forms were
used to examine the effects of marking
on the emission of formaldehyde vapor.
Thirty forms (120 sheets) were placed
inside the chamber for each test. A tem-
plate was used to achieve consistent pen-
cil lines. The desired rate of marking
was 40 lines/minute, 20 lines/form,
repeated four times throughout the 1-hr
sampling period. This rate was
achieved on the second test; the first
test averaged a rate of approximately
28.7 lines/min. The sampling flow rate
was approximately 0.5 L/min. The
maximum average formaldehyde con-
centration for two replicates was
0.402 ppm after 1 hr.
 Marking and separating forms: Four-ply
forms were used to examine the effects
of marking and separating pages on the
emission of formaldehyde vapor. Thirty
forms (120 sheets) were placed inside
the chamber for each test and a template
was used to achieve consistent pencil
lines. Each form was marked with 20
lines and separated in 1 min. After the
30-min marking and separating period,
the forms were left exposed in the cham-
ber the rest of the 1-hr sampling process.
The sampling rate was approximately
0.5 L/min. The maximum average formalde-
hyde concentration for 2 replicates was
0.402 ppm after 1 hr.
 Separating unmarked forms: Four-ply
forms were used to examine the effects
of separating unmarked forms on the
emission of formaldehyde vapor. Thirty
24 Carbonless Copy Paper
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Table 3–8. Formaldehyde concentrations in a test













Adapted from Hazelton Laboratories [1985].
*Sixty sheets were placed in the chamber, turned at the rate of 4 sheets/min, and left stacked for 15 min before they were repackaged in
aluminum foil pouches. Air samples were then collected.
†SC=self-contained.
‡The four-part form consisted of a CB sheet, two CBF sheets, and a CF sheet.
forms (120 sheets) were placed inside
the chamber for each test. Sheets were
separated at the rate of 1 form or
4 sheets/min. After the 30-min separat-
ing procedure, the sheets were left ex-
posed in the chamber for the rest of the
1-hr sampling process. The sampling
flow rate was approximately 0.5 L/min.
The maximum average formaldehyde
concentration for 3 replicates was
0.37 ppm after 1 hr.
 Ventilation studies: Four types of paper
were used to examine the effect of
ventilation on the concentration of form-
aldehyde in the chamber air. For each
test, 120 sheets of paper were placed
inside the chamber. Page turning, venti-
lation, and sampling all began at time
zero. Pages were turned at the rate of
4 sheets/min for 30 min and were left
exposed in the chamber for the final
30 mins. Ventilation and sampling were
continuous for the full hr. Ventilation
was simulated by forcing compressed air
into the chamber and allowing the air to
flow out through a hole in the rear of the
chamber. The ventilation rate was ap-
proximately 0.5 air change/hr for CB–15
blue, CB–15 black, and self-contained-17
black. This rate was obtained by using a
flow rate of 2.6 to 2.9 L/min. Ventilation
for SC–14 black was approximately 1 air
change/hr, obtained by using a flow rate
of 5.1 L/min. The sampling flow rate
was approximately 0.5 L/min. The re-
sults are shown in Table 3–9.
The release of formaldehyde for the combined
marking and separating activity demonstrated
a value between the maximum concentrations
for either activity measured alone. The maxi-
mum average formaldehyde concentration was
0.402 ppm after 1 hr for 2 replicates for mark-
ing and separating. Marking the forms (maxi-
mum average formaldehyde concentration was
0.497 ppm after 1 hr for two replicates) had a
greater impact on the release of formaldehyde
than did separating them (maximum average
formaldehyde concentration was 0.37 ppm af-
ter 1 hr for 3 replicates). The results permitted
the investigator to develop a formula for pre-
dicting formaldehyde release in the office en-
vironment. Using the rate constants developed
(the assumptions and calculations used were
not provided), the investigator predicted a
formaldehyde concentration of 0.033 ppm
for a worker confined to a 1,000 ft3 room
with no ventilation while marking and separat-
ing 30 four-ply forms/hr for 8 hr. This value is
between the NIOSH recommended exposure
limit (REL) of 0.016 ppm as an 8-hr
time-weighted average (TWA) (with a 15-min
ceiling limit of 0.1 ppm) and the OSHA per-
missible exposure limit (PEL) of 0.75 ppm as an
8-hr TWA (with a 2-ppm short-term exposure
limit [STEL]).
3.3 Conclusions
Little consistency has been found in the litera-
ture when various investigators elected to per-
form air sampling analyses to assess potential
exposure to CCP and its components as sum-
marized in Table 3–1. The most frequently
chosen analyte was formaldehyde. Of the
seven studies reporting formaldehyde concen-
trations (summarized in Table 3–10), nearly all
measurements exceeded the NIOSH REL of
0.016 ppm as an 8-hr TWA with a 15-min
ceiling limit of 0.1 ppm [NIOSH 1981]; how-
ever, none exceeded the OSHA PEL of
0.75 ppm as an 8-hr TWA with a short-term
exposure limit of 2 ppm [29 CFR 1910.1048].
Short-term exposures to this strong-smelling
gas cause eye, nose, and throat irritation in
some persons at concentrations of <1 ppm. At
5 to 30 ppm, formaldehyde causes cough,
chest tightness, unusual heartbeat, and lower
airway and chronic pulmonary obstruction
[NIOSH 1996, 1998; NRC 1981]. The OSHA
formaldehyde standard [29 CFR 1910.1048]
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Table 3–9. Effect of ventilation on formaldehyde
concentrations in test chambers containing CCP
Average formaldehyde concentration in test chamber (ppm)
Exposure time (min) CB–15 blue CB–15 black SC–17 black SC–14 black
0–10 0.050 0.080 0.166 0.065
5–15 0.049 0.089 0.216 0.072
10–20 0.071 0.099 0.214 0.072
15–25 0.060 0.089 0.219 0.074
20–30 0.055 0.093 0.227 0.068
25–35 0.039 0.064 0.173 0.023
30–40 0.028 0.042 0.113 0.010
40–50 0.007 0.032 0.053 0.001
50–60 0.0 0.010 0.059 0.004
Adapted from Hazelton Laboratories [1985].
Table 3–10. Summary of formaldehyde




Gockel et al. [1981] <0.51
Norbäck [1983b] 0.08–0.24
Hazelton Laboratories [1985] 0.033‡
Apol and Thoburn [1986] ND§
Chovil et al. [1986] 0.015–0.022
Omland et al. [1993] 0.08–0.5
Zimmer and Hadwen [1993] 0.019–0.028
*The NIOSH REL is 0.016 ppm as an 8-hr TWA with a 15-min ceiling limit of 0.1 ppm. The OSHA permissible exposure limit is 0.75 ppm
as an 8-hr TWA with a short-term exposure limit of 2 ppm.
†1 ppm=1.23 mg/m3.
‡For marking and separating 30 four-ply forms/hr for 8 hr (range 0.009–0.693).
§Limits of detection varied from 0.04 to 0.08 ppm.
is based on a number of adverse health effects
ranging from irritation to cancer [57 Fed. Reg.
22290 (1992)]. A full discussion of the health
effects of formaldehyde is beyond the scope
of this review.
Reported measurements for kerosene and
total dust were far below the occupational
exposure limits. The NIOSH REL for kero-
sene is 100 mg/m3 as a 10-hr TWA during a
40-hr workweek [NIOSH 1977]. No NIOSH
REL has been established for total dust.
OSHA has a PEL of 5 mg/m3 for the respira-
ble fraction of particulates not otherwise
regulated [29 CFR 1910.1000(z)(1)]. Ker-
osene is defined as Fuel Oil No. 1, Range
oil (note: a refined petroleum solvent [pre-
dominantly C9–C16] that is typically 25%
normal paraffins, 11% branched paraffins,
30% monocycloparaffins, 12% dicycloparaf-
fins, 1% tricycloparaffins, 16% mononu-
clear aromatics, and 5% dinuclar aromatics)
[NIOSH 1997]. Santosol, SurSol, and odor-
less kerosene are similar in chemical composi-
tion to kerosene. Symptoms of kerosene
exposure include eye, skin, nose, and throat
irritation; burning sensation in the chest;
headache; nausea; weakness; restlessness;
incoordination; confusion, drowsiness; vom-
iting, diarrhea; dermatitis; and chemical pneu-
monia (if liquid kerosene is aspirated).
Airborne exposures at concentrations cited in
the CCP studies are not likely to lead to eye or
upper respiratory irritation. Quantitation of
skin exposure to kerosene from CCP has not
been reported. However, skin contact with
CCP containing kerosene or its components
could result in skin irritation.




During the early 1970s, manufacturers,employers, and occupational safety and
health organizations received numerous com-
plaints of skin and mucous membrane symp-
toms related to handling or working in close
proximity to CCP [Calnan 1979; Göthe et al.
1981; Parmeggiani 1983]. The association of
CCP with cases of occupational contact derma-
titis was first investigated by Calnan [1979],
who also reviewed reactions to ordinary car-
bon paper, which CCP has largely replaced.
According to Calnan, proven allergic contact
dermatitis from carbon paper was a rarity. Four
early outbreaks of CCP health effects were de-
scribed by Calnan [1979] and Göthe et al.
[1981] at a scientific symposium in Stockholm
in 1981. Although skin-patch tests were nega-
tive and therefore did not support allergic con-
tact dermatitis as the mechanism of CCP health
effects, five pieces of evidence indicated an oc-
cupational origin for the CCP symptoms:
 The reporting of symptoms from several
workers in a number of unrelated and
unconnected companies
 The receipt of customer complaints by
all of the CCP manufacturers
 The similarity of reported symptoms and
signs
 The similarity of complaints from differ-
ent countries
 The absence of reported symptoms be-
fore the introduction of CCP
Calnan [1979] concluded that the reactions
appeared to be toxic (i.e., irritant) rather than
allergic because the affected workers were
able to continue working in the same general
environment without immediate recurrence of
their symptoms and because many of the
workers related their symptoms to periods of
intensive work handling large amounts of
CCP.
Calnan [1979] noted that the CCP manufactur-
ers had reported an absence of skin, oral, ocu-
lar, or respiratory tract symptoms among their
own workers employed in packing large quan-
tities of CCP. However, subsequent investiga-
tions identified health problems in these
groups as well. Calnan also pointed out that all
CCP complaints were associated with used
CCP paper, indicating that the rupture of the
microcapsules containing the color formers
and solvents may be important—even though
only a small proportion of capsules in each
sheet of paper are broken. Ultimately, Calnan
concluded that the eye, nose, mouth, and throat
symptoms were caused not by the color former
chemicals but rather by the encapsulated sol-
vents, which would presumably have to evapo-
rate to cause other than dermal symptoms.
In a review of the evidence, Buring and
Hennekens [1991] found most of the available
studies on CCP health effects to be critically
lacking epidemiologically and difficult to in-
terpret. They were able to find no “analytic
studies” of CCP health effects for review.
However, they concluded that unequivocal ev-
idence was not likely ever to be available, even
with great expenditure of effort and resources.
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They recommended instead that consideration
be given to “implementing measures to prevent
or reduce the frequency” of the reported ef-
fects.
Murray [1991] also conducted a review of the
potential health effects of CCP exposure at
the request of the Commission of the European
Communities. He noted an absence of docu-
mented cases of skin disorders among workers
in the manufacturing industry—despite the fact
that workers in this industry would be ex-
pected to have much higher exposures than
office workers. On the basis of both his review
of the literature and his experiences as a con-
sultant for a manufacturer of CCP, Murray
concluded that although individual cases
of sensitivity to CCP components would con-
tinue to be reported, a “negligible” threat is
posed to the health of producers and users.
Since 1991, additional studies (including some
that qualify as analytical epidemiology) have
appeared in the scientific literature. The fol-
lowing review considers not only information
published in the scientific literature but also
information that was submitted to NIOSH in
response to announcements in the Federal
Register in 1987 and 1997. More than 14,000
pages of combined submissions were received
in response to the 1987 and 1997 Federal Reg-
ister notices. Most of the submissions were
made after the latter notice. No materials were
accepted or reviewed if the submitter consid-
ered the items to contain proprietary informa-
tion that could not be made available to the
public. Information that contained personal
identifiers was blocked out unless the
submitter wanted the information to remain
public.
The following review of CCP health effects
separately considers the information from
human and animal studies.
4.2 Human Studies
Human studies of CCP have dealt mostly
with exposures in office settings. Three types
of human studies of CCP have been con-
ducted: individual case studies or case series,
cross-sectional studies, and laboratory studies
in humans. The following sections separately
review each type of study.
4.2.1 Published Case Reports and
Case Series
The case report is a detailed profile of a single
subject; case series describe the characteristics
of a number of patients with a given disease.
Case reports and series document unusual fea-
tures of a disease or a patient’s exposure his-
tory; they are a type of descriptive
epidemiologic assessment. Case reports and
series can present a major problem in
interpretability because the presence of any
risk factor may be simply coincidental. Their
usefulness is generally limited by the lack of a
comparison group (i.e., persons without such
symptoms who had similar opportunity for ex-
posure). The lack of a formal comparison
group in these studies can make it difficult to
determine whether the observed associations
represent more than the normal background
rate of disease. Lack of a comparison group is
particularly problematic when the cases in-
volve common diseases or symptoms and
when the exposure is relatively common
(which is clearly the case with these reports for
CCP exposures). In the absence of a compari-
son group, case reports and series can provide
the first clues to the identification of new dis-
eases or exposure effects, and they are poten-
tially useful for formulating research
questions; however, the evidence usually can-
not be used to test hypotheses [Buring and
Hennekens 1991]. On the other hand, when
characteristic symptoms and clinical signs
vary over time in direct correspondence with
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changing work exposures, it may be possible to
reliably discern a causal relationship. Further-
more, some of these reports included individ-
ual experiments in which subjects were
exposed to CCP or its components and objec-
tive signs and symptoms were evaluated fol-
lowing these exposures. These studies can
provide stronger evidence for causality than
ordinary case reports that are based on subjec-
tive reports of past experiences.
Table 4–1 lists 39 currently available, pub-
lished case reports and case series related to
CCP, including a number of series assembled
in NIOSH Health Hazard Evaluations
(investigations conducted under the authority
of the Occupational Safety and Health Act of
1970 [29 USC* 1900]). Nine reports provided
information about the experience of a single
worker. In the case series, ranging from 2 to
276 workers, symptoms were generally clus-
tered within a defined period and involved a
number of employees at a single workplace,
often situated in a single room or activity. The
observed symptoms varied considerably from
site to site, but most included skin problems
such as itching, rash, dryness, and eczema as
well as mucous membrane irritation,
particularly of the eyes, mouth, nose, and throat.
Lower respiratory problems were less frequent.
Headache was also reported as a problem (to a
smaller extent), and fatigue was also
mentioned.
The following are summaries of the studies
outlined in Table 4–1.
Magnusson 1974. Magnusson [1974] con-
ducted his investigation in Sweden at a
workplace where 15 of 18 women working
with CCP had reported itching and dryness of
the skin, lips, tip of nose, and eyes as well as
burning sensations or dryness in the mouth. The
*United States Code. See USC in references.
symptoms mostly appeared a few weeks after
the first exposure to CCP. Seven of the 15
women showing symptoms were skin-patch
tested using the paper in question and a stan-
dard series. All tests were negative but one,
which showed reaction to nickel and cobalt.
Symptoms disappeared after introduction of a
new type of paper containing a resin to bind the
clay material.
Hannuksela 1975. A report by Hannuksela
[1975] (unavailable to NIOSH but cited by
Jeansson et al. [1983]) found 20 workers
among several hundred in a Swedish bank who
suspected that eczema on their hands was
caused by contact with CCP. None of the 19
workers who were skin-patch tested with a
CCP bottom sheet emulsion showed an allergic
reaction. One later case was reported as posi-
tive, with most of the complaints attributed to
physical factors (such as abrasiveness) related
to CCP.
Wahlberg 1975. In a personal communication
reported by Jeansson et al. [1983], Wahlberg
found the CCP-related problems to be rela-
tively evenly distributed between two main
types of CCP used in Sweden at the time—
clay- and polymer-based papers. He suggested
that a finely distributed dust arising from leaf-
ing through and tearing the paper was a likely
explanation of the symptoms.
Hirvonen et al. 1976. Hirvonen et al. [1976]
obtained positive skin-patch test reactions for
irritation in 4 of 32 cases associated with CCP
from a total of 1,050 cases of occupational
dermatitis in Sweden during the period 1973 to
1976. In all four cases, the rash began in areas
typical of paper contact—the finger tips of one
or both hands and the outer edges of the hand.
The eyelids of one worker also revealed a rash.
Of the four patients, two reacted only to the top
side of the paper but not to the CB or CF por-
tions. Two patients reacted to all of the
4 HEALTH EFFECTS
30 Carbonless Copy Paper
Table 4–1. Published case reports, case series, and health hazard evaluations
involving exposure to CCP or CCP components
Authors Country Number of cases Symptoms*
Magnusson 1974 Sweden 15 Itching and dryness of skin, lips, tip of
nose, eyes; burning or dryness of
mouth
Hannuksela 1975 Sweden 20 Eczema
Wahlberg 1975 Sweden NR† “Problems”
Hirvonen et al. 1976 Sweden 32 Skin irritation
Maggio et al. 1978 Italy NR Acne, headaches, nausea
Andanson et al. 1979 France 27 Skin symptoms (pruritus of uncovered
areas on hands, face, forearms, thorax,
and legs); eye symptoms (pruritus,
conjunctival hyperemia with tearing




obstruction, glottal edema, asthma)
Calnan 1979, 1981 United Kingdom Several Itchy hands, swollen eyelids,
headaches
2 Burning face and forehead, fatigue,
thirst, sore throat and tongue, chills,
aching limbs, small itchy blisters on
palms
4 Burning lips and tongue, sore eyes,
dry throat and skin




1 Rash on hands
England 4 Dry, burning lips, and tongue;
stinging, running eyes and nose; dry,
cracked skin on hands; facial rash;
chest tightness
Cronin 1980 United Kingdom 4 Eczema
________________
See footnotes at end of table. (Continued)
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Table 4–1 (Continued). Published case reports, case series, and health hazard evaluations
involving exposure to CCP or CCP components
Authors Country Number of cases Symptoms*
Dodds and Butler 1981 Belgium 17 Eczema, itching, red spots, itching
eyes
Marks 1981 United States 1 Dermatitis on face and neck
Menné et al. 1981 Denmark 38 Skin redness, burning, itching; itching
eyes, nose; hoarseness; burning
mouth, red face, headache, dizziness
Chrostek and Moshell
1982
United States 21 Eye and nose itching and burning; dry
throat; headaches; facial itching; and
sinus, skin, and respiratory problems
Levy and Hanoa, 1982 Norway 13 Perception of unpleasant odor; itching
eyes, face, and hands; rashes;
headaches
Roure et al. 1982 France 28 Pruritis on the hands, face, forearms,
or thorax and legs
11 Burning sensation, nasopharyngeal
tingling, slight dysphagia,
photophobia, eye irritation, and
conjunctival pruritus
3 Dryness of the mouth, burning, and
taste perturbations
3 Headache




1 Conjuntivitis with eyelid edema





See footnotes at end of table. (Continued)
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Table 4–1 (Continued). Published case reports, case series, and health hazard evaluations
involving exposure to CCP or CCP components
Authors Country Number of cases Symptoms*
4 Spasmodic cough and asthmatic
breathing
Certin and Zissu 1983 France 46‡ Skin, eye, and respiratory irritation;
headache; arthralgia
Jeansson et al. 1983, 1984 Sweden 148 Irritation of the eyes, nose, throat,
arms, face, and scalp; cold symptoms;
hoarseness; sores behind the ears or
in the nose; itching, dryness, redness,
or eczema of the hands; unpleasant
odor or taste; fatigue; headache;
nausea; joint pains; a feeling of
paralysis
Norbäck et al. 1983a,b Sweden 80 Respiratory tract and eye irritation
Marks et al. 1984;
Trautlein et al. 1984
United States 1 Pruritus, eye and throat irritation,
hoarseness irregular heartbeat,
headache, nausea, tightness of chest,
shortness of breath, and fatigue;
challenge test with CCP indicated
contact urticaria, changes in
pulmunary function indicative of
upper airway obstruction, and













See footnotes at end of table. (Continued)
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Table 4–1 (Continued). Published case reports, case series, and health hazard evaluations
involving exposure to CCP or CCP components
Authors Country Number of cases Symptoms*
Dodds and Butler 1981 Belgium 17 Eczema, itching, red spots, itching
eyes
Marks 1981 United States 1 Dermatitis on face and neck
Menné et al. 1981 Denmark 38 Skin redness, burning, itching; itching
eyes, nose; hoarseness; burning
mouth, red face, headache, dizziness
Chrostek and Moshell
1982
United States 21 Eye and nose itching and burning; dry
throat; headaches; facial itching; and
sinus, skin, and respiratory problems
Levy and Hanoa, 1982 Norway 13 Perception of unpleasant odor; itching
eyes, face, and hands; rashes;
headaches
Roure et al. 1982 France 28 Pruritis on the hands, face, forearms,
or thorax and legs
11 Burning sensation, nasopharyngeal
tingling, slight dysphagia,
photophobia, eye irritation, and
conjunctival pruritus
3 Dryness of the mouth, burning, and
taste perturbations
3 Headache




1 Conjuntivitis with eyelid edema





See footnotes at end of table. (Continued)
Roure et al. 1982
(continued)
Table 4–1 (Continued). Published case reports, case series, and health hazard evaluations
involving exposure to CCP or CCP components
Authors Country Number of cases Symptoms*
Marks et al. 1984;




Messite and Baker 1984;
Messite and Fannick 1980
United States 6 Skin and eye irritation
Menné and Hjorth 1985 Denmark 3 Contact dermatitis, eczema on fingers
Olsen and Mørck 1985 Denmark 1 Skin irritation
Apol and Thoburn 1986 United States NR Voice change, cough, chest tightness




United States NA Respiratory problems reported but not
attributed to CCP; some mention of
formaldehyde exposure that was
assumed to originate from CCP
Chovil et. al. 1986 United States 9 Eye irritation, sinusitis, dermatitis,
psychological manifestations
Shehade et al. 1987 United Kingdom 1 Allergic contact dermatitis
LaMarte et al. 1988 United States 2 Hoarseness, wheezing, coughing,
flushing, pruritus, rash, laryngeal
edema, localized angioedema
Norbäck et al. 1983c; 1988 Sweden    276 Skin and mucous membrane and skin
irritation
Hammel 1990 United States 2 Hoarseness, cough, flushing, pruritus,
rash
1 Nausea, dizziness
1 Redness and itching on hands
Kanerva et al. 1990a,b;
1993
Finland 1 Allergic contact dermatitis
Burton and Malkin 1993 United States 1 Chest tightness, cough
1 Cough, rhinitis, headache, rash
________________
See footnotes at end of table. (Continued)
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Table 4–1 (Continued). Published case reports, case series, and health hazard evaluations
involving exposure to CCP or CCP components
Authors Country Number of cases Symptoms*
Sim and Echt 1993 United States NA Itchy skin and rashes attributed to
fibrous glass
Zimmer and Hadwen 1993 United States 6 Odor in archives area
Ziem and McTamney
1997
United States 2 Multiple chemical sensitivity disorder
Smith et al. 1999 United Kingdom 1 Eczema of the thumbs
Adapted from Buring and Hennekens [1991], with additional references added.
*Symptoms were observed in one or more subjects. Exact numbers are supplied in parentheses if they were reported.
†Abbreviations: NA=not available; NR=not reported.
‡Requests for CCP analysis—not cases.
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surfaces of the papers. Tests on the ingredients
of the papers were negative. The authors attrib-
ute the reactions to nonspecific irritation of the
skin.
Maggio et al. 1978. Maggio et al. [1978]
reported an investigation of the chemical com-
position of CCP in Italy. They identified or-
ganic dyes dissolved in mineral oil or PCBs
enclosed in the microcapsules made of
urea-formaldehyde resins or gelatin. The
symptoms reported by those using CCP were
skin complaints such as acne and general com-
plaints such as headache, nausea, and uncom-
fortable olfactory sensations. The authors
assumed the symptoms to be related to the
PCB exposure.
Andanson et al. 1979. In France, Andanson et
al. [1979] described the chemical composition
of CCP and the spectrum of symptoms result-
ing from handling sheets of CCP directly or
possibly from contact with vapor. The onset of
symptoms (reported by 27 of 35 exposed
workers) varied but generally developed a few
weeks after first exposure. The authors men-
tioned symptoms of the skin (pruritus of un-
covered areas on the hands, face, forearms,
thorax, and legs), eyes (pruritus, conjunctival
hyperemia with tearing and photophobia), and
respiratory system (pruritus, burning, prick-
ling, dysphagia, throat constriction accompa-
nied by rhinorrhea, nasal obstruction, glottal
edema, and one case of true immediate
asthma). The authors noted that chemical in-
formation from the manufacturers was inade-
quate to relate the symptoms to the exposure
and that office environments involved nonex-
istent or inadequate ventilation. The authors
reported that symptoms disappeared soon after
exposure ended. They considered the irritant
symptoms definitive but performed no tests to
assess the allergic potential. The authors con-
cluded that while some of the cases were rela-
tively severe, they did not consider them “a
great historic pathology.”
Calnan 1979, 1981. Calnan [1979, 1981] re-
ported on three episodes of complaints from
various types of office workers in the United
Kingdom who attributed their symptoms to the
use of CCP. The first episode occurred in 1965
in a group of nine women who worked with
business forms in an enclosed computer room
at an insurance company. Within a few weeks
of the introduction of CCP, several of the
women complained of itchy hands, swollen
eyelids, and headaches. Skin-patch testing to
the paper and all of its constituents was nega-
tive. At the time, the solvent for the ink was
chlorobiphenyl (a PCB), which was suspected
as the causal agent. When ventilation in the
workroom was improved, the episode sub-
sided. Soon afterwards, the PCB use was dis-
continued by all manufacturers.
A second episode occurred in 1975 and in-
volved two men working intensively over a
long, hot weekend checking a large number of
forms in a small office. One reported a burning
sensation on his face and forehead, fatigue,
thirst, sore throat and tongue, chills, and aching
limbs. He recovered in a few days without
treatment, returned to the office to continue his
work, and suffered a recurrence of the same
symptoms. The other man was similarly but
less severely affected and had small, itchy blis-
ters on the centers of his palms.
The third episode described by Calnan occurred
in 1976 in a small office where all four workers
complained of similar symptoms whenever they
handled large amounts of CCP. They reported
a burning sensation of the lips and tongue, sore
eyes, dry throat, and some dryness of the skin.
Calnan [1979] also reported on complaints
from three users of CCP made in Japan. The
complaints included nausea, sore eyes and
throat, and skin irritation (see Table 4–1).
Among all of these reported episodes, no
workers changed jobs or were forced to stop
work. All skin test investigations were nega-
tive, and the CCP came from different
manufacturers. Calnan hypothesized that if
there was a responsible agent, it was most
likely to be the solvent in the microcapsules,
which could include kerosene, diarylethanes,
alkyl naphthalenes, cyclohexane, and dibutyl
phthalate.
Cronin 1980. Cronin [1980] reported that four
workers involved in the making of microcap-
sules for CCP in the United Kingdom were
found with eczema of the hand (which had
been present in one worker for 4 years) or
palms (present in one worker for 10 years).
Two Proxel compounds (Imperial Chemical
Industries) were used as preservatives for gela-
tin in a factory making the emulsion for CCP.
Both contained the active ingredient 1,2-ben-
zisothiazolin-3-one, and one also contained
ethylenediamine. Both the active ingredient
and the Proxel provoked positive skin-patch
test reactions in all four workers, but the
ethylenediamine provoked a response in only
two of them [Kanerva et al. 1993]. The author
concluded that two of the workers’ eczema
predated their contact with the agents, and the
sensitization was thought to be an aggravating
factor in their dermatitis rather than its com-
plete cause. Another dermatitis case was cited
in a paper mill worker.
Dodds and Butler 1981. In Belgium in 1975,
these investigators described five female
workers who handled paper forms and reported
skin and eye irritation (specifically eczema,
itching, and red spots). An additional 12 work-
ers reported itching of the eyes. The incident
coincided with the use of a new desensitizing
ink (“D-ink,” a coating to disable the color for-
mation process). Before the use of this ink, no
symptoms had been reported for 7 years. A
hamster cheek-pouch test resulted in transient
ischemia that lasted approximately 15 min.
Detailed studies of the new desensitizing for-
mula led to the conclusion that one of its ingre-
dients (1-hydroxyethyl-2-oleylimido-azoline)
caused the severe effect. In a second case in
Denmark, similar symptoms were reported af-
ter workers handled paper that contained the
same desensitizing ink. The manufacturer was
reported to have immediately terminated pro-
duction of the formulation.
Marks 1981. Marks [1981] reported the fol-
lowing case of a 21-year-old woman in the
United States who had a 1.5-year history of an
intermittent eruption of the face and neck. She
worked as a clerk in a college registrar’s office
where CCP forms were used for student regis-
tration. Within 24 to 48 hr after using the
forms, she developed pruritic, erythematous,
and edematous dermatitis. She was skin-patch
tested with a standard series of allergens as
well as with pieces of paper and the compo-
nents of the paper backing. She reacted to three
of the four colored sheets of CCP. She also
tested positive to the color former, identified as
paratoluene sulfinate of Michler’s hydrol, a
component of some CCP. She was further
skin-patch tested with paratoluene sulfonic acid
(results were negative) and with the Michler’s
hydrol (4,4-bis[dimethylamino]benzhydrol)
(results were positive). Twelve control subjects
tested negative to the paper and coating
materials.
Menné et al. 1981. Menné et al. [1981] per-
formed an investigation resulting from 70
complaints at a telephone company in Den-
mark that employed 2,600 workers who han-
dled up to 900,000 sets of CCP per year (i.e., an
average of 1.3 sets per person per day). They
first investigated 38 of the complaints and
found that 26 workers had skin symptoms
only, 9 had skin and mucous membrane symp-
toms, and 3 had mucous membrane symptoms
only. Among the workers with skin symptoms,
22 reported that they started on the hands, and
4 reported that they began on the face. The skin
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symptoms were temporary redness, burning,
and itching that occurred after 2 to 3 hr of
work; they disappeared overnight or over the
weekend. Itching of the eyes or the nose,
hoarseness, and burning in the mouth were
the other symptoms recorded. Twenty-nine of
the 38 received standard skin-patch tests, and
11 were found with one or more reactions.
Twenty-five workers were further skin-patch
tested with 17 paper substances and with
the paper. Eight workers were tested with the
paper components plus the paper, but no
reactions were observed. Other tests included
prick testing, photo-patch testing, open tests on
the forehead (dab testing), and short-term
patch testing for 20 min. All results were
negative. The three skin-prick tests using the
paper components were negative. Eight were
photo-patch tested, and eight had open-patch
tests to assess phototoxicity, but all reactions
were negative. Twenty-six were skin-prick
tested with two types of CCP; six reacted to
one type, and five reacted to the other type with
reactions the size of one histamine equivalent.
However, authors considered these responses
to be nonimmunological. Among the 35 con-
trols, one had a positive reaction to one of the
skin-paper prick tests. The controls were also
tested with 17 different components of the CCP;
all tests were negative. The authors stated that
approximately 4,000 separate tests were car-
ried out without reaching any definite
conclusions.
Menné et al. [1981] also reported on the case of
a worker from a different company who began
experiencing redness of the face, headache,
and dizzy spells on the day that a new delivery
of CCP was made. The worker’s symptoms
disappeared 2 hr after he returned home. Two
months later, the paper was replaced and his
symptoms disappeared.
Chrostek and Moshell 1982. Chrostek and
Moshell [1982] conducted a walk-through sur-
vey and administered nondirected medical
interviews with 21 workers at a U.S. telephone
company. These service department workers
acted on reports of malfunctioning telephone
service and requests for new services, which
were printed on yellow CCP. Previously, car-
bon paper had been used with no complaints.
The following health complaints were de-
scribed after the introduction of CCP: eye itch-
ing and burning, nose itching and burning, dry
throat, headaches, facial itching, and sinus,
skin, and respiratory problems. Some of the
workers stated that the adverse health prob-
lems existed only when handling yellow
CCP—not white CCP. Five air samples were
collected for total dust; they ranged from 0.06
to 0.2 mg/m3. The two samples collected for
formaldehyde were 0.22 mg/m3. Workers han-
dling the CCP were asked to wear white cotton
gloves, which were analyzed. The common
contaminant in both the gloves and the CCP
was dibutyl phthalate, although other contami-
nants (diethyl phthalate and dioctyl adipate)
were also detected in the gloves. Qualitative
analysis of the carbonless paper did not detect
formaldehyde. On May 13–14, 1981, a NIOSH
dermatologist interviewed and examined 33
workers. Of these, 28 were skin-patch tested
with unmarked white and yellow CCP and a
marked yellow CCP. On the basis of the nega-
tive skin-patch tests and a lack of skin findings
consistent with allergic contact dermatitis, the
authors ruled out type IV allergic phenomena
as a major problem. However, they allowed
that certain individuals might have been aller-
gic to a component of the paper.
Levy and Hanoa 1982. Levy and Hanoa
[1982] reported on an isolated epidemic that
occurred in northern Norway when a new type
of invoice form (30,000 sets) had been intro-
duced by a builder’s supply company. During
the first week of use, workers complained
about an unpleasant odor, rashes, headaches,
and itching eyes, face, and hands. Thirteen fe-
male workers were examined in June 1979; six
had serious symptoms and three exhibited mild
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symptoms. These workers were again exam-
ined in November 1979 when some CCP sets
were still in circulation but most had been
returned to the supplier. The complaints gradu-
ally declined until none of the workers exhib-
ited serious symptoms and eight had only mild
symptoms. In September 1980, when none of
the original CCP remained in use, only one of
the workers (who had a previous history of al-
lergy) complained of itching and irritation of
the eyes. The solvent MIPB and associated im-
purities (which had a characteristic odor) were
suspected. Formaldehyde was not thought to
be of any importance in the incident.
Roure et al. 1982. Roure et al. [1982] de-
scribed subjective symptoms and objective
signs occurring in 22 of 35 workers exposed in
a French company during the introduction of
CCP. The following frequencies of subjective
symptoms were observed: pruritis localized on
the hands (13 cases), face (9 cases), forearms
(5 cases), or thorax and legs (1 case); burning
sensation, nasopharyngeal tingling, slight
dysphagia, photophobia, eye irritation, and
conjunctival pruritis (11 cases); dryness of the
mouth, burning, and taste perturbations
(3 cases); and headache (3 cases). All symp-
toms appeared as early as the start of the work-
week, lessened in the evening, and disappeared
on the weekends. Objective signs in 18 work-
ers consisted of erythematous patches on the
hands and face (9 cases), urticaria (1 case), mi-
gratory edema (1 case), conjunctivitis with
edema of the eyelid (1 case), conjunctival hy-
peremia with lacrimation (2 cases), rhinorrhea
(4 cases), glottal stricture (1 case), nasal ob-
struction (1 case), and spasmodic cough and
asthmatic breathing (4 cases). An etiologic sur-
vey showed evidence of previous allergies in
three subjects and enabled a distinction to be
made between the risks due to “transfer-contact”
and “chemical-contact” copy papers.
Certin and Zissu 1983. Results of analyses
requested of the French National Research
and Safety Institute were reported by Certin
and Zissu [1983] and compared with other
published studies. They reported 51 requests
for analysis of CCP during the 10 years pre-
ceding publication of the results. Reasons
stated in 46 of the requests included cutaneous
problems (allergies, irritation, pruritis, and
chapping) (41), respiratory problems (12), oc-
ular disorders (lacrimation, conjunctivitis)
(10), irritation of the nasal mucosa (2), and
others including asthenia, anemia, headache,
and arthralgias. According to the authors, derma-
tological and respiratory problems seemed to be
linked to the use of these papers and were more
likely to be due to irritation than to allergy.
Norbäck et al. 1983a,b,c; 1988. Norbäck et al.
[1983a] summarized conclusions from five
studies in Sweden. Studies in 80 office workers
observed only eye and respiratory tract irrita-
tion caused by CCP. Norbäck et al. [1983b]
found no correlations between airborne solvent
concentrations from CCP and the occurrence
of irritative symptoms. Formaldehyde, glutar-
aldehyde, and the organic solvents in which the
color formers are dissolved were studied under
standardized conditions. According to the au-
thors, the emission of aldehydes from CCP was
too low to cause the irritative symptoms. The
highest airborne concentration was that of ker-
osene, which could not be related to
symptoms.
Norbäck et al. [1983c, 1988] searched for the
discomfort-inducing factors in 276 paper
samples (233 of which were CCP) submitted
by workers claiming to have experienced
irritative symptoms while handling the papers.
Interviews regarding symptoms and handling
volume were conducted with subjects who had
submitted 190 of the CCP samples. To distin-
guish between CCP of different makes, GC of
paper extracts was performed, sometimes
combined with thin-layer chromatography
(TLC) of the color formers. Coded paper sam-
ples were used to permit blind analyses of the
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papers and blind interviews of the exposed
persons. The samples were extracted with car-
bon disulfide, and the extracts were analyzed
by GC or TLC. Most correlations of CCP with
discomfort were not statistically significant but
were found in one brand of paper that used
MIPB as the solvent for the color formers.
However, the authors concluded that the dis-
comfort-inducing factor was unlikely to be
MIPB because two types of MIPB paper were
on the market at the time of this study, but pa-
tient complaints identified only one of them.
CCPs treated with D-ink were more frequently
linked to work-related skin symptoms than
those not treated with the ink. This correlation
was statistically significant (P<0.05). No such
correlation was seen for mucous membrane
irritation symptoms. The authors concluded that
the causal factor was probably two desensitiz-
ing inks available on the Swedish market dur-
ing the investigation period (from January 1 to
October 27, 1980)—but not necessarily to D-inks
in general. The suspected ingredient in one of
the D-inks was 1-hydroxyethyl-2-oleylimido-
azoline—the same ink that had previously been
associated with skin and eye irritation among
office staff in Belgium [Dodds and Butler 1981].
Jeansson et al. 1983, 1984. See Section
4.2.3.1 for a discussion of this study.
Marks et al. 1984; Trautlein et al. 1984. A
27-year-old woman in the United States had an
8-year history of pruritus, eye and throat
irritation, hoarseness, irregular heartbeat,
headache, nausea, tightness of the chest,
shortness of breath, and fatigue within 30 min
of exposure to CCP [Marks et al. 1984;
Trautlein et al. 1984]. For 10 years, she had
worked in the same factory, which printed, cut,
collated, and packaged CCP. She reported that
her symptoms became progressively worse as
she processed greater amounts of CCP in her
job of removing and stacking forms from a col-
lating machine. When working with regular
paper, she was asymptomatic. Her symptoms
disappeared on weekends, nights, and after 1 hr
of exposure to fresh air. On two occasions, she
was challenged in a controlled-blinded fashion
with portions of complete forms of the CCP.
Both challenges resulted in contact urticaria of
the hand that held the paper and changes in pul-
monary function characteristic of upper airway
obstruction. To determine whether alterations
in prostaglandin (PG) metabolism might ex-
plain these findings, plasma PGF2 alpha and
thromboxane B2 (both capable of causing
these symptoms) were measured before and
during the second exposure period. Both PGF2
alpha and thromboxane B2 increased substan-
tially. The authors concluded that the cutane-
ous and respiratory symptoms induced by
CCP were probably related to PG release and
caused by a chemical formed from the reac-
tion of the color former with the color devel-
oper, since the patient reacted only to the
complete forms and not to the single sheets.
When the patient was relocated within the fac-
tory with no exposure to CCP, she was
asymptomatic.
Similar symptoms were found in 9 of 59
workers in a subsequent plant survey. The
symptoms reported by the 9 workers included
throat irritation (8), skin itching (5), headache
(4), hoarseness (3), difficulty breathing (3),
chest tightness (3), rash (2), burning eyes (2),
chest pain (2), nausea (1), weakness (1), and
rapid heartbeat (1). A statistically significant
(P<0.01) relationship existed between symp-
toms and high exposure to CCP (compared
with low exposure to CCP).
Messite and Baker 1984; Messite and
Fannick 1980. Messite and Baker [1984]
summarized a number of NIOSH Health Haz-
ard Evaluations dealing with indoor environ-
mental quality and specifically reported on a
previous study involving CCP [Messite and
Fannick 1980]. Six complaints of skin and eye
irritation among 100 office staff members and
faculty at a school were related to heavy CCP
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exposure during marking periods of 1 to
2 days. Analysis of the paper did not identify
the sensitizing agents or significant irritants.
The problem was alleviated by spreading the
task of marking papers over several days and
frequent hand-washing during handling of the
paper.
Menné and Hjorth 1985. Menné and Hjorth
[1985] reported from Denmark that frictional
trauma with CCP to the palms and fingertips
can provoke dermatitis. Elimination of the ex-
posure led to healing within 2 to 3 weeks.
Three case histories of patients with frictional
contact dermatitis were examined.
Case 1 involved a 35-year-old male office
worker. Each day for 2 years, he had handled
100 to 200 documents written on CCP. He
gradually developed a scaling patch of dermati-
tis on the left hypothenar, second finger, and
tip of the right index finger at areas of contact
with paper. Standard skin-patch tests and pa-
per- and glue-patch tests were negative.
In Case 2, a 64-year-old female medical secre-
tary spent long hours handling CCP. She had
noted pruritic vesicles on the left palm surface
of the thumb that was in contact with the paper.
Eruptions decreased when she wore gloves.
Standard skin-patch tests and patch tests to the
carbonless paper were negative.
In Case 3, a 37-year-old male bus driver had a
fissured eczema of the fingertips, apparently
caused by tearing CCP tickets from the stub.
The eczema cleared during holidays and on
night shifts when there were fewer passengers.
Standard skin-patch tests and patch tests with
the ticket paper were negative. The histo-
pathology of this type of dermatitis was char-
acteristic, showing necrosis of prickle cells
with intraepidermal vesicles and an absence of
spongiosis, which excludes a diagnosis of
chemical dermatitis. The authors concluded that
in patients with dermatitis of the palm or fin-
gertips, frictional trauma should be considered.
Olsen and Mørck 1985. See Section 4.2.3.2
for a discussion of this study.
Apol and Thoburn 1986. Apol and Thoburn
[1986] reported on an investigation requested
by an authorized representative of the Associa-
tion of Western Pulp and Paper Workers in the
United States. They examined employee expo-
sure to diethylenetriamine (DETA), hexa-
methylene diisocyanate (HMDI), and other
chemicals used during the production of CCP
at the Boise Cascade facility in Vancouver,
Washington. This facility makes paper from
pulp and applies CCP coatings to the paper.
Personal breathing zone samples and area
samples were collected to determine worker
exposures to chemicals used by the coater
preparation operators, coating operators, and
maintenance personnel. The airborne concen-
trations were as follows: HMDI (<0.7 to
14.0g/m3), DETA (<0.01 to <0.35 part per mil-
lion [ppm]), phenol (<0.02 to 0.15 ppm), form-
aldehyde (<0.04 to <0.08 ppm), biphenyl
(0.003 to <0.02 ppm), butyl biphenyl (0.12 to
0.29 ppm), petroleum solvents (0.7 to 12 mg/m3),
and total particulate (one sample was 2.70 mg/m3).
All the sample results were less than the regu-
latory limits for these substances. Symptoms
reported as a result of exposure included voice
change, cough (sometimes productive), tight-
ness and soreness in the chest, running sinuses,
and skin rashes.
Medical interviews with 65 employees sug-
gested that when the process was operating
properly, few (number unspecified) health
complaints were associated with the coating
process. The maintenance workers had symp-
toms associated with exposure to the coating
equipment, with the HMDI equipment re-
portedly being the worst offender. Four work-
ers reported pulmonary symptoms consistent
with exposure to diisocyanates. Breathing
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zone concentrations of biphenyl were below
the limit of detection (i.e., <0.02 ppm),
butylobiphenyl concentrations ranged from
0.12 to 0.29 ppm, and HMDI concentrations
ranged from 0.7 to 4.5 g/m3 for coater and as-
sistant coater operators. On the basis of the
medical questionnaire data obtained during the
investigation, the authors concluded that some
workers may have had pulmonary problems re-
lated to past diisocyanate exposure. This inves-
tigation is one of several that document
CCP-attributable health effects at a CCP man-
ufacturing facility.
Bennett and Chrostek 1986. At the request of
the management of the Defense Industrial Sup-
ply Center in Philadelphia, Pennsylvania,
NIOSH evaluated possible excess cancer
deaths and respiratory problems encountered
among workers [Bennett and Chrostek 1986].
Measurements were taken for carbon dioxide,
carbon monoxide, temperature, relative hu-
midity, organic vapors, and airborne dust.
Samples were taken of insulation, solvent
cleaners, and CCP used at the facility. The
amount of outside air being introduced into the
building was occasionally in the low
range—such that headaches and complaints of
respiratory and mucous membrane problems
could develop, even though concentrations of
carbon monoxide and carbon dioxide were
within safe limits. In addition, the building was
overcrowded. The authors concluded that haz-
ards were posed by inadequate ventilation,
high temperatures, and low humidity. The au-
thors recommended improvements in ventila-
tion and the use of impermeable gloves when
using solvents. However, they made no state-
ments or recommendations about the use of
CCP—other than the possibility of formalde-
hyde release.
Chovil et al. 1986. Chovil et al. [1986]
reported cases of eye irritation, sinusitis, derm-
atitis, and psychological manifestations
associated with an outbreak of a building-related
illness at a U.S. university. As part of a build-
ing expansion program in August 1983, the
student advisement office was relocated to a
renovated area on another floor. Shortly after
the move, the nine-member staff began com-
plaining of skin and mucous membrane irrita-
tion. The presence of asbestos increased staff
concern over their symptoms. Medical histo-
ries were taken and clinical examinations were
performed. Air flow in the ventilation system
was evaluated. Seven staff members reported
symptoms that they believed were work re-
lated. All claimed that their symptoms oc-
curred when they were in the file storage area
or when they handled the files.
Air-flow measurements indicated that any
noxious agent originating from the files would
tend to stay localized in the filing area instead
of being dispersed throughout the work area.
An inquiry revealed that the university had
changed suppliers of advisement forms com-
posed of CCP in April 1983. The authors sug-
gest that the outbreak was due to low-level
environmental pollution, probably originating
from the CCP in the forms. Reported symp-
toms may have been exacerbated by the fear of
asbestos. In all but one case, symptoms were
mild. The worker who exhibited severe symp-
toms restricted contact with CCP and had no
recurrence. The authors added that informal in-
quiries revealed at least two workers in other
departments who had symptoms of mucous
membrane irritation during periods of peak us-
age of these forms (at the beginning of each se-
mester). A followup 8 months later revealed
that the staff members were no longer com-
plaining about symptoms—in spite of the fact
that previous recommendations for improving
the ventilation and for reducing CCP handling
had not been implemented.
Shehade et al. 1987. In the United Kingdom,
Shehade et al. [1987] identified a case of aller-
gic contact dermatitis associated with exposure
to CVL in CCP. Skin-patch tests were
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employed to identify the cause of an irritant ve-
sicular rash on the hands and fingers of a fe-
male office worker whose occupation entailed
the day-long handling of significant quantities
of CCP. The symptoms developed within 2
days of the subject’s return to work after 18
months of leave. They resulted in the patient’s
stopping work after 3 weeks. Initial skin-patch
tests to nickel sulfate, cobalt chloride, and fra-
grance mix gave positive results, but there was
no reaction to the CCP. The patient improved
during 3 months on sick leave, but the condi-
tion recurred severely as soon as she returned
to work. Subsequent skin-patch tests to the five
color formers supplied by the manufacturer of
the CCP showed an allergic reaction to CVL at
concentrations of 0.01% to 5%. The authors
concluded that the patient was allergic to CVL
and that CCP skin-patch tests with CCP only
are not sufficient to detect allergies to color
formers. They therefore suggested that the color
formers themselves be used to test patients
with hand eczema and regular contact with
CCP.
LaMarte et al. 1988. Acute systemic reactions
to CCP, including laryngeal edema, were re-
ported in two U.S. office workers by LaMarte
et al. [1988]. The first case was a 39-year-old
woman with a 2-year history of recurring epi-
sodes of hoarseness, coughing, flushing, pruri-
tus, and rash appearing within 30 min of
topical exposure to CCP. She was a clerk/typist
with frequent exposures to CCP during her
working hours. Cutaneous application tests
were performed using six chemical ingredients
of CCP. Approximately 15 min after 1%
alkylphenol novolac resin dispersion was
rubbed onto her forearm, she was noted to de-
velop hoarseness, wheezing, and angioedema
of both arms. A subsequent challenge with the
material was followed by hoarseness, wheez-
ing, and angioedema at the challenge site.
Video endoscopy of the larynx was interpreted
as showing diffuse swelling and marked edema
of the true vocal cords. Plasma histamine
levels obtained at the onset and peak of symp-
toms were sixfold higher than the prechallenge
level.
The second case described by LaMarte et al.
[1988] was a coworker of the patient in the first
case. This 45-year-old woman had a 6-month
history of hoarseness, coughing, flushing, and
localized angioedema subsequent to skin con-
tact with CCP. She was challenged by rubbing
1% alkylphenol novolac resin onto one arm
and was reported to have angioedema of the
arm and hoarseness 30 min after the challenge.
The authors concluded that the reaction was
mast cell/basophil-mediated, that these cases
demonstrate a connection to a specific compo-
nent of CCP, and that they indicate a poten-
tially life-threatening adverse reaction in
susceptible patients.
Hammel 1990. Hammel [1990] reported the
results of a NIOSH Health Hazard Evaluation
of a U.S. consumer refrigeration manufacturer
employing 2,600 workers, including 900 office
personnel. CCP was used in all departments,
but most users were in the export and purchas-
ing departments. Medical interviews were per-
formed for four workers who felt that their
health problems were associated with CCP ex-
posure. Two of four workers had developed re-
current episodes of hoarseness, coughing,
flushing, pruritis, and rash, which would occur
within 30 min of handling CCP. The third
worker described having nausea and dizziness
when handling one type of CCP form but not
other types. The fourth worker developed red-
ness and itching on the edges of both hands
when handling CCP forms (a dermatitis that
resolved during weekends). Symptoms im-
proved in all four workers when they avoided
exposure to CCP. Two of the four workers be-
came so sensitized that they could not be in the
vicinity of CCP without being hoarse. Medical
evaluations confirmed acute systemic reac-
tions to CCP (laryngeal edema and sixfold in-
creases in plasma histamine levels) after
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blinded, provocative, cutaneous challenges
with alkylphenol novolac resin, a component
of CCP. Subsequently, both workers devel-
oped hoarseness as a response to other chemi-
cals such as paint, wall paper adhesives, and
colognes. Job rotation to positions with mini-
mal or no contact with CCP effectively allevi-
ated health problems in all four workers.
Kanerva et al. 1990a,b; 1993. Kanerva et al.
[1990a,b; 1993] investigated the case of a
43-year-old machinist in Finland whose work
involved the manufacture of CCP and who de-
veloped occupational dermatitis on the hands.
The worker was a healthy man with no previ-
ous skin disease. He had been employed by the
same paper-making company for 23 years.
During the last 4 years, he was exposed to the
agents used in the CCP manufacturing sys-
tem—initially, just on the weekends. After a
new microcapsule machine was introduced,
the patient was given the responsibility of get-
ting the machine into operation. Because of
problems with the new machine, his exposure
exceeded what would have been expected in
normal use. He had direct contact with the
microcapsule dispersion and contracted hand
dermatitis within a month of the installation of
this new machine. Vesicular eczema devel-
oped on both hands but cleared over a 3-month
sick leave followed by vacation. Upon return-
ing to work, the worker relapsed.
Skin-prick testing was negative for 20 com-
mon allergens and natural rubber latex. On
skin-patch testing using a series of standard
European allergens and CCP, both CCP and
one of the chemicals used to produce the micro-
capsules of CCP provoked a strong (3+) aller-
gic reaction. Analysis of the paper showed that
it contained enough DETA to induce allergic
contact dermatitis. The patient tested negative
to ethylenediamine, para-phenylenediamine,
hexamethylenetetramine, 4-tolyldiethanolamine,
and triethanolamine; but he cross-reacted to
triethylenetetramine  and diaminodiphenyl-
methane.
Twenty control subjects were skin-patch tested
with the microcapsule dispersion substance,
the microcapsule paste, and the paper. They all
reacted negatively.
The source of the DETA in this case was its use
as a cross-linking agent that was added to a so-
lution of color formers in a suitable organic
solvent and then mixed with a polyisocyanate.
The authors commented that DETA remained
even though the vendor claimed that the pro-
cess ensures that all of the polyisocyanate has
reacted. The authors recommended that work-
ers who handle CCP and develop symptoms of
contact dermatitis be skin-patch tested with
DETA. This patient was the only one who re-
acted to DETA among the 20 to 30 subjects
tested each year since 1986 at the facility—ex-
cept for a painter who also tested positive to
ethylenediaminetetraacetic acid (EDTA),
which was a component of the hardener in an
epoxy resin paint.
Burton and Malkin 1993. Burton and Malkin
[1993] responded to a management request
based on a report that a former worker at the
Michigan Printers in Chicago, Illinois, had suf-
fered adverse reactions to CCP and solvents.
They conducted an industrial hygiene and medi-
cal survey. The facility employed 12 workers in
check printing and other offset printing on
CCP. Samples of personal breathing zone and
area air quality were analyzed for printing sol-
vents and metal particles. Workers were inter-
viewed and work practices were observed. The
ventilation units appeared to be operating well
and were well maintained. The authors con-
cluded that workers were not overexposed to
organic solvents or metals at the time of the
survey. Of the 11 workers interviewed, 1 re-
ported chest tightness and cough. The former
employee (on which the investigation was
based) had reportedly experienced cough,
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rhinitis, headache, and rash when using CCP;
however, management reported that the cur-
rent CCP was a different brand than that used
by the former worker. The authors were unable
to evaluate the effects of the previously used
CCP and concluded that no symptoms were re-
lated to the current use of CCP.
Sim and Echt 1993. In response to a request
from the Health Commissioner for Kentucky,
Sim and Echt [1993] investigated an outbreak
of skin disorders among 10 laboratory work-
ers at the Health Services Building in Frank-
fort, Kentucky. Workers were concerned about
their symptoms, which they felt resulted from
contact with CCP forms that accompanied the
biological specimens analyzed in the laborato-
ries. Itchy skin and rashes on exposed skin and
areas where clothes rub were reported in early
May of 1993, soon after the start of fibrous
glass insulation installation in the mechanical
rooms that housed the air-handling units for
the laboratories. Symptoms were reported
more often in the early part of the week, were
less severe in the latter part of the week, and
usually resolved on the weekends. The symp-
toms tended to recur upon returning to work
the following week. Several nonskin symp-
toms were reported during medical interviews
with some workers, including breathing diffi-
culties, headaches, sinus infections, irritated
eyes, and a tingling sensation of the nose and
lips. Three of the workers reporting skin symp-
toms did not handle CCP forms. The number of
workers with symptoms who handled CCP was
not reported. Although a new printing of CCP
forms occurred at the beginning of 1993, the
manufacturer indicated that no change to the
forms had recently occurred. The nature of
some of the symptoms was consistent with the
irritant dermatitis caused by exposure to insu-
lation, and the onset of symptoms also coordi-
nated well with the timing of this operation.
The authors concluded that the most likely
cause of the symptoms was irritant dermatitis
due to contact with glass fibers.
Zimmer and Hadwen 1993. See Section 3.2.1
for a description of this study.
Ziem and McTamney 1997. In the United
States, Ziem and McTamney [1997] published
a case series of patients assigned the diagnosis
of multiple chemical sensitivity (MCS). MCS
is a controversial diagnosis used by some prac-
titioners to refer to illness in persons who typi-
cally describe multiple symptoms attributed to
numerous and varied environmental chemical
exposures in the absence of objective, diagnos-
tic physical findings or laboratory test abnor-
malities that define an illness. A new name for
the condition—idiopathic environmental in-
tolerances—was recommended in 1996 by a
workshop organized by the International
Programme on Chemical Safety of the World
Health Organization [American Academy of
Allergy, Asthma, and Immunology 1999;
Miller 1997]. Cullen [1987] proposed the most
commonly referenced definition of MCS: an
acquired disorder characterized by recurrent
symptoms that (1) are referable to multiple or-
gan systems, (2) occur in response to demon-
strable exposure to many chemically unrelated
compounds at doses far below those known to
cause harmful effects in the general popula-
tion, and (3) do not correlate with any single
widely accepted test of physiological function.
The Interagency Workgroup on Multiple
Chemical Sensitivity [1998], in reviewing
three categories of proposed theories of causa-
tion (immunological, neurological, and psy-
chological), found many variations and
theories that were interrelated.
Two of 91 patients attributed their conditions
to CCP. For one of these patients, few immu-
nologic changes were demonstrated, and most
of the values were within normal limits. The
authors believed that immune measures pre-
and post-challenge testing were unlikely to
show major changes and were therefore not di-
agnostic of specific MCS etiologies. They re-
ported that after being away from exposure for
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many months, this patient showed significant
clinical improvement. They also mentioned that
another investigator had seen chemical sensi-
tivity in about 100 patients with substantial oc-
cupational exposure to CCP, but this
information was unpublished.
Smith et al. 1999. In the United Kingdom, a
49-year-old male forklift driver at a paper mill
producing CCP described a 2-year history of
hand dermatitis and was diagnosed as having
fissured hyperkeratotic eczema of the thumbs.
He responded positively to patch testing with
para-phenylenediamine in a standard series;
and when tested with a dye series, he reacted to
the azo dye Disperse Orange 3. Several azo
dyes were used at the mill to produce colored
paper; the patient’s job entailed transportation
of dye containers. Skin contamination was
thought to have occurred during the collection
of the used dye containers. Work restrictions
from handling the dyes led to resolution of
the hand dermatitis. The azo dyes were not
likely to have been part of the CCP system, but
they were used as a background color for the
paper; the authors did not explain the use of the
dyes.
4.2.2 NIOSH Docket Submissions
4.2.2.1 Unpublished Case Reports and
Case Series Submitted by
Individuals
This subsection describes case reports or case
series that were submitted to the NIOSH
docket from sources other than CCP manu-
facturers in response to the 1987 and 1997
Federal Register notices regarding CCP
[52 Fed. Reg. 22534 (1987); 62 Fed. Reg.
8023 (1997)]. Twenty-six cases involving
health effects attributed to CCP were sub-
mitted. The sex of the respondent is men-
tioned in 14 cases, all of which were female.
Age was mentioned in 11 cases. Mean age
was 43, with a range from 32 to 55. Symptoms
were reported in 23 cases. Multiple symptoms
were attributed to CCP in many cases, with
5 or more symptoms reported in 14 of the 23
cases. The most common symptoms attributed
by patients or their doctors to CCP included skin
symptoms (irritation, rash), respiratory
symptoms (breathing difficulty/shortness of
breath, nasal/respiratory irritation, lip sores,
frequent colds, hoarseness or loss of voice),
eye symptoms (eye irritation, blurred vision,
eyes feeling swollen and hurt), and general
symptoms (fatigue, dizziness, vertigo, lack of
energy, fever, malaise, trouble thinking/fo-
cusing, and weakness/pain of muscles in gen-
eral or specifically of the legs, back, or arms).
Some information about laboratory workup
was provided in eight cases. Immunologic
testing, performed in six cases, was extensive
but used tests of unknown utility. Small devia-
tions from laboratory normal ranges were at-
tributed to or said to be compatible with
immunotoxicity. Extensive neuropsychiatric
testing was reported in seven cases, and ab-
normal results were attributed to or said to
be compatible with neurotoxicity. Sophisti-
cated neuroimaging studies such as magnetic
resonance imaging (MRI) scans of the brain
and single positron emission computed to-
mography (SPECT) scans of the brain were
reported in three cases. Abnormalities in
SPECT scans of unknown importance were
often attributed to or said to be compatible
with neurotoxicity. Eleven of the subjects were
characterized as suffering from MCS or
“chemical sensitivity.” In four cases, symp-
toms were attributed to formaldehyde sensi-
tivity. Diagnoses of chronic Epstein-Barr
virus infection and chronic fatigue syndrome
were each made in one case. One subject re-
ported having been treated with “drops under
tongue of formaldehyde and petrochemicals.”
Another reported having been treated with “an-
tigen.”
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4.2.2.2 Inquiries about Health Effects
Submitted by CCP Manufacturers
NIOSH also received docket submissions from
CCP manufacturers describing inquiries they
had received about alleged adverse health ef-
fects associated with use of CCP. These inqui-
ries are summarized in this section.
Appleton Papers, Inc. 1987. A letter from
Duane Jones at Appleton Papers, Inc. (dated
August 18, 1987, and submitted to the
NIOSH docket) reported that from 1976 to
1986, Appleton received an average of six in-
quiries per month (with a range of one to nine
per month) regarding skin, headache, nausea,
odor, breathing, eyes, nose, mouth, and un-
specified symptoms. No seasonal or other pat-
terns were reported in the frequency of
symptoms. Table 4–2 summarizes these data.
Other details are contained in the NIOSH
docket submission.
Moore Business Forms, Inc. 1987. An Au-
gust 24, 1987, letter to Richard Lemen from
Dr. Norman Macaulay of Moore Business
Forms, Inc., noted that in the past 5 years (1982
to 1987), Moore had received only 23 inquiries
concerning CCP, and only 6 of 7,500 custom-
ers had inquired about skin irritation that they
thought was associated with CCP. Also, Moore
had produced 13 billion CCP forms during the
previous year.
CCP Manufacturers 1998. A letter dated
October 6, 1998, was received from Robert G.
Tardiff, Ph.D. (representing the CCP manufac-
turers in the United States) in response to a
query from NIOSH. The Institute had asked
whether the end users of CCP were reporting
to the CCP manufacturers and sellers any
health-related symptoms that might be perceived
to be associated with CCP in the workplace
over the last 10 years (1987–1996). Each of the
five U.S. manufacturers contributed data, which
were normalized to the amount of paper sold
yearly. The letter stated that the figure might be
overestimated, based on the following ratio-
nale: (1) customers, unsure of which manufac-
turer’s paper was and is being used, might have
addressed the same inquiry to several different
companies; (2) a customer might inquire at dif-
ferent levels within the manufacturing and dis-
tribution chain, with each contact being treated
as a separate report; (3) a consumer might
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Table 4–2. Summary of health-related inquiries from customers




Headache, nausea 46 5.2
Odor 151 17.4
Breathing 33 3.3
Eyes, nose, throat 108 12.4
Unspecified 284 32.7
Total 868 99.3
inquire repeatedly over time to the same com-
pany regarding the claim of a single
health-related symptom; and (4) inquiries
received at one CCP company might not re-
late to that company’s products, since some
sample CCP forms submitted were those of
manufacturers.
The letter further explained that most of the in-
formation they receive is anecdotal and incon-
sistent in terms of type, quantity, and quality of
information, including the circumstances of
product use. Most often the inquiry is received
indirectly from merchants, printers, brokers,
etc. The yearly average of health-based inqui-
ries is stated to include claims from companies
alleging health symptoms and may or may not
have included the regular inquiries. Further-
more, some inquiries do not state the number
of workers affected and are thus treated as a
single inquiry. Some of the inquiries result
from odors associated with CCP. Also, some
inquiries result from news articles and may
have no temporal relationship with actual ex-
posure. For the years 1987 to 1996, the yearly
average (±standard deviation) for health-based
inquiries for all U.S. CCP manufacturers was
113 (±4) for 960,115 (±6,473) tons of paper
sold—or approximately 1 inquiry per 10,000 tons
of CCP sold (equivalent to less than 1 inquiry
per 1 billion 8.5- × 11-in. sheets). The informa-
tion was examined for trends by the companies.
They found an increasing volume of CCP sold
during the period 1987–1992, with a corre-
sponding increasing rate of inquiries followed
by an apparent sharp decrease in health inqui-
ries over the last 5 years (1992–1996) (see Fig-
ure 4–1). CCP manufacturers have provided no
descriptive details (such as conditions of work
or volume of CCP used) for the health com-
plaints that led to the reported inquiries.
4.2.3 Cross-Sectional Studies
The cross-sectional studies reviewed in this
section were conducted to evaluate either the
potential health effects of indoor air contami-
nants in general or those of CCP specifically.
Both types of studies are summarized in Ta-
ble 4–3. In both cases, the information about
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Figure 4–1. Production of CCP and number of inquiries per year for all U.S. manufacturers
from 1987 to 1996. (Source: Graves et al. [2000]. Reprinted with permission. Copyright© by
Academic Press.)
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Studies of indoor air contaminants:
Skov et al. 1987, 1989 Denmark Questionnaires were sent to
4,369 municipal workers in
different buildings. Ambient
measurements were taken for







Clerks had the highest
frequency of mucosal
irritation; social workers had
the highest frequency of
general symptoms. Other
significant correlations with
mucosal irritation and general
symptoms included sex, job
category, photoprinting, and
VDTs. Older buildings had




buildings. Handling CCP was
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Zweers et al. 1992 Netherlands Authors surveyed 10,500
workers in 61 office
buildings.
Unknown Unknown Unknown The study found statistically
significant associations of
handling CCP with oronasal
symptoms (OR=1.18),





elevations found for eye and
fever symptoms.
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Mendell 1991 and Fisk et al. 1993 United States Authors surveyed 880 office




measures of air quality were
taken.
142 82 58 Increased prevalence of some
symptoms was associated with
several job and workspace
factors—including the
presence of carpet, the use of
CCP and photocopiers, space-
sharing, and distance from a
window. Statistically
significant associations were
observed between use of CCP
and symptoms such as eye,
nose, or throat (OR=1.6) and
chest tightness/difficulty
breathing (OR=2.3).
Zweers et al. 1992 Netherlands 10,500
61
Unknown Unknown Unknown The study found statistically
ignificant associations of
handling CCP with oronasal
symptoms (OR=1.18),





elevations found for ye and
fever symptom .
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Jaakkola and Jaakkola 1999 Finland Authors conducted a
population-based, cross-
sectional questionnaire




910 Unknown Unknown Statistically significant
associations (ORs) observed
between work with CCP (34%
of population) and symptoms
such as eye (OR=1.56), nose
(OR=1.48), pharyngeal
(OR=1.89), and skin symptoms
(OR=1.68); headache
(OR=1.66); and lethargy
(OR=1.38). The ORs for
chronic respiratory symptoms
and some measures of
respiratory infection (acute
bronchitis and sinusitis) were
significantly elevated
(ORs=1.3–1.8). In contrast,
only the OR for the common
cold was significantly
elevated in those performing
photo-copying, as were the
ORs for otitis and general
symptoms in those using
VDTs.

































Table 4 3 (Continued). Sum ary of cross-sectional studies that used questionnaires to assess
the health effects of indoor air contaminants in general or CCP specifically
Table 4–3 (Continued). Summary of cross-sectional studies that used questionnaires to assess










Fristedt and Pettersson 1980 Sweden Authors surveyed 3,000
workers and described those
with complaints.
180 122 68      A greater incidence of skin
symptoms was reported with
clay-based CF than with




CF than with clay-based CF.
Andersson et al. 1980 Sweden Authors surveyed subjects at 
5 sites comparing atopics











Increased complaints of skin,
eye, and mucous membrane
irritation were associated with
CCP. More frequent itching
and dry skin were reported in
atopic patients or those with
existing skin disease than in
nonatopic patients or those
lacking prior skin symptoms.
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Öberg 1980 (cited in Murray
1991†)
Sweden Authors surveyed 205
workers; 74% handled more
than 10 CCP forms daily.
205 82 40 Respondents complained of
itching and dryness of the
hands, eyes, and mouth;
4 reported eczema.
Sondergard 1981 (cited by
Murray 1991 and Olsen and
Mørck 1985†)
Sweden Surveyed offices of an
airline.
93 68 73 Symptoms not described;
dose-response connection
was not statistically
significant because of small
numbers of workers in two
groups.
Menné et al. 1981 Denmark Authors surveyed those




1,855 208 11 5.1 % of men (32 of 624)
and 14.3% of women (176
of 1,231) reported skin
symptoms or mucous
membrane irritation.
Symptoms were unrelated to
the type of building in
which subjects worked. A
dose-response relationship
was noted.
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Göthe et al. 1981 and




paper, or carbon paper;
used a comparison group
of 22.
Unknown 58 Unknown The prevalence of mucous
membrane symptoms (P<0.01)
was greater with CCP than
with ordinary bond or carbon
paper.




       workers
Hospital office workers














sheets (unspecified no.) and
office controls who handled
no CCP. Symptom
prevalence: 92%, 32%, and
10%, respectively.
Kleinman and Horstman 1982 United States Authors surveyed workers in
61 U. of Washington offices
with heavy CCP use.
Subjects were asked about
symptoms caused by CCP;
respondents had a physical
examination.
265 71 27 Significant dose-response
relationship reported
between CCP use and
health complaints.
Estimated minimum rate of
complaints across different
offices was 11%.
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court office and 8 age-
and sex-matched controls
in accounting office.
8 Unknown Unknown Eye, nasal, and throat com-
plaints were higher in CCP-
exposed workers than in con-
trols, but numbers were too
small for meaningful
comparison.
Olsen and Mørck 1985 Denmark Authors surveyed employees
of 2 form-printing shops.
129 40 31 31% reported skin and mucous
membrane symptoms; 22.5%
reported skin symptoms only.
Omland et al. 1993 Denmark Authors surveyed 20
government office workers
handling large amounts of
CCP and a comparison
group of 20.
20 10 50 Increased incidences of pruri-
tus (P=0.007) and skin irrita-
tion (P=0.03) were associated
with CCP. A dose-response re-
lationship was established be-
tween pruritus and increased
handling of CCP (P=0.049).
Apol and Thoburn 1986 United States Authors surveyed 65
employees making CCP.
Ambient evaluation was also
performed.
65 Unknown               —     No numbers were presented.
Maintenance workers in the
coater area reported the most




*The number of CCP-exposed workers surveyed was not generally known except for those responding to the surveys; therefore, response rates were unknown.
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health effects (symptoms) was generally iden-
tified by surveys of workers using a question-
naire. A major concern with studies based on
questionnaires is the potential for overreporting
of symptoms, particularly when the study sub-
jects are already concerned about the exposure
being studied.
This concern is greater for the CCP studies
than for the indoor air quality studies be-
cause the CCP studies were generally con-
ducted at facilities where complaints of
symptoms were allegedly related to CCP. The
indoor air quality studies were not conducted
in facilities where complaints were related to
CCP, and thus they are generally considered to
provide better information than the CCP
cross-sectional studies. The indoor air quality
studies and the CCP studies are considered
separately below.
4.2.3.1 Cross-Sectional Studies of
Indoor Air Contaminants
A number of studies on indoor air quality
have associated CCP exposure (and other fac-
tors) with workers’ symptoms (Table 4–3).
Three indoor air quality studies—Knave et al.
[1985], Reinikainen et al. [1990], and Thomp-
son [1996]—are not included in this review
because they were judged to be largely uninfor-
mative with respect to potential health effects
associated with CCP exposure. One common
limitation of the studies described below is that
they generally include only two or at most three
categories of CCP exposure and thus provide a
very limited assessment of exposure-response.
Skov et al. 1987, 1989. Skov et al. [1987]
conducted a cross-sectional survey of office
workers and indoor climates in 14 town halls
and other affiliated buildings in Copenhagen.
Researchers administered a questionnaire to
4,369 workers and measured indoor climate
factors in town halls. The return rate for the
questionnaire was 80%. Measurements of the
many indoor climate factors yielded values
considered acceptable or within a typical
range for office buildings as previously re-
ported. The analysis showed that the follow-
ing tasks were significantly correlated with
the presence of mucosal and general symp-
toms: photocopying, working at video display
terminals (VDTs), and handling CCP. How-
ever, in this univariate analysis the potential
exists for confounding between CCP, photo-
copying, and VDT exposures.
Subsequently, Skov et al. [1989] described the
influence of personal characteristics as well
as job-related and psychosocial factors on
indoor air quality complaints in the same
population. Of the 3,507 respondents (2,347
women), the CCP-exposed included 1,102
women and 424 men. For the 19 buildings
studied, numbers were sufficient for multi-
variate analyses. The questionnaire provided in-
formation about work activity, previous and
present diseases, the presence of mucous mem-
brane and general symptoms (headache,
fatigue, and malaise), indoor climate, family
and housing conditions, exercise habits, smok-
ing, and consumption of alcohol and other bev-
erages. Thirty-six percent (397) of these
women reported complaints, as did 26% (110)
of the men. In logistic regression analyses, sex,
type of job, and the following job activities
were significantly related to mucous mem-
brane symptoms: handling CCP (P<0.0001),
handling carbon papers (P<0.0001), photo-
copying (P<0.0001), working at VDTs
(P<0.0001), dissatisfaction with one’s superiors
(P<0.0001), and work overload (P<0.0001).
Crude prevalence rates showed a dose-response
between frequency of CCP exposure and mu-
cous membrane symptoms:
%
Monthly or less frequent use· · · · · · · · · 24
Weekly use of 25 sheets or fewer · · · · · · 32
Weekly use of more than 25 sheets · · · · · 43
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With multiple logistic regression analysis,
handling CCP weekly or daily had a significant
effect on mucosal irritation (odds ratio [OR]=1.3,
95% confidence interval [CI]=1.1–1.6), and han-
dling CCP was the only exposure with a signifi-
cant effect on general symptoms (see above;
OR=1.6, 95% CI=1.1–1.7). Also the authors com-
mented that these office workers handled rela-
tively small quantities of CCP.
Zweers et al. 1992. Zweers et al. [1992]
conducted a cross-sectional epidemiologic study
of indoor air quality and health effects in the
Netherlands. Approximately 10,500 workers
in 61 office buildings were studied. CCP usage,
which was not the primary focus of the study,
was ascertained in a questionnaire and analyzed
as a dichotomous variable—handling “more
than zero CCP per day” versus handling “zero.”
No usage prevalence was reported. Multivariate
logistic regression models adjusted for personal
variables, type of air-handling system, and
various job and workspace variables. Con-
trolling for some variables in the multivariate
models (e.g., allergic or respiratory symptoms)
may have underestimated actual CCP effects, as
these factors may themselves have resulted from
CCP exposures. Despite these limitations, the au-
thors found associations of CCP handling with
oronasal symptoms (OR=1.18, 95% CI=1.00–1.39),
perception of air contaminants (OR=1.48, 95%
CI=1.15–1.89), air quality complaints (OR=1.21,
95% CI=1.05–1.40), and lighting complaints
(OR=1.30, 95% CI=1.12–1.51).
Mendell 1991 and Fiske et al. 1993. Mendell
[1991] and Fiske et al. [1993] conducted a
cross-sectional epidemiologic study in North-
ern California among 880 office workers in
12 office buildings. A strength of this study,
unlike previous studies, was that the study
facilities were selected without regard to
worker complaints. Work-related symptoms
used in the analyses were defined as those that
“occurred often or always in the last year and
improved when away from work.” The
questionnaire response rate was 85%. A num-
ber of factors (including CCP) were associated
with the prevalence of work-related symptoms
after adjustment in a logistic regression model
for personal, psychosocial, job, workspace,
and building factors (Table 4–4). The OR was
not increased for a set of control symptoms in-
cluded to detect overreporting associated with
risk factors of possible concern (such as
air-conditioning or CCP). In multivariate
analyses adjusted for other workplace expo-
sures, the authors reported that the use of
CCP for more than 1 hr/day was associated
with increased ORs for the following: eye,
nose, and throat symptoms (OR=1.6, 95%
CI=1.0–2.6); chest tightness or difficult
breathing (OR=2.3, 95% CI=1.1–4.9); and
fatigue or sleepiness (OR=2.1, 95% CI=1.3–3.5).
Omland et al. 1993. See Section 4.2.3.2 for a
discussion of this study.
Jaakkola and Jaakkola 1999. Jaakkola and
Jaakkola [1999] conducted a cross-sectional
epidemiologic study of office workers in 41
randomly selected buildings in Helsinki in
1991. They used a questionnaire to investigate
associations of health effects with work in-
volving CCP, photocopying, and VDT use.
The populations studied had not been selected
on the basis of prior complaints or concerns
about CCP. The response rate to the question-
naire was 81%, representing a study popula-
tion of 2,678 (1,119 men and 1,559 women).
Of these workers, 910 were exposed to CCP.
The outcomes studied included the work-related
symptoms often associated with sick building
syndrome as well as chronic respiratory symp-
toms and respiratory infections. Multivariate
analyses controlled for building ventilation
type in addition to a number of demographic,
psychosocial, and other environmental factors.
Blinding to the specific study hypotheses re-
duced the likelihood of information bias in
reporting exposure.   Known confounders
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Table 4–4.  Job or workspace factors associated with the prevalence of work-related symptoms
after adjustment* for other personal, psychological, job, workspace, and building factors in
















OR† 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR  95% CI OR 95% CI
Managerial job 1.2 0.7–2.2 0.8 0.2–3.2 1.7 0.2–1.3 0.8 0.4–1.6 0.6 0.2–1.4 1.2 0.4–3.8 1.2 0.5–2.9
Case worker job 1.2 0.6–2.5 0.8 0.2–3.0 1.0 0.1–7.5 1.2 0.6–2.4 0.6 0.3–1.5 2.2 0.7–7.3 1.7 0.7–4.3
Technical job 1.9 0.9–4.0 0.5 0.1–3.1 3.1 0.4–2.3 0.5 0.2–1.1 1.3 0.5–3.2 2.5 0.8–8.2 1.6 0.6–4.6
Clerical job 1.3 0.8–2.1 1.3 0.4–3.8 2.9 0.5–1.7 0.9 0.5–1.5 1.2 0.6–2.4 1.5 0.6–3.9 1.7 0.8–3.5
CCP use more than
1 hr/day 1.6† 1.0–2.6 2.3 1.1–4.9 1.7 0.7–4.6 2.1 1.3–3.5 1.4 0.8–2.4 0.9 0.5–1.9 1.4 0.8–2.4
Photocopier use
more than 1 hr/day 1.6 0.8–3.1 1.7 0.6–4.7 0.4 0.1–2.1 1.4 0.7–2.8 1.5 0.7–3.1 3.1 1.4–6.9 1.4 0.6–2.9
Space-sharing with 
2 or more workers 1.3 0.9–1.9 2.0 1.0–3.9 1.3 01.21 1.6 1.1–2.3 1.8 1.2–2.7 1.6 0.9–2.8 1.4 0.9–2.2
New paint within
15 ft of workstation 0.6 0.3–1.1 0.5 0.2–1.6 0.9 0.2–3.5 0.4 0.2–0.8 0.7 0.4–1.4 0.5 0.2–1.2 1.0 0.5–2.0
New walls within
15 ft of workstation 1.4 0.8–2.4 1.9 0.7–5.0 2.2 0.7–7.0 1.3 0.7–2.3 1.8 0.9–3.4 1.5 0.7–3.4 0.8 0.4–1.7
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Table 4–4 (Continued). Job or workspace factors associated with the prevalence of work-related symptoms
after adjustment* for other personal, psychological, job, workspace, and building factors in
















OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR  95% CI OR 95% CI
New carpet within
15 ft of workstation 3.0 1.0–8.8 14.2 3.2–63 1.2 0.1–15 1.4 0.4–4.4 2.6 0.8–9.2 0.5 0.0–6.0 2.8 0.8–9.5
Carpet—any in
study space 1.7 1.1–2.6 2.5 1.0–6.2 1.4 0.5–3.7 1.1 0.7–1.7 2.0 1.1–3.4 0.9 0.5–1.8 1.1 0.6–1.9
Cloth partitions—
any in study space 0.5 0.3–0.8 0.2 0.1–6.2 0.5 0.1–1.6 0.5 0.1–1.6 0.6 0.4–1.1 0.5 0.2–1.0 1.2 0.7–2.0
No windows within
15 ft of workstation 1.6 1.1–2.3 1.6 0.8–3.2 2.4 1.1–5.6 1.5 1.0–2.5 2.1 1.3–3.3 1.6 0.9–2.7 1.3 0.8–2.1
Inability to see out
of window from
workstation 0.8 0.5–1.3 0.8 0.3–1.7 0.4 0.2–1.2 1.6 1.0–2.5 1.0 0.6–1.7 1.1 0.6–2.1 1.0 0.6–1.7
Source: Mendell [1991].
*ORs and 95% CIs were adjusted in a logistic regression model.

































(including personal characteristics, smoking, so-
cioeconomic status, and psychological and so-
cial factors at work) were controlled in the
analysis. CCP use was analyzed as “any” versus
“none.”
Statistically significant associations were ob-
served between work with CCP (involving
34% of the population) and most of the out-
comes studied—including weekly work-related
eye, nose, pharyngeal, and skin symptoms,
headache, and lethargy (ORs=1.56, 1.48, 1.83,
1.68, 1.66, and 1.38, respectively); chronic re-
spiratory symptoms including wheeze, cough,
mucus, and chronic bronchitis (ORs=1.29, 1.43,
1.41, and 1.79, respectively); and respiratory in-
fections including sinusitis and acute bronchi-
tis (ORs=1.46 and 1.54, respectively).
In contrast, only one of the 20 or so outcomes
assessed (the common cold) was significantly
elevated among workers with light or heavy
photocopying work, and two symptom catego-
ries (otitis and general symptoms) were ele-
vated for light or heavy VDT users. Additional
analyses focused only on VDT and photocopier
users; they identified several additional out-
comes related specifically to these activities.
This study provides strong support for the CCP
health effects hypothesis. The numerous
relationships found between health outcomes
and CCP use (but not between health out-
comes and photocopying or VDT work) make
overreporting due to health concerns in the ran-
domly selected buildings an unlikely explana-
tion for these findings.
4.2.3.2 Cross-Sectional Studies of
CCP Exposures
Sixteen cross-sectional studies using ques-
tionnaires to assess health problems in rela-
tion to CCP exposure were conducted in Swe-
den, Denmark, and the United States (see
Table 4–3). These studies attempted to
describe and estimate the prevalences of vari-
ous symptoms, primarily mucous membrane
and skin irritation associated with the handling
or manufacturing of CCP. A few of these stud-
ies had strong cross-sectional designs with ap-
propriate unexposed comparison groups,
ascertainment of symptoms independent of
workers’ opinions on their association with
CCP use, and multivariate analysis allowing
determination of the association with CCP ex-
posures independent of other factors. In
surveys with data on self-reported and uncon-
firmed symptoms that respondents subjec-
tively attributed to CCP handling, concern
about the use of CCP might (through
hypervigilance or enhanced recall) upwardly
bias estimates of symptom prevalence.
Fristedt and Pettersson 1980. Fristedt and
Pettersson [1980] conducted a questionnaire
survey of 180 persons (88% were women) in
Sweden. Of these 180 study subjects, 135 had
been identified in a previous survey† of the
Swedish Association of Municipal Technol-
ogy (SKTF) union as having reported symp-
toms related to CCP exposure. An additional
45 cases were identified from interview refer-
rals (i.e., workers who had not previously dis-
closed symptoms but were mentioned in
interviews with other workers). The average
duration of CCP exposure was 5 years (maxi-
mum of 18 years), with 87% handling paper for
more than 50% of their working time.
By correlating the time and use patterns, 68%
(122 workers) were thought to have symptoms
related to work with CCP, including some
workers in printing operations. Fifty-three
percent of this group with symptoms reported
mucous membrane symptoms (primarily of the
nose and eyes), and 47% reported skin symptoms
†In this previous survey, only 243 (8%) of the 3,000
persons surveyed responded to the questionnaire, which
raises serious concerns about the representativeness of
the respondents.
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(see Table 4–5). The skin disorders consisted
mainly of dryness that occurred first on the
hands and later on the face. The latter is
localized around the eyes and sometimes
combined with irritation of the eyes (assumed
to be caused by touching the face with the
hands). According to the authors, the most
striking disorders occurred among the 67 who
had a history of similar complaints or “a ten-
dency to allergy.” Of the 180 interviewees, 22
complained of an unpleasant smell that could
not be linked to a specific CCP. One
interviewee lost the sense of smell and taste,
and two stated that they no longer had feeling
in their tongues.
The authors stated that in the original survey
of 3,000 workers, 30% to 50% of the em-
ployees at some workplaces had complained;
but at others, no one had complained in spite
of massive handling of CCP. Workers who
handled clay-based papers reported skin disor-
ders more frequently than those who handled
polymer-based (phenolic) papers (71% [29/41]
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Table 4–5. Types and locations of skin and mucous membrane










































































Source: Fristedt and Pettersson [1980].
compared with 52% [36/69]). But those who
worked with polymer-based (phenolic) papers
reported mucous membrane disorders more of-
ten (81% [56/69] compared with 68% [28/41]).
Solvents used in the clay paper consisted of hy-
drogenated terphenyls plus kerosene, and
those in the polymer paper consisted of
phenylxylylethane plus diisopropylnaphthalene
[Norbäck et al. 1988]. Other numbers of symp-
toms were too small to discern patterns. Of the
35 workers who were skin-patch tested with
CCP, none had positive reactions. Environ-
mental factors such as high temperature, low
humidity, and dust were thought to be contrib-
uting. The authors concluded that it was diffi-
cult to decide which symptoms could
definitely be correlated with CCP. The preva-
lence of complaints was 4% of the 3,000 work-
ers who came in contact with CCP; but if slight
complaints of doubtful origin were ignored,
the prevalence was 2.4%. Symptoms were
more severe in those predisposed to allergy,
but no allergy to CCP components was demon-
strated. Also, the authors remarked that most
of the workers interviewed had reported ill
health symptoms only after the newspaper
publicity had appeared.
Andersson et al. 1980. This Swedish study
used a questionnaire to address CCP effects
among 158 workers at an insurance office
who had reported symptoms of the skin (irrita-
tion and itching of hands, forearms, and face),
eyes (itching and burning), and mucous mem-
branes (dryness of mouth and throat, nasal
stuffiness, and catarrh). To obtain comparative
data, the same kind of questionnaire was dis-
tributed to four other office places (183 per-
sons). The authors examined the type of paper
in question as well as other environmental fac-
tors. The prevalence of symptoms increased
when subjects were exposed to CCP or to
wall-to-wall carpeting. This increase was ob-
served in both atopic and nonatopic patients.
Öberg 1980. As cited in Murray [1991], Öberg
conducted a questionnaire study of 205 people;
74% handled more than 10 CCP forms per
day. Forty percent of the study population re-
ported symptoms, including itching and dry-
ness of the hands, eyes, and mouth. Four cases
of eczema were found. The author reports a
dose-response relationship, but Murray sug-
gests that information was inadequate to verify
this result.
Sondergard 1981. Sondergard [1981], as cited
by Murray [1991] and Olsen and Mørck
[1985], conducted a questionnaire study of
workers at two locations of Scandinavian Air-
lines Systems. The frequency of symptoms re-
ported was 73% (68 of 93 workers studied),
and the symptom frequency increased with the
amount of CCP handled daily (see Table 4–6).
The author noted that the dose-response con-
nection was not statistically significant be-
cause of the small number of workers in
Groups 2 and 4 (numbers were not reported by
the reviewers).
Menné et al. 1981. Menné et al. [1981] admin-
istered a questionnaire survey to workers at the
Danish telephone company; the authors also
performed a clinical evaluation of the cases
(see Section 4.2.1). Approximately 77% of the
workers responded to the questionnaire. Of
these, some were eliminated because they did
not handle CCP. Of the remaining 1,855 re-
spondents, 208 (11%) indicated that they had
experienced skin and/or mucous membrane ir-
ritation. Analysis revealed that the symptoms
were not related to the type of building in
which the subjects worked. According to the
authors, the number of CCP contacts per day




0–10 · · · · · · · · · · · · · · · 5
10–50 · · · · · · · · · · · · · · 15
>50 · · · · · · · · · · · · · · · 20
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The authors suggested that mass psychosis was
an unlikely explanation for their findings since
an exposure-response relationship was identi-
fied—not the all or nothing response expected
with mass psychosis. The authors also sug-
gested that mass psychosis was inconsistent
with the fact that no relationship existed be-
tween the age of the workers and the number of
complaints: they would expect younger work-
ers to have the weakest ties to the company and
thus to be more likely to report symptoms. In
rejecting mass psychosis as an explanation for
their findings, the authors suggested that some
component of the paper was responsible for the
observed symptoms.
Göthe et al. 1981 and Norbäck et al. 1983b.
Göthe et al. [1981] and Norbäck et al. [1983b]
presented findings about the frequency of re-
spiratory symptoms in three groups of Swedish
patients:
 Group A: 19 patients referred to the
Clinic of Occupational Medicine at
South Hospital
 Group B: 38 patients at the Karolinska
Clinic of Occupational Dermatology
 Group C: a random sample of 22 pa-
tients with no CCP exposure
The patients in Groups A and B were referred
during the period January 1976 to October 1980
because of health problems associated with oc-
cupational handling of CCP. However, be-
cause the authors did not describe the
population from which the patients were re-
ferred, population prevalence rates could not
be calculated. Among patients with health
complaints from handling CCP, roughly half
reported irritative symptoms involving the
eyes or upper respiratory tract, and 11%
(Group A) to 28% (Group B) experienced na-
sal catarrh or congestion. In the unexposed
group (Group C), 14% experienced ocular or
upper respiratory irritation, and there were no
cases of nasal catarrh or congestion. The dif-
ference in incidence between the exposed
groups (A and B) and the unexposed group (C)
was statistically significant (P<0.01) for eye
and upper respiratory irritation. The elevated
incidence of nasal catarrh or congestion was
statistically significant (P<0.01) in Group B
but not in Group A relative to the unexposed
Group C. Symptoms such as headache, fatigue,
nausea, and a metallic taste in the mouth oc-
curred at a low rate (1% to 9%), with no statis-
tically demonstrable correlation with the type
of exposure or the volume of CCP handled.
The results in Table 4–7 contrast patients in a
high-exposure group (150 sheets per day)
with those in a low-exposure group
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Table 4–6. Dose-response relationship of CCP handling frequency
with symptoms reported by respondents
Group








Source: Sondergard [1981] as cited by Murray [1991] and Olsen and Mrck [1985].
(<150 sheets per day). Patients were excluded
if they had irritation of the respiratory tract
that was not specifically related to work with
paper. The data show that throughout, the fre-
quency of complaints was higher in the
high-exposure groups than in the correspond-
ing low-exposure groups for all types of paper,
including ordinary paper. These data also dem-
onstrated a higher prevalence of work-related
respiratory symptoms in patients seen at
the clinic and exposed to CCP containing
MIPB—a solvent used in the microcapsules.
This prevalence rate was 100% in the
high-exposure group.
Norbäck et al. [1983b] also investigated
whether the dose-response associations might
be due to an increased proportion of sensitive
workers among those who handle large
amounts of paper. They determined whether
patients with atopy or nonspecific hyper-
reactivity of the respiratory tract were concen-
trated among these highly exposed
individuals. Atopy was assumed to be present
if the patient had a history of asthma or hay
fever or a tendency to develop eczema.
Nonspecific hyperreactivity was assumed to be
present if the patient had reported experiencing
respiratory tract irritation when exposed to
nonspecific irritants such as perfume, cigarette
smoke, and vehicle exhaust in the everyday en-
vironment. Fewer sensitive patients (P<0.05)
were identified among those who handled
large volumes of paper than among those who
handled small volumes of paper, indicating
that confounding by atopy could not explain
the observed exposure-response relationships.
These authors also investigated the role of
D-inks, which were present in about 20% of
the CCP. A significant increase (P=0.00009)
occurred in the prevalence of work-related pru-
ritus combined with erythema in those working
with CCP treated with D-ink versus those not
working with these inks (39% versus 0%).
Analysis of other contributing factors in this
population revealed that work involving pho-
tocopies or the presence of wall-to-wall carpet-
ing was not significantly correlated with skin
or mucous membrane symptoms. The authors
concluded that a significant dose-response
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Table 4–7. Frequency of respiratory tract symptoms
by type of paper and exposure level
*








in group Number % Total
Total
number
in group Number % Total
Paper containing
MIPB 6 3 50 5 5 100
Other CCP 21 4 19 26 13 50
Ordinary paper
and carbon
paper 7 0 0 15 3 20
Source: Göthe et al. [1981] and Norbäck et al. [1983b].





relationship could be shown only between ex-
posure to CCP and mucous membrane irrita-
tion of the upper respiratory tract. The authors
stated that the same phenomenon occurs with
ordinary paper and carbon paper but that CCP
can produce symptoms when lower volumes of
paper are handled.
Kolmodin-Hedman et al. 1981. At a clinic for
occupational medicine in Uppsala, Sweden,
Kolmodin-Hedman et al. [1981] conducted an
inquiry among those employed by an insurance
office (total of 145 workers) and a hospital
laboratory (12 workers). A comparison group
of 20 was composed of hospital office staff
who did not handle CCP. The investigation
was triggered by six cases in an insurance of-
fice; the main symptoms were irritation of the
upper respiratory tract. The prevalence of
symptoms was greatest in the hospital labora-
tory (92%), where about 1,000 forms were
handled per day by each of the five reception-
ists and seven computer operators. The insur-
ance office workers worked with fewer forms
(number not given) than the laboratory work-
ers; they reported a 32% prevalence. The com-
parison group reported a 10% prevalence of
symptoms. Of those in the insurance group who
complained of symptoms (46), 17 were diag-
nosed as atopic and 6 with underlying allergic
or eczematous conditions. Of the remaining 23,
one had symptoms connected with handling
“wet copies,” and another had a complaint that
was clearly linked to the use of a certain type of
stamp pad. The remaining 21 had skin and/or
mucous membrane complaints: 13 stated that
they had the most trouble at work, and 8 stated
that their symptoms were independent of
where they were. None of the six types of CCP
forms used were known to contain D-inks, and
three contained hydrogenated terphenyls,
diethylethane, and diisopropylnaphthalenes.
Two contained unknown solvents. Among the
workers who handled only clay-based paper at
the insurance office, the frequency of mucous
membrane symptoms was approximately
equal to that of the comparison group. The skin
(hands and face) and eye symptoms were con-
sidered likely to be related to CCP exposure,
since their frequency (21% among insurance
workers versus 67% in laboratory workers)
was much higher than that of the comparison
group (5%).
Kleinman and Horstman 1982. In the United
States, persistent health complaints attributed
to the use of CCP by office workers on the
campus of the University of Washington led to
a preliminary study by Kleinman and
Horstman [1982]. The goals were (1) to esti-
mate the extent of the problem in a population
of known CCP users, (2) to describe the health
problems that the users attributed to CCP, and
(3) to make a preliminary determination of the
chemical constituents of the paper. An un-
known number of office workers were asked to
complete a health questionnaire and to attach
to it copies of the forms they used. Among the
265 subjects respondng to the survey, 71
(27%) reported complaints. Across different
offices, the minimum estimate was 10.7 health
complainants per 100 users, similar to that
found by investigators in the United Kingdom
and Denmark [Calnan 1979; Menné et al.
1981], but this estimate was lower than that re-
ported by other investigators and by anecdotal
material. Of the 108 respondents who an-
swered “yes” (n=71) or “don’t know” (n=37)
to the question relating symptoms to CCP, 53
participated in a medical exam. The positive
findings are tabulated in Table 4–8. Kleinman




the amount of CCP used daily and worker re-
ports of health effects they attributed to CCP:
41.3% of the heavy users of CCP (those who
handled 51 or more forms/day) responded
“yes” to the question relating health effects
with CCP, compared with 29.9% of moderate
users (11 to 50 forms/day) and 18.8% of mini-
mal users (1 to 10 forms/day).The authors hy-
pothesized that concurrent factors such as poor
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ventilation, high temperature, and/or low hu-
midity might play a role in the clinical expres-
sion of CCP effects.
Pryor et al. 1983. In response to a request for a
NIOSH Health Hazard Evaluation, Pryor et al.
[1983] investigated complaints of respiratory,
eye, and skin irritation and one case of
thrombocytopenia at a Colorado municipal
court house. A questionnaire was administered
to eight employees who worked in an area with
intensive storage and use of CCP forms and
also to eight others who worked in an area with
little CCP contact. The CCP storage was im-
mediately next to 2- and 4-inch pipes carrying
hot water during the winter for heating the
building; these pipes were believed to be caus-
ing increased emissions from the CCP.
Heating CCP paper samples in the NIOSH lab-
oratory produced formaldehyde and also sub-
stituted biphenyls and terphenyls typical of
CCP. However, air samples taken in the office
at various times during the months of Decem-
ber and March identified only formaldehyde.
CCP-exposed workers during the month of
April had somewhat higher prevalences of
eye, nasal, and throat complaints (ranging
from 25% to 75%) than non-CCP-exposed
workers, whose symptoms ranged from 0% to
50%. However, small numbers precluded a
statistical test.
Olsen and Mørck 1985. Olsen and Mørck
[1985] administered a questionnaire and physi-
cal exams to the 129 workers at two Danish
form-printing shops. The authors confirmed
complaints that the CCP-exposed parts of the
skin exhibited “heavy erythema, combined
with irritative itching, vesicles, and wounds to-
gether with more chronic changes with
lichenification, furrows, and chaps.” The fre-
quency of symptoms increased significantly
(P<0.01) with the volume of CCP handling
(see Table 4–9).
Omland et al. 1993. Omland et al. [1993] in-
vestigated the extent to which handling large
amounts of CCP caused skin and mucous
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Table 4–8. Positive findings from physician interviews
of 53 respondents to a health questionnaire
Finding % total





Infected, itching, red conjunctiva 29.6
Red, swollen eyelids 20.4
Red face 17.0
Shortness of breath 15.1
Coughing 13.2
Red, crusted skin 7.5
Wheezing 7.5
Red arms 5.7
Adapted from Kleinman and Horstman [1982].
membrane symptoms in a cross-sectional study
of 20 Danish government workers who were
highly exposed to CCP and a comparison group
of 20 workers who were generally not ex-
posed. These groups were matched for sex,
age, location of workplace, known skin
diseases, history of childhood asthma, known
allergy to nickel, asthmatic conditions, chronic
bronchitis, eye diseases, nettle rash, and use
of tanning facilities. Double-blind derma-
tological exams included observations and his-
tories, skin-prick tests for allergens, scratch
tests for CCP and its components versus ordi-
nary paper, objective measures of dermal ery-
thema after occluded testing, and skin-patch
tests. Temperature, humidity, formaldehyde,
and total dust were measured. Two groups of
workers were exposed to CCP. Over a period
of 4 weeks, the first group of 5 sent out 120,000
identical forms printed on CCP that had been
stored in the work area. Their work consisted
of tearing off forms from a continuous paper
web and stuffing the forms into envelopes
(about 1,200 per day per worker). The second
exposure group of 15 workers processed the
42,000 returned forms over a 2-week period,
checking and entering information into com-
puters (about 280 per day per worker). The
comparison group was selected from 122 em-
ployees who worked in the same large office
building and had returned completed question-
naires about symptoms and exposure to CCP.
These questionnaires were administered weekly
during the exposure periods. They included
questions about CCP exposure, work with
computers and photocopying, and subjective
symptoms of skin and respiratory irritation.
Temperature was 23.5 NC and humidity was
about 40% in both offices. These were reported
along with six formaldehyde measurements,
(including both area and personal samples)
ranging from 0.1 to 0.62 mg/m3. Total dust
measurements were 0.34 mg/m3 in the study
office and 0.28 mg/m3 in the comparison group
office. Table 4–10 shows the incidence of
symptoms during both exposure periods
among the exposed workers and their matched
comparison workers. A significantly greater
incidence of skin irritation (P=0.03) and pruri-
tus (P=0.007) occurred in the exposed group
during the first exposure period. However, no
differences occurred in the incidence of
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Table 4–9. Dose-response relationship between CCP handling and
mucous membrane and skin symptoms in two form-printing shops
Workers with symptoms
Skin and mucous






of workers Number % Number %
0–5 26 0 0 0 0
6–20 26 0 0 0 0
21–75 28 9 32.1 5 17.9
76–250 25 14 56.0 10 40.0
251–2000 24 17 70.8 14 58
Total 129 40 31.0 29 22.5
Source: Olsen and Mørck [1985].























   worker 18 33.3 22.2 16.7 11.1 0 22.2 11.1 11.1 5.6 0 11.1
Exposed worker 5 60.0 20.0 80.0 0 20.0 100.0 0 60.0 0 20.0 60.0
Exposure period 2:‡
Comparison
   worker 16 25.0 25.0 25.0 6.3 6.3 18.8 12.5 6.3 18.8 0 12.5
Exposed worker 15 20.0 20.0 13.3 20.0 13.3 33.3 6.7 20.0 20.0 6.7 20.0
Source: Omland et al. [1993].
*Some comparison workers were unable to respond because they were absent from work.
†Workers were exposed to 1,200 fresh forms per day during period 1.

































symptoms reported by the exposed and com-
parison workers during the second exposure
period, which involved processing forms that
were several months old. Exposed workers re-
ported large decreases in most symptoms dur-
ing the second period, when they handled the
completed forms with broken microcapsules
(280/day) rather than the fresh forms
(1,200 per day) during the first period. These
symptom decreases during the second period
included a sixfold decrease in skin irritation
and threefold decreases in eye irri ta-
t ion, pruritus, nasal congestion, nose-
bleed, and cough. However, increases
occurred in facial erythema, rash, and runny
nose.
Figure 4–2 shows the relationship between
pruritus and increasing CCP exposure. Four of
the 18 comparison workers (22.2%) during the
first exposure period and 3 of the 16 compari-
son workers (18.8%) during the second expo-
sure period reported pruritus. Ten of the 20
workers (50%) exposed to CCP experienced
pruritus: 4 of 10 employees (40%) who worked
daily with 101 to 750 form sets, and 6 of 10
employees (60%) who worked with >750 form
sets reported pruritus. These results show a sta-
tistically significant increase in the prevalence
of pruritus with increasing exposure to CCP,
regardless of whether the responses were used
from the first exposure period (P=0.049) or the
second exposure period (P=0.03). Clinical ex-
amination revealed no significant differences
between atopic workers in the exposed and
comparison groups. The duration of pruritus
after histamine provocation was also the same
in both groups. Erythema index measurements
showed large variations, and no significant dif-
ferences existed between the reactions of
workers in the exposed and the comparison
groups to contact with paper, CCP, the con-
tents of the microcapsules, or a damping solu-
tion from CCP. Scratch tests with CCP were
negative, and skin patch tests with nickel
yielded four reactions in the exposed group and
one reaction in the comparison group. Al-
though these differences were not statistically
4 HEALTH EFFECTS


































Figure 4–2. Prevalence of pruritus among CCP handlers by sheets of CCP handled during
the exposure period.
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significant, the authors noted that the higher
number of nickel reactions in the exposed
group may indicate a higher prevalence of
atopic workers in that group and thus a poten-
tial bias in the study. No increased skin dryness
or desiccation was noted in the exposed or
comparison groups. Possible shortcomings of
this otherwise well-designed study are that
(1) the matched comparison workers were not
matched for the amount of ordinary paper they
handled, and (2) the matching does not appear
to have been considered in the analysis of the
data. Thus the study results may be potentially
confounded by the matching factors and by or-
dinary paper exposure. On the other hand, the
strength of the association (P<0.007) and the
evidence of an exposure-response relationship
(P=0.049) support an association of some
types of CCP with pruritus.
Apol and Thoborn 1986. See Section 4.2.1 for
a discussion of this study.
4.2.4 Laboratory Studies in Humans
This section reviews studies that used some
form of experimental testing in humans (such
as patch or prick tests) under controlled labora-
tory conditions to assess the potential health
effects of exposure to CCP or its components.
These studies are distinct from the laboratory
studies performed in some of the case studies
and cross-sectional studies reviewed earlier in
this chapter (see Sections 4.2.1 and 4.2.3),
which generally involved a few cases from a
specific company and did not employ a rigor-
ous experimental design. In addition to the
peer-reviewed literature, this section examines
unpublished experimental studies that were
usually sponsored by the U.S. manufacturers
of CCP and were submitted to the NIOSH
docket.
The experimental nature of laboratory studies
offers advantages over the observational stud-
ies described in earlier sections. These studies
do not have the potential for confounding or re-
call bias that the observational studies had.
However, laboratory studies also have limita-
tions that undermine their usefulness for judg-
ing the causal relationship between CCP
exposure and health effects. First, these studies
are largely limited to the inclusion of healthy
volunteers. A consequence of this approach is
that persons with a history of allergy or irrita-
tion reaction might be less likely to volunteer
than those with no symptoms, thus creating se-
lection bias. Second, it is unclear whether the
exposures in laboratory studies are representa-
tive of those actually experienced by workers
in the field. Third, most of the laboratory stud-
ies did not include ordinary paper as a control.
Thus it is not possible to determine whether
the effects observed in some studies result




Table 4–11 summarizes the three experimental
studies in humans that have appeared in the
peer-reviewed literature. These studies are dis-
cussed below.
Nilzen 1975. At the request of a CCP manufac-
turer, Nilzen [1975] of Sweden conducted pro-
vocative tests (including patch, prick, eye, and
nose irritation tests with water extracts) and va-
por inhalation studies with crushed CCP and
ordinary bond paper. The patch tests in eight
subjects were negative, but prick tests resulted
in an unspecified number of weak and me-
dium-strong reactions to both CCP and ordi-
nary bond paper. Two subjects were tested by
inhalation of vapors from CCP or bond paper,
and both resulted in irritation; however, the
CCP caused a greater reaction. The author con-
cluded that (1) certain persons with a history of
allergy or irritative reactions may react to CCP
as well as to ordinary bond paper and a variety
of other materials and (2) despite evidence of
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Table 4–11. Experimental laboratory investigations of allergic and irritative
reactions in humans exposed to CCP
Authors Country Number tested Agents Type of test
Comparison
workers Results




tests, eye and nose
irritation, inhala-





No positive patch tests; some weak
and moderate reactions to prick test
with CCP and ordinary paper; two
subjects had irritation reactions to











None Positive reactions to 2 types of
carbon paper. Slight irritation from
50% kerosene (1/59), 50%
isoparaffins (1/59). Slight redness
from 100% alkylated benzene (1/1),
but no reaction with a 50%
concentration (0/54). Primary
irritation from 2 D-inks (1 at 5%
concentration [19/44] and 1at 1%
[26/44]). CCP-exposed patients had
a longer duration of itch in tests
assessing skin response to
histamine. Two probable allergic
reactions to synthetic resin
components (1 to melamine
formaldehyde and 1 to resorcin). No
specific reactions to subjects’
exposures to their own CCP.

































Table 4–11 (Continued). Laboratory investigations of allergic and irritative reactions in humans exposed to CCP







28 Vapors from CCP
and bond paper
Nasal impedance None In clerical workers, nasal
impedance increased 34%
(P<0.025) after exposure to CCP
vapors and 8% after exposure to
plain paper (P>0.01). In atopic
workers, nasal impedance increased
significantly after exposure to both
CCP vapors (30% to 40%) and
plain paper.

































CCP reactions, nonreacting persons (those
without a history of allergy or irritative reac-
tions) can handle CCP without risk.
Jeansson et al. 1983, 1984. During patient
followup visits, the authors investigated pa-
tients who had complaints related to any type
of paper and who had been referred to an oc-
cupational dermatitis clinic in Sweden from
January 1974 to December 1980. Their com-
plaints included irritation of the eyes, nose,
throat, arms, face, and scalp; cold symptoms;
hoarseness; sores; itching, dryness, redness, or
eczema of the hands; unpleasant odor or taste;
fatigue; headache; nausea; joint pains; and a
feeling of paralysis.
Jeansson et al. [1983] appraised the chemical
contents of the papers by skin tests (patch and
scratch) and by other examinations of 148 pa-
tients. No controls were included in this study.
Three of the original 151 complainants were
lost to followup. The focus of the study was to
find the triggering chemical factor by (1) ex-
amining the chemical content and the toxico-
logical effects of the paper, (2) examining the
distribution of patients according to the sus-
pected cause of problems, and (3) investigating
the relative prevalence of contact allergies.
The complaints involved multiple brands of
CCP. Manufacturers submitted lists of the
composition of 13 brands of CCP on the Swed-
ish market along with samples of the chemicals
from the production process. The authors ap-
plied a series of patch tests using a standard
panel of 30 known antigens as well as samples
of paper (CCP, data paper, carbon paper, and
photocopying paper) and CCP components.
The tests were performed on 134 patients
(those with CCP-related complaints) using the
CCP with which they worked. Of these pa-
tients, about 50 were also tested with approxi-
mately 60 chemicals from the paper production
process. The authors tested the following CCP
components: those in the CB and CF surfaces
in both wet and dry preparations, saline
extracts of CCP, 62 chemical components
(representing about 95% of the components on
the Swedish market), 7 desensitizing chemi-
cals, and 3 adhesive products.
Specific antibodies (IgE, RAST) against dust
and molds were identified in 4 of 35 cases,
none of whom were among the patients with
CCP complaints. The authors noted that this
number was not an overrepresentation for a
group such as this. The only positive reactions
that occurred from any of the test materials
other than the standard ones were from two
types of carbon paper (not CCP). Slight irrita-
tion occurred when testing 50% kerosene (1 of
59) and 50% isoparaffins (1 of 59). Slight red-
ness (1 of 1) occurred with 100% alkylated
benzene, but no reaction occurred at repeat
testing with a 50% concentration in 54 test sub-
jects. Two of five D-inks produced primary ir-
ritation at 5% concentration: the first ink
resulted in a slight redness in 43% of patients
(19 of 44); and at 1% concentration, the second
caused slight redness in 59% of those tested
(26 of 44). “Itch” tests assessing skin response
to a nonantigenic stimulus (histamine) were
performed. Responses were measured as the
duration of the sensation of itch and the size of
the reddened area after administration of 3 con-
centrations of histamine below the epidermis.
Twenty patients having CCP-related com-
plaints were compared with 17 patients having
previous complaints about non-CCP paper.
The CCP patients suffered a significantly lon-
ger duration of itch (0.05>P>0.01 [Göthe et al.
1981]) than the matched comparisons; how-
ever, the area of redness did not differ between
the two groups. The authors commented that
the longer-lasting itch correlated with the
higher prevalence of mucous membrane irrita-
tion on exposure to CCP (65% versus 50%).
Among the patients examined with possible
CCP-related symptoms, no allergic or single
irritant mechanism was found to explain how
the handling of CCP directly resulted in
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medical problems. On the basis of the available
assays of irritant or allergenic potency, the au-
thors were unable to conclude that a specific
chemical was common to CCP complaints.
Two patients had probable allergic reactions to
components in the synthetic resins (one to mel-
amine formaldehyde and one to resorcin), but
those reacting to resins or solvents did not react
in patch tests to their own CCP. Other contrib-
uting factors were mentioned, such as the han-
dling of paper generally (i.e., carbon paper,
plain paper, CCP, etc.) and atopy. The authors
asserted that there were no differences by CCP
brand; however, because of the design of the
study (only symptomatic workers were in-
cluded) differences in prevalence or incidence
of symptoms across CCP brands could not be
assessed. The authors concluded (based on the
absence of a causal agent) that CCP was not the
leading suspect responsible for symptoms in
most of the patients exposed to CCP.
Morgan and Camp 1986. Morgan and Camp
[1986] conducted an experiment in the United
States under controlled laboratory conditions
to quantify upper respiratory congestion in
clerical workers reporting prior sensitivity
when exposed to CCP. Seventy percent of the
subjects reported having symptoms associated
with CCP use. These symptoms included dry-
ness, light-headedness, headache, dry mouth,
burning sinuses, dizziness, sore throat, tickle in
throat, sneezing, irritation, itching nose, con-
gestion in throat, and flushed face. The symp-
toms reportedly increased with increased use
of CCP and tended to dissipate rapidly when
the worker was removed from the exposure.
The authors used an objective measure of nasal
congestion—measurement of the nasal contri-
bution to the work of breathing (nasal
impedence) by posterior rhinomanometry. The
subjects were 28 clerical workers who reported
handling 1 to 200 CCP forms per day, with an
average of 90 forms per day. These workers
were subjected in random, single-blind fashion
to controlled exposures of vapors from two
sets of three-page, blue-dye CCP forms and to
vapors from plain bond paper. Any particles
released by the paper were removed by a
0.3-µm particle filter. Total hydrocarbon con-
centration during CCP exposure averaged
1 ppm. Nasal impedance increased 34% after
exposure to CCP forms (P<0.025) and 8% af-
ter exposure to plain paper (P>0.10). How-
ever, frequency of symptoms did not differ
between exposure to CCP and plain paper, and
they were not correlated with the nasal mea-
surements. The authors concluded that quanti-
tation of nasal congestion by this technique
may be a sensitive measure of short-term reac-
tion to inhalation of irritants. In subjects with a
history of allergy, changes in nasal function
were reported after exposure to both paper
types, but only the change after CCP exposure
was statistically significant (paired t-test,
P<0.05). In these patients, nasal aerodynamic
response to CCP vapor was significant even
with low concentrations of hydrocarbon expo-
sure, and objective changes were measured in
the absence of consistent subjective
complaints.
4.2.4.2 NIOSH Docket Submissions
RIPT Studies. NIOSH reviewed all of the in-
dustry-sponsored laboratory studies in humans
submitted to its docket as a result of the Fed-
eral Register notices in 1987 and 1997. Most
of these studies were RIPT studies, which are
summarized in Table 4–12. The RIPT is a test
method designed to evaluate the potential of
a material to induce and elicit type IV skin sen-
sitization reactions (allergic contact dermati-
tis) in humans [ASTM 1999]. In general, these
tests were performed by administering multi-
ple potentially sensitizing doses of study ma-
terial as occlusive patch tests over a
several-week period. After 2 to 3 weeks,
subjects were challenged with an additional
diagnostic patch test and evaluated for responses
consistent with allergic contact dermatitis.
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See footnotes at end of table. (Continued)
Table 4–12. Analysis of repeated insult patch test (RIPT) studies submitted by industry clients















(Y/N)§,¶ Current use of material
1955 E–107 Hill Top
Research, Inc.
“Internal phase” diluted 50% w/oil, CB,
CF, carbon, and base paper
ND ND — N Solution of CCP component;
end-user not exposed;
discontinuedi after 1971
1972 SH–72–4 Shelanski Holding
Co.
Monsanto Co. Lot QA-I-SHC No.
M–77 (100% Santosol 100 solvent only)
1/50 ND — Nc Component of CCP; 
end-user would not be exposed
1977 77–512–70 Hill Top
Research, Inc.
A. Paper, CF surface colored by
transfer from ruptured CB surface
0/71 NR — N Test materials discontinued in
late 1970s
B. Paper, CF surface not colored 0/71 NR — N




D. Dark liquid 3/71 N
1 1
2 2
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Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
77–512–70
(continued)
F. Purple granules 1/71 5 1 Yc
G. No sample —  — — —
H. Brown liquid   0/71** NR — N
I. Amber liquid 1/71 1 1 N
J. Paper, CB surface with ruptured
capsules
1/71 2 1 N
K. Paper, CB surface with intact
capsules
0/71 NR — N
1977 77–513–70 Hill Top
Research, Inc.
A. Code 29 CFB, sheets of paper (CF
surface colored from ruptured
capsules of CB surface)
0/12 NR — N Test materials discontinued in
late 1970s
B. Code 29 CFB, sheets of paper
(uncolored CF surface)
0/12 NR — N
C. 24W CB (E73–8) plus, blue liquid 0/12 NR — N
D. Code 23 oil plus, blue liquid 1/12 1 1 N
E. Code 24 CB (E73–8) dried, white
powder
0/12 NR — N
F. Code 24 CB (E73–8) plus, light
blue powder
1/12 1 1 N
G. No G sample N/A NR — N

































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
77–513–70
(continued)
I. Code 27 oils, amber liquid 0/12 NR — N
J. Code 29 CFB, sheets of paper (CB
surface with ruptured capsules)
0/12 NR — N
K. Code 29 CFB, sheets of paper
(CB surface with intact
capsules)
0/12 NR — N
1977 77–896–71 Hill Top
Research, Inc.
A. CF surface colored by transfer from
CB surface













































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
77–896–71
(continued)
D. No description 3/97 N
1 1
3 2
E. Code 24 CB (E73 dried) 2/97 N
1 1
2 1




G. No G sample — — — —
H. Code 28 oil 0/97 NR — N
I. No description 1/97 2 1 N





































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
77–896–71
(continued)




1977 77–926–71 Hill Top
Research, Inc.
A. Not identified 1/163 1 1 N Test materials discontinued in
late 1970s
J. Not identified 2/163 1 2 N
K. Not identified 4/163 N
1 3
4 1
1978 78–557–71 Hill Top
Research, Inc.
A. Blue print internal phase, liquid  85/211 N Solution of CCP component;







B. Blue print emulsion, lavender liquid 0/211 NR — N
C. Blue transfer paper, off-white paper 2/211 1 2 N

































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
78–557–71
(continued)
E. Black print capsule slurry, lavender
liquid
0/211 NR — N
F. Black transfer paper, off-white
paper
2/211 1 2 N
G. Internal phase black print, liquid 1/211 1 1 N
H. Black print self-contained capsules,
lavender liquid
1/211 2 1 N
I. Self-contained black, off-white
paper
5/211 1 5 N
1978 78–578–70 Hill Top
Research, Inc.
A. CF surface colored by transfer from
CB surface
1/152 2 1 N Test materials discontinued in
mid-1980s
B. CF surface uncolored†† 1/152 1 1 N
J. CB surface used in developing color 0/152 NR — N
K. CB surface with intact capsules 0/152 NR — N
1979 79–512B–70 Hill Top
Research, Inc.
A. Imaged CF colored ruptured
capsules of CB surface
1/2 ND — Nc Not known
B. Unimaged CF surface 0/2 ND — N
1979 79–0002–73 Hill Top
Research, Inc.
A. CFB CF surface colored 1/166 2 1 N Test materials discontinued in
mid-1980s

































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
79–0002–73
(continued)
C. CB surface ruptured capsules 2/166 N
1 1
2 1
D. CF surface colored 0/166 NR — N
E. CF surface uncolored 1/166 2 1 N
F. CB surface ruptured capsules 0/166 NR — N
1979 79–0085–73 Hill Top
Research, Inc.
A. CF surface, colored 1/151 3 1 Nc Test materials discontinued in
mid-1980s
B. CF surface uncolored 1/151 3 1 Nc
C. CB surface ruptured capsules 0/151 NR — N
D. CB surface capsule not ruptured 0/151 NR — N
E. CF surface colored, code 94 2/151 Yc
1 1
5 1



































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
79–0085–73
(continued)
G. Code 94 CB, ruptured capsule 2/151 N
2 1
4 1
H. Code 94 CB, capsules not ruptured 1/151 4 1 N
1979 79–0246–73 Hill Top
Research, Inc.




B. CF surface uncolored 2/136 N
3 1
4 1
C. CB surface, ruptured capsules 1/136 2 1 N
D. CB, unruptured capsules, code 95 2/136 N
1 1
4 1
E. CF colored 2/136 1 2 N
F. CF uncolored 1/136 4 1 N



































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
79–0246–73
(continued)
H. CB, unruptured capsules, code 96 0/136 NR — N
1979 79–0801–73 Hill Top
Research, Inc.
A. Yellow paper CB surface
unruptured capsules










C. Yellow paper uncolored CF surface 1/122 1 1 N





E. White paper self-contained surface
of paper imaged
2/122 2 2 N





































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
1980 80–0079–73 Hill Top
Research, Inc.
A. 118 CF surface uncolored
(unimaged)
0/99 NR — N Test materials never marketed
B. 118 CF surface colored (imaged) 1/99 1 1 N
C. 121 CB surface unruptured capsules 0/99 NR — N
D. 121 CF surface uncolored
(unimaged)
0/99 NR — N
E. 121 CB surface ruptured capsules 0/99 NR — N
F. 121 CB surface colored
(imaged)
0/99 NR — N
G. 122 CB surface unruptured
capsules
0/99 NR — N
H. 122 CF surface uncolored
(unimaged)
0/99 NR — N
I. 122 CB surface ruptured
capsules
0/99 NR — N
J. 122 CF surface colored
(imaged)
0/99 NR — N
1981 81–0138–73(2) Hill Top
Research, Inc.
B. T–3012PP—White paper 0/207 §§ §§ N Discontinued in mid-1980s
C. T–3013PP—Pink paper 0/207 ¶¶ ¶¶ N
1983 83–0305–70 Hill Top
Research, Inc.
C1.  Pink paper, CB surface with
        unruptured capsules
0/93 NR — N Not repeatable results; test
materials discontinued in
mid-1980s

































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
83–0305–70
(continued)
C3. Pink paper, CB ruptured capsules 0/93 NR — N
C4. Blue and imaged pink paper CF
(blue) surface with color transferred
from ruptured capsules
0/93 NR — N
D1. White paper, CB surface with
unruptured capsules
0/93 NR — N
D2. White paper, CF uncolored surface 1/93 1 1 N
D3. White paper, ruptured capsules, CB
surface
0/93 NR — N
D4. Blue and imaged white paper CF
(blue) surface with color transferred
from ruptured capsules
0/93 NR — N
1983 83–3592H Biosearch Moore Business forms, MCP 2010 0/200 NR — N Test material discontinued in
early 1980s
1983 83–0771–70 Hill Top
Research, Inc.
“Sample A” - no other information
given
1/14 ND — Y Solution of CCP formulation;
end-users not exposed
1986 3683 Inveresk Research
International
A. Resin CF based on Durez resin
32131






































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
3683
(continued)
B. CF control, standard production
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(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
3683
(continued)
E. CB control, E20 formulation in 2:1














1987 83–0091–70 Hill Top
Research, Inc.
CB and CF paper, crushed and
uncrushed, aqueous and intact
  ND ND — ND 
 
Test materials discontinued
since sponsor no longer in
this business
1987 86–5436H Biosearch MCP 1010— “#1 formulation” CFB
sheet CB side, white paper
0/206 NR — N Test materials discontinued
in late1980s
MCP 1010— “#4 formulation” CFB
sheet CF side, white paper
0/206 NR — N
MCP 2010— “#1 formulation” CFB
sheet CF side, white paper

































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
86–5436H
(continued)
MCP 2010— “#1 formulation” CFB
sheet CB side, white paper
0/206 NR — N
MCP 2010— “#2 formulation” CFB
sheet CF side, yellow paper
0/206 NR — N
MCP 2010— “#4 formulation” CFB
sheet CB side, white paper
0/206 NR — N
White paper 0/206 NR — N
1989 89–1107–70 Hill Top
Research, Inc.
T/R CB from No. 12 coater 2/103 1 — N Test materials discontinued in
mid-1990s
Imaged T/R CB 3/103 1 — N
Fraser CF 1/103 3‡‡‡ — Y
Fraser CF imaged by T/R CB 1/103 2‡‡‡ — N
Georgia Pacific CF 1/103 2‡‡‡ — N
Georgia Pacific CF imaged by T/R CB 1/103 3‡‡‡ — Y
James River CF 1/103 3‡‡‡ — Y
James River CF imaged with T/R CB 3/103 Y
1 2
3‡‡‡ 1
1989 89–1106–70 Hill Top
Research, Inc.
304.   OPAS CF ink FH–378 1/10 1 — N Test materials discontinued
in mid-1990s

































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
1989 89–1105–70 Hill Top
Research, Inc.
308a.  CB of CFB 2/105 1 — N Test materials discontinued
in mid-1990s
308b.  Imaged CF of CFB 4/105 1 — N
308c.  CF of CFB 3/105 1 — N
308d.  CB of CFB after imaging
   w/CF
1/105 1 — N
309a.  CB of CFB 4/105 1 — N
309b.  Imaged CF of CFB 5/105 1 — N
309c.  CF of CFB 3/105 1 — N
309d.  CB of CFB after imaging
   w/CF
3/105 1 — N
1989 89–6733H Biosearch 151. Unimaged CB 0/99 0 — N Test materials in use
152. Imaged CB 0/99 0 — N
153. Unimaged CF 1/99 +§§§ — N
154. Imaged CF 0/99         0 — N
157. Unimaged CB 0/99         0 — N
1989 89–1359–70 Hill Top
Research, Inc.
161. Unimaged CB 0/109                     0 — N Test materials in use
162. Imaged CB 0/109 0 — N
163. Unimaged CF 0/109 0 — N

































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
1990 K23–33T–3E Keyline Research T–5205 carbonless blue image paper,
EM0571
0/204 0 — N Test materials in use
1990 90–2826–70 Hill Top
Research, Inc.
182. Imaged CB 0/110 0 — N Text materials in use
183. Unimaged CB 0/110 0 — N
184. Imaged CF 0/110 0 — N
185.  Unimaged CF 0/110 0 — N
186.  Imaged self-contained CB 0/110 0 — N
1991 90–2846–70 Hill Top
Research, Inc.
325.  Thick, gray, opaque liquid 0/107 0 — N Test materials discontinued
mid-1990s
325AD Thick, gray, opaque liquid 0/107 0 — N
326A Paper 2/107 2 — N
326B Paper 0/107 0 — N
1991 91–1141–70 Hill Top
Research, Inc.
343a.  Unimaged CF 0/117 0 — N Test materials discontinued
mid-1990s
343b.  Imaged CF 0/117 0 — N
343c.  Unimaged CB 0/117 0 — N
343d.  Imaged CB 1/117 1 — N
322a.  Unimaged SC surface 2/117 1 — N

































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
1991 K23–33T–6B Keyline Research T–5282 impact carbonless paper,
Lot X0510, CF imaged
0/224 0 — N Test materials in use
1991 K23–33T–6F Keyline Research T–5283 impact carbonless paper,
Lot X0510, CF unimaged
0/224 0 — N Test materials in use
1991 K23–33T–6A Keyline Research T–5284 impact carbonless paper,
Lot X1820, CF imaged
0/224 0 — N Test materials in use
1991 K23–33T–6G Keyline Research T–5285 impact carbonless paper,
Lot X1820, CF unimaged
0/224 0 — N Test materials in use
1991 K23–33T–6C Keyline Research T–5280 carbonless paper, Lot E,
EM0581, No. AI01540, CB imaged
0/224 0 — N Test materials in use
1991 K23–33T–6E Keyline Research T–5281carbonless paper, Lot E,
EM058, No. A101540, CB unimaged
0/224 0 — N Test materials in use
1993 93–1141–70 Hill Top
Research, Inc.
Imaged 368 0/15 0 — N Test materials discontinued
mid-1990s
Unimaged 368 0/15 0 — N
Imaged 369 0/15 0 — N
Unimaged 369 0/15 0 — N
Imaged 370 0/15 0 — N
Unimaged 370 0/15 0 — N
Imaged 371 0/15 0 — N

































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
1993 93–1034–70 Hill Top
Research, Inc.
Imaged 368 0/107 0 — N Test materials discontinued
mid-1990s
Unimaged 368 0/107 0 — N
Imaged 369 0/107 0 — N
Unimaged 369 0/107 0 — N
Imaged 370 0/107 0 — N
Unimaged 370 0/107 0 — N
Imaged 371 0/107 0 — N
Unimaged 371 0/107 0 — N
1994 93–1206–70 Hill Top
Research, Inc.
Imaged 368 0/94 0 — N Test materials discontinued
mid-1990s
Unimaged 368 0/94 0 — N
Imaged 369 1/94 1 — N
Unimaged 369 0/94 0 — N
Imaged 370 0/94 0 — N
Unimaged 370 0/94 0 — N
Imaged 371 1/94 1 — N

































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
See footnotes at end of table. (Continued)
1995 95–1631–70 Hill Top
Research, Inc.
396a. Unimaged CB 3/110 1 — N Test materials discontinued
mid-1990s
396b.  Imaged CIF 5/110 1 — N
396c.  Unimaged CF 2/110 1 — N
396d.  Imaged CB 2/110 1 — N
407a.  Unimaged CB 4/110 1 — N
407b.  Imaged CF 2/110 1 — N
407c.  Unimaged CF 2/110 1 — N
407d.  Imaged CB 4/110 1 — N
402a.  Unimaged self-contained 5/110 1 — N
402b.  Imaged self-contained 1 — N
1996 95–1632–70 Hill Top
Research, Inc.
419a.  Unimaged CB 0/118 0 — N Test materials in use
419b.  Imaged CF 2/118 1 — N
422aq.  Liquid 0/118 0 — N
424a.  Unimaged CB 0/118 0 — N
424b.  Imaged CF 0/118 0 — N
424c.  Unimaged CF 0/118 0 — N

































Table 4–12 (Continued). Analysis of repeated insult patch test (RIPT) studies submitted by industry 














(Y/N)§,¶ Current use of material
1998 98–101080–76 Hill Top
Research, Inc.
215.  CF unimaged 8/100 N Test materials in use
+ 7
1 1
215.   Back of CF 11/100 N
+ 9
1 1
217.   CB side 2/100 2     1¶¶¶ N




1999 99–101981–70 Hill Top
Research, Inc.
215. CF side unimaged 5/115 + — N Test materials in use
215. CF side imaged 16/115 — N
215. Backside of CF 6/115 — N
217.  CB side unimaged 8/115 + — N
217.  CB side imaged 1/115 + — N
220.  Non-CB side 1/115 + — N
226.  CB side imaged 3/115 — N
227.  CF side imaged 3/115 + — N




































Adapted from Graves and Tardiff [1999] supplemental submission of peer review comments.
*The report numbers refer to submissions to the NIOSH docket; they are not listed in the references. Except in Report 86–5436H, no test results for control materials are included in this table.
†Number of responders/total number of persons who completed the study.
Footnotes continued on next page.
‡Highest recorded grade of skin reaction per study participant for a particular test material (based on multiple applications). Before 1980, Hill Top Research, Inc. employed a scoring scale that ranged from
0 to 7 (a score of 5 or greater=primary skin irritant; less than 5=nonirritating). Since 1980, Hill Top has used a scoring scale that ranges from 0 to 5 (a score of 3 or greater=primary skin irritant; less than 3=nonirritating).
Inveresk Research International used a scoring system of 0 to 8, with a score of 5 or greater indicating irritancy. This laboratory scoring system is more analogous to the Hill Top pre-1980
    system, even though it is a post-1980 study.
§Abbreviations: CB=coated back; CF=coated front; CFB=coated front and back; N=no; NA=not applicable; ND=no data provided; NR=no reaction; Y=yes.
¶ Y and N were determined by NIOSH according to the scoring system listed in footnote‡.
iDiscontinued means that (1) the ingredient is no longer used to make CCP, or (2) the formulation as constituted is no longer used to make CCP, or (3) the CCP product is no longer sold in the United States.cThe study
director described skin reactions as sensitization.
#Responders to sample E (grade 2 and grade 6 reactions) were dropped from the study (77–512–70).
**A responder to sample H (grade 1 reaction) was dropped (77–512–70 H).
††Responder to sample B (grade 1 reaction) was dropped (78–578–70).
§§Two reactors with grade 2 reactions and one reactor with grade 3 reaction to T3012PP dropped out of the study [81–0318–73(2)] and are not included in the denominators.
¶¶One grade 3 reactor to T3013PP was dropped from the study [81–0138–73(2)].
iiTwo dropped out with a score of 1; 1 dropped out with a score of 2.
ccOne dropped out with a score of 1; 2 dropped out with a score of 2.
˜˜Three dropped out with a score of 1; 1 dropped out with a score of 3.
##One dropped out with a score of 1; 1 dropped out with a score of 3.
***Three dropped out with a score of 1; 1 dropped out with a score of 2.
†††Two dropped out with a score of 1; 2 dropped out with a score of 2.
‡‡‡These results reflect the same person who expressed elevated scores throughout this study, regardless of the material tested. In addition, the scoring responses conflict with the study methodology
  since the responses increased, rather than decreased, across primary, secondary, and tertiary application sites. Therefore, the results for this person are suspect.
§§§As designated by performing laboratory, “+” denotes “slight, confluent or patchy erythema.” This symbol indicates a score between 0 and 1 on a scale of 0 to 7 (see footnote ‡) and is not used universally.
¶¶¶The analytical laboratory that conducted this study concluded that this irritancy score was likely to be a recording error because of deviations from the study protocol.
One of the difficulties in interpreting the
RIPT studies is that although there is a stan-
dard procedure for evaluating changes consis-
tent with allergic contact dermatitis, no
guidelines exist for determining what consti-
tutes a significant irritant response in humans
[Gupta 1999]. OSHA [29 CFR‡ 1910.1200,
Appendix A] and the Consumer Product Safety
Commission (CPSC) [16 CFR Part 1500.41]
have guidelines for animal testing but not for
human testing. Report 81–0138–73(2) from
Hill Top Research, Inc., (Table 4–12) defines
categories of responses for interpreting the
findings in their test reports [Graves and
Tardiff 1999]. The test report states the
following:
If Category I responses (defined as negative or
insignificant findings or significant findings un-
related to the test material) are projected to
98 percent or more of the total population, then
the results are not significant for dermatotoxic
potential. This means that two percent or less of
the population could possibly have some type of
mild reaction.
A mild significance is one where no Category III
reactions (no vesicular, bullous, or spreading) ex-
ist and Category I (negative) reactions exist in
95 percent or more of total population. This
means, that at most five percent of the population
could have some type of mild, non-vesicular,
non-bullous, non-spreading response.
A strong significance for dermatotoxic potential
exists if there are any Category III responses
(vesicular, bullous, strong spreading reactions) or
if enough Category II responses (significant re-
sponses excluding vesicular, bullous, and spread-
ing reactions) exist to decrease Category I to
85 percent or less of total population. This means
that if any one person (approximately 1/200 or
one-half percent of the test subjects) would have
vesicular, bullous, or spreading reaction or 15 per-
cent or more would have some type of significant
reaction, then the test would be defined as having
‡Code of Federal Regulations. See CFR in references.
strong statistical significance for dermatotoxic po-
tential. Eighty-five (85) percent of the population
could have non-significant or negative reactions
and the test would still be considered strongly sig-
nificant.
This definition, which henceforth will be re-
ferred to as the “Hilltop Guidelines,” combines
information about the likelihood of the re-
sponse with information about the severity of
the response to determine whether the overall
response is significant. With this definition a
test would be declared negative or insignificant
even if mild reactions occurred in a small pro-
portion (2%) of the test population. More-
over, as the ASTM standard argues, from a
population experiencing 1.5 allergic reactions
per 100 users, a sample of 200 could easily
yield no cases just by chance [ASTM 1999].
Most of the RIPT reports submitted to NIOSH
were judged to be negative by the investigators
using criteria similar to those described above.
However, in 8 of 217 test material combina-
tions shown in Table 4–12, study directors in-
dicated that skin sensitization occurred among
human subjects. A few of the RIPT reports
submitted in response to the 1987 Federal
Register notice document responses to CCP or
its components that were consistent with the
induction of allergic contact dermatitis under
the intensive exposures of the experimental
protocols. These RIPT reports include Hill Top
Research, Inc., Report 77–512–70,
77–896–71, 79–512–70, and 79–0085–73; and
Shelanski Holding Company Report SH–72–4
(Table 4–12). Note, however, that reactions
occurred in response to types of CCP that man-
ufacturers claim are no longer in use. Cases of
allergic contact dermatitis were not observed
in any of the studies submitted in response to
the 1997 Federal Register notice.
Two of the RIPT reports (e.g., Hill Top Re-
search, Inc., Reports 98–101981–76 and
99–101981–70) suggest that some CCP test
materials have a minor potential for skin
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irritation. Test results for these materials did
not meet the testing laboratories’ criteria for
primary skin irritants, but they provided evi-
dence of an irritant response. Because most
studies did not include comparison groups ex-
posed to plain paper, it is unclear whether this
potential for skin irritation would have been
much different from that of paper alone.
Tests Under Simulated Conditions of Use.
Three industry-sponsored tests evaluating the
irritation potential of CCP under simulated
conditions of office use were submitted to the
NIOSH docket in response to the 1987 and
1997 Federal Register notices.
Hill Top Research, Inc., conducted a dou-
ble-blind placebo study in which subjects were
provided with scissors and asked on 4 consecu-
tive days to cut up samples of paper for 60 min
under controlled temperature and humidity
(Hilltop Research, Inc., Report 83–0965–70).
Three types of CCP and a control (“white”) pa-
per were tested in random order by two groups
of 10 and 9 subjects. After the 19 study sub-
jects were exposed to one of the CCP samples
(sample B), 10 (53%) reported irritation of the
eyes, nose, or skin. When exposed to the sec-
ond and third of the remaining CCP samples, 3
subjects (16%) and 2 subjects (10%), respec-
tively, reported irritation symptoms. One
subject (5%) reported irritation following expo-
sure to the control paper. The authors con-
cluded that their results demonstrated an
unequal distribution of irritation symptoms
among the samples tested and that the number
of symptoms reported was particularly high
with exposure to one of the CCP samples. The
eyes were the most sensitive indicator, and
some symptoms persisted for 24 hr. The
authors recommended that studies of this type
allow greater separation in time between sam-
ples to prevent carryover effects from preced-
ing samples.
Hill Top Research, Inc., (Report 83–0123–70)
conducted another double-blind study in which
20 subjects were recruited to handle a stack of
120 sheets of test paper. Every 30 sec, the sub-
jects ran their hands over each side of another
piece of paper until all the pieces had been han-
dled at the end of 1 hr. The testing was done in
a single room, with four different types of pa-
per being handled each day. Subjects were ex-
amined for signs of irritation and were
questioned regarding symptoms before expo-
sure and 30 min, 60 min, and 24 hr after expo-
sure. One subject dropped out. No irritation
responses were reported or observed for the
eyes, forearms, or face with any of the test
papers. Seven subjects reported respiratory
symptoms, but four of them demonstrated
these effects with all four samples. These latter
symptoms appear to have resulted from preex-
isting cold symptoms rather than from expo-
sure to the paper samples. The results of this
study are difficult to interpret in light of the co-
existing cold symptoms and pretest symptoms
present even for the control exposure.
In 1998, Moore Business Forms, Inc., reported
on tests for scoring irritation or sensitization as
a result of challenge with Moore Clean Print®
CB, CF, and CFB. This test was performed by
Biosearch in 1983 (Table 4–12). The volun-
teers included 200 men and women aged 16 to
68. Of the 200 subjects, 33 had allergies to typ-
ical materials. Subjects were instructed to rub a
sheet of the test paper (CFB) on their hands and
wrists using a hand-washing motion. The pro-
cedure was performed over a 4-week period
using 8 sheets of paper per day for 5 days per
week. The subjects were examined weekly and
were instructed to report any unusual interim
occurrences. After day 20 of treatment, the
subjects rested for 2 weeks and again per-
formed the same procedure with 8 sheets of
CCP. They were examined immediately after
the challenge and 4 and 24 hr later. The com-
mercial laboratory that performed the test re-
ported that none of the 200 subjects had any
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signs of irritation or sensitization following
any of the 20 initial or challenge exposures.
4.2.4.3 Summary
In summary, the results of these laboratory
studies in humans suggest that under some
conditions of exposure to CCP or its compo-
nents, workers may experience irritation of the
upper respiratory tract or skin, and/or they may
develop allergic contact dermatitis. It must be
emphasized that most of these studies were
negative, and the reactions observed in the pos-
itive studies were extremely rare. Furthermore,
cases of allergic contact dermatitis were re-
ported only in the earlier RIPT studies, which
tested CCP types that are no longer in use; the
more recent RIPT studies have detected only
minor signs of skin irritation. If the Hill Top
Research, Inc., guidelines are applied, then the
mild irritation responses identified in some of
the industry-sponsored RIPT studies would be
considered Category I responses, which are de-
fined as negative or insignificant findings, or
significant findings unrelated to the test mate-
rial. However, these same results do suggest
that 2% or less of the population could have
some type of mild reaction to CCP. Whether
these mild irritation reactions would have been
observed with ordinary bond paper is unclear,




Hasegawa et al. 1982a. Hasegawa et al.
[1982a] reported that diisopropylnaphthalenes
(Kureha Micro Capsule Oil [KMC-A]) and
1-phenyl-1-xylyl-ethanes (SAS) are two
classes of solvents that are used in the manu-
facture of CCP. They were introduced in Japan
as replacements for PCBs in 1971. KMC is
used by the Federal Republic of Germany and
by Japan at a rate of 10,000 tons per year
[Sturaro et al. 1994]. Large amounts of both
materials were found in the body fat and sub-
cutaneous fat of male JCL-SD rats 2 hr after a
single oral dose of 0.1 mg/kg. The amounts in-
creased with time until 24 hr after the dose. In
the liver, the amounts were nearly the same
as those in the fat after 2 hr, but they rapidly
disappeared thereafter. The concentrations in
blood were similar to those of the heart, kid-
neys, and brain. Although the ratio of isomers
in the KMC-A did not change, those of the
SAS 296 differed by a ratio of 3:1 for
1-phenyl-1-metaxylyl to 1-phenyl-1-orthoxylyl-
ethane, respectively. This result was attributed
to differences in hepatic metabolic rates. No
accumulation was found in the organs, and lit-
tle accumulation was found in the fat after
daily administration for 1 month.
Hasegawa et al. 1982b. Hasegawa et al.
[1982b] administered 0.1g/kg body weight of
KMC-A and SAS 296 to JCL-SD rats every
day for 1 month. Biochemical examination re-
vealed (1) a slight decrease in body weight and
a small increase in liver weight (0.3% to 0.6%)
compared with the controls; (2) disturbance of
lipid metabolism in the liver (statistically sig-
nificant decreases in triglycerides, glycolipids,
and phospholipids) and serum (statistically
significant free fatty acid twofold to threefold
increases, total and free cholesterol decreases);
and (3) disturbance of glucose metabolism in
the liver (statistically significant decrease in
glycogen and increase in pyruvate) from ad-
ministration of both substances. A significant
increase in alkaline phosphatase activity in the
serum occurred in the case of SAS 296
administration.
Löfroth 1982. Löfroth [1982] examined a
number of office materials for their potential
mutagenic activity and found that none of the
CCPs contained detectable amounts of muta-
genic components. However, the author com-
mented that some impurities in triaryl methanes
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(used as color formers) have been reported to
be mutagenic [Bonin et al. 1981].
Certin and Zissu 1983. Certin and Zissu [1983]
performed cutaneous irritation tests in rabbits.
They compared extracts of 12 CCPs with 5
highly irritant reference oils, acetone (CB), or
ethyl acetate or acetone (CF) extracts (4 hr
of soxlet extraction of 50 g, or acetone extrac-
tion of 1 kg CB sheets in an ultrasonic tank for
1 hr). The CCP extracts were moderately or
severely irritating using the Draize method
(Table 4–13). Chemical analysis using GC/MS
analysis identified the “oils” listed in Table 4–13.
Thirteen papers contained a phenolic resin in
the CF layer and traces of free phenols, bis-
phenol A, and phenylphenol. For all of the CF
analyses, compounds similar to abietic acid
were found. Certin and Zissu [1983] reported
that 8 of the 12 extracts were moderately irri-
tating (irritation index from 2.7 to 4.7), and the
remaining 4 extracts were severely irritating
(irritation index from 5.6 to 7.3). Histopathology
results from animals exposed to moderately
irritating products exhibited epidermal
acanthoses alternating with superficial epider-
mal necrosis, which led to thin, scaly crust that
was sometimes continuous over the entire ex-
tent of the lesion. The severely irritating prod-
ucts caused more pronounced morphological
findings. These were characterized by necrosis
of the epidermis and superficial dermis, with
inflammatory exocytosis and homogeneous
degeneration of the connective tissue of the
mid-dermis. The authors concluded that it was
probably the oily constituents of the papers
that produced the observed irritation of the
skin and mucosa of office workers. However,
they also noted that the animal test results are
probably more grave than those experienced
by humans, since human exposures were lim-
ited to several hundred micrograms on the fin-
gers at the end of a day of handling. The authors
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Table 4–13. Frequency of occurrence and animal
irritation category for chemicals identified in 12 French CCPs
Chemical
Number of times identified
by GC/MS analysis Irritation category
Hydrogenated terphenyls 16 Severe
Diisopropylnaphthalenes 11 Severe
Phenylxylylethanes* 10 Moderate to severe
Alkylbenzenes 6 Severe
Methybutyl naphthalenes 1 Not tested
Benzylxylenes 1 Not tested
Chlorinated paraffins 1 Not tested
Chlorinated biphenyls 1† Not tested
Dibutylphthalate 1 Not tested
Kerosene ‡ Severe
Source: Certin and Zissu [1983].
*This constituent was noted to have a very pungent odor.
†1972.
‡Not enumerated.
remarked that nasal or ocular irritation is prob-
ably explained by contact with soiled fingers.
They did not think that it was likely that the oils
produced respiratory irritation because of the
low volatility of their constituents; however,
they did not discuss paper fibers as a potential
vehicle for the irritants.
Cameron et al. 1986. Cameron et al. [1986]
studied the percutaneous absorption of triaryl-
methane and phenoxazine-type color former
components of CCPs. The percutaneous ab-
sorption of carbon-14-labeled color former
components of CCP was investigated in the rat
as a model for assessing possible absorption of
these components by human users of such pa-
pers. Formulations of a proprietary color for-
mer/solvent mixture were applied to the
shaved backs of hooded rats. The mixture con-
tained carbon-14-labeled 6-(dimethyl-amino)
-3,3-bis(4-(dimethyl-amino) phenyl)-1(3H)-
isobenzofuranone (CVL), a triarylamine color
former, or 10-benzoyl-N,N,N′ ,N′-tetraethyl
-3,7-diamino-10H-phenoxazine (BLASB),
a phenoxazine color former. Some of the
rats had been surgically prepared with bile
duct and urinary bladder cannulae. Urine
and bile samples were collected hourly for
24 hr and assayed for carbon-14 activity.
The animals were then sacrificed, and car-
bon-14 activity was measured in the skin,
skin dressing, and body. Selected animals
were sacrificed 2, 6, 24, or 96 hr after
application, and carbon-14 activity in the ex-
creta, skin and dressings, and body was de-
termined. Microhistoautoradiography was
performed on the skins of some animals.
Nearly all the CVL- or BLASB-derived car-
bon-14 activity was retained in or on the
skin. Only 2.6% to 3.4% of the CVL and
1.0% to 2.1% of the BLASB doses were ab-
sorbed. During the 12 to 24 hr after
application, 0.02% of the CVL and 0.11% of the
BLASB doses were eliminated in the urine and
bile. The authors conclude that CVL and BLASB
are slowly absorbed into the systemic circulation
following topical application to rat skin. The au-
thors concluded that these results (if extrapolated
to humans) suggest that percutaneous absorption
of these compounds should not be significant dur-
ing normal handling of CCP.
Wolkoff et al. 1988. Wolkoff et al. [1988] re-
ported airway-irritating effects in mice ex-
posed to CCP using sensory irritation
techniques [Alarie 1973]. Four mice were ex-
posed for 10 min to emissions from CCP and
emissions from crushed and compressed virgin
copy papers. One CCP suspected of causing
complaints decreased the respiratory rate sig-
nificantly more than did a second CCP used
without adverse effects. This result suggests ir-
ritation. Because the CB layer of the first CCP
produced only negligible irritation, the authors
concluded that neither the solvent nor the color
formers caused the irritation. The authors sug-
gested that the irritation was due to one or more
of the following: the evolution of formalde-
hyde or other unidentified irritants in the paper,
the evolution of irritant solvents from the paper
and their transfer to the hands of the users, and
the transfer of irritant particulate matter from
the paper to the hands. The authors concluded
that it would be beneficial to minimize the free
formaldehyde content of the paper, eliminate
volatile irritants from the CCP, and minimize
the transfer of irritant particulates or solvents
to the skin.
Anderson 1992. Anderson [1992] used stan-
dard method ASTM E 981 [ASTM 1984] an
adaptation of the Alarie [1973] method (which
evaluates respiratory irritation) in mice to as-
sess the offgassing of CCP and determine its
effects on sensory irritation (upper airway) and
pulmonary irritation (deep lung). Using groups
of mice, the author concluded CCP to be a de-
monstrable irritant for both upper and lower
airways, causing a greater than 50% change in
respiratory rate. The type or composition of the
CCP was not given except that it was
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commercially purchased. No other details
were provided.
4.3.2 NIOSH Docket Submissions
Most information submitted to the NIOSH
docket concerned animal testing of CCP or its
components in extensive, widely accepted tox-
icology test procedures. The coded submis-
sions did not allow specific identification of
chemicals or formulations. Each of the approx-
imately 1,500 animal studies submitted to the
docket was reviewed independently by a
NIOSH toxicologist. Most materials had been
tested in a series of protocols such as inhalation
LC50, cutaneous and/or oral LD50, skin and/or
eye irritation, and skin sensitization. Some ma-
terials had been tested for mutagenesis, repro-
ductive toxicity, or upper airway irritation. Not
all materials were tested using every protocol.
Most test results were negative; but positive re-
sults that were reported during the NIOSH re-
view summarized as follows:
 The Mead Corporation sent summaries
of eight reports to the NIOSH 1987
docket. The material tested was
code 151 (chemical identification code),
and all tests were negative except for a
1980 study of acute dermal toxicity in
rabbits that estimated the acute dermal
LD50 to be greater than 2 g/kg body
weight. However, slight to well-defined
erythema was noted in all animals on
days 1, 3, and 7; it continued in most of
the animals through day 14.
 Hazelton Laboratories in Madison, Wis-
consin, and Vienna, Virginia, submitted
a series of 22 reports to the NIOSH 1987
docket. Irritation was produced by some
of the samples, but sensitization did not
occur. Inhalation experiments were neg-
ative, but exposure concentrations were
very low in most cases.
 Biosearch evaluated CCP constituents
from Moore Business Forms, Inc., and
submitted the results to the NIOSH 1987
docket for acute oral toxicity, primary
eye irritation, primary skin irritation,
and 5-day repeated dermal irritation. All
products tested were considered nontoxic,
with LD50s greater than 5 g/kg. None of
the materials were classified by the Food
and Drug Administration’s regulatory
definition as primary eye irritants, pri-
mary skin irritants, or dermal sensitizers.
Several of the materials acted as mild or
moderate skin and eye irritants.
 A series of toxicological test reports on a
variety of CCP constituents were sub-
mitted to the NIOSH docket and re-
viewed. These test reports (Documents
002 through 148) were originally pre-
pared for the Monsanto Company in
St. Louis, Missouri. The tests had been
conducted between 1956 and 1980. Test
material ranged from “white paper” to
“yellow liquid” or “white powder.” The
toxicological tests included acute oral
and dermal toxicity and dermal and eye
irritation. They also included a few
90-day feeding studies, mutagenesis as-
says, and inhalation studies as well as
two aquatic studies with trout fry and
midge larvae. Most substances were
nontoxic or exhibited mild toxicity.
Some caused mild or moderate irritation
to the skin or eyes. However, in most
cases, the low scores on the dermal or
ocular irritation assays resulted in their
classification as nonirritants. A few of
the tests (2/69 primary irritation assays
and 3/69 primary eye irritation assays)
were graded as positive. From the other
tests, NIOSH could infer that the product
would cause mild irritation in humans.
However, it must be recognized that such
testing of pure compounds may produce
more exaggerated results than testing the
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final CCP product, since less of the toxic
component is available to consumers in
the finished product. In the brief com-
ments noted below, substances identified
as mild irritants were not classified as pri-
mary irritants, even though some irritation
occurred in more than one animal. Many
of the compounds caused diarrhea. These
observations are probably not relevant to
humans—especially when animals were
gavaged with a large volume of a slurry of
white paper. Also of questionable rele-
vance was the liver damage caused by
compound 043. This effect occurred when
animals were exposed to 10,000 ppm for
90 days.
 In a NIOSH docket submission numbered
Document 050–EMI, a crystalline white
powder was suspected to be relatively
toxic. Peer reviewers from the industry
noted that at full strength, this substance
was corrosive to the skin, severely irri-
tating to the eyes, and acutely toxic by
oral ingestion [Graves and Tardiff 1999].
However, comments from the same peer
reviewers noted that this component was
never used in CCP production or offered
for sale commercially. When the com-
ponent was tested as part of a trial CCP,
the paper was negative for acute and der-
mal toxicity and eye and skin irritation.
 Also of concern were a few studies in
which compounds (033, 034, 036,
038–TR–33 to TR–38) were tested by
inhalation or dermal application. Al-
though these compounds did not produce
any deaths or pathological findings, expo-
sures resulted in modified behavior. An-
imals became hyperactive, salivated,
became ataxic, and lost their righting re-
flex. NIOSH concluded that low expo-
sures to these compounds could produce
comparable effects in humans. Peer re-
viewers from the industry noted that
these tests involved pure compounds,
and that tests of the finished CCP prod-
ucts containing these compounds were
negative [Graves and Tardiff 1999]. The
chemical or component identification
was unknown to NIOSH because of
trade secret claims by the industry. Thus
connecting the test results from pure
compounds to finished products was not
possible. None of the mutagenicity stud-
ies were positive, but not all substances
were tested for mutagenicity.
 Another NIOSH docket submission
from Monsanto is a series of 44 toxicity
reports conducted by various testing lab-
oratories on papers and dyes that were
tested during the years 1978 to 1986.
Each report consists of one to six toxic-
ity tests that include oral and dermal tox-
icity, skin and eye irritation assessment,
mutagenicity testing, and skin sensitiza-
tion testing in animals.
Santosol 150 dye solution was tested
more than any other product. Tests in-
cluded a 90-day feeding study, develop-
mental toxicity testing, and a series of
studies in fish and midges. Unlike the
other products tested in the Monsanto
series, an LD50 and a maximum tolerated
dose were determined for Santosol 150.
In general, this dye solution exhibited
low toxicity.
None of the products tested in the
Monsanto series (including Santosol
150) were mutagenic, but not all prod-
ucts were tested for mutagenicity. None
of the products were skin sensitizers in
animals or humans, but not all products
were tested for skin sensitization. Most
compounds were not acutely toxic by the
oral or dermal route. This conclusion
was based on the fact that they were not
lethal at 5 g/kg (oral route) or 2 g/kg
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(dermal route). However, many of the
products induced modified behavior (in-
cluding lethargy, ataxia, and even paral-
ysis) from which the animals recovered.
At necropsy, some animals exhibited
mottled kidneys or livers. Diarrhea was
a common symptom. For example, rat s
gavaged with a slurry of white paper ex-
hibited white diarrhea for 1 to 2 days.
The relevance of such exposures and ef-
fects is questionable.
One product (96 Solvent CB Paper Inter-
nal Phase) was tested for developmental
toxicity; it produced fetal malformations
at a concentration that was toxic to the
mother.
None of the products were corrosive,
and very few were classified as primary
irritants. However, some of the products
caused mild eye irritation and transitory
erythema and edema of the skin.
Several paper products were tested for
formaldehyde content, which ranged
from 0.014 to <0.001 µg/g in the prod-
ucts tested. Levels of detection for the
methods were not noted. Overall, the
materials tested exhibited low or negli-
gible toxicity. Some could act as mild ir-
ritants.
 The Mead Corporation submitted toxi-
cology tests performed between March 3,
1987, and July 18, 1996. Tardiff [1997]
reviewed the complete testing program of
the Mead Corporation’s evaluation of
CCP and of the ingredients used to man-
ufacture Mead’s CCP. (These same ma-
terials were also submitted to and
reviewed by NIOSH.) The Tardiff re-
view encompasses 191 substances con-
sisting of individual chemicals, mixtures
used in the production of CCP, and vari-
ous batches of CCP. The individual
chemicals and mixtures included
various inks, dyes, powders, coatings,
adhesives, and other materials. Their
identities were not known because of
trade secret considerations by the com-
pany. Ingredients were selected for test-
ing to supplement information provided
by the suppliers of the raw materials and
to test chemicals considered for formu-
lations that were sufficiently reactive to
have the potential for producing syner-
gistic reactions with other ingredients of
CCP. The following is a list of assays
that were selectively performed (based
on scientific judgment) with the test sub-
stances:
—Eye irritation test in the rabbit
—Primary skin irritation test in the
guinea pig
—Skin sensitization test in the guinea
pig
—Acute oral toxicity test in the rat
—Acute dermal toxicity test in the rabbit
—Acute inhalation toxicity test in the rat
—Genotoxicity tests (Ames mutagen-
icity assay and chromosomal aberra-
tion test)
The toxicity studies summarized in
Tardiff [1997] were evaluated using data
interpretation methods and guidelines
accepted by the CPSC. Since that
commission does not require the geno-
toxicity testing mentioned above, Tardiff
[1997] used conventional professional
practice found acceptable by the U.S.
Environmental Protection Agency and
supported by the National Academy of
Sciences. To confirm the quality of the
toxicologic tests summarized in the re-
port, each study was verified as having
been conducted in accordance with the
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testing requirements of the CPSC or the
Organization for Economic Cooperation
and Development. Each of the protocols
included stipulations for adhering to
good laboratory practices.
The following results were reported.
Oral toxicity in rats was tested with
84 chemicals and mixtures. Each pos-
sessed an LD50 of >5 g/kg. According to
CPSC criteria, these materials are nega-
tive and unlikely to pose an acute hazard
to humans by ingestion. Ocular irritation
tests in rabbits were conducted with
83 chemicals or mixtures; 55 produced
no ocular irritation. According to Tardiff
[1997], the 28 materials that tested posi-
tive consisted of powders, liquids, and
pastes. They produced a range of treat-
ment-related effects, including iridal
and/or corneal involvement and slight to
moderate conjunctival irritation (which
cleared within 24 to 72 hr of the test ma-
terial administration). According to the
author, these substances are unlikely to
lead to positive results in humans ex-
posed to CCP because the test results in-
dicated only mild and transitory effects
with liquids, and end users would not be
exposed to the liquids.
Primary skin irritation tests in the guinea
pigs were conducted with 86 chemicals
or mixtures. Each produced a skin irrita-
tion score of less than 5. Tardiff [1997]
states that based on CPSC criteria and
the primary irritation scoring data, these
materials are negative and are unlikely
to cause primary skin irritation in hu-
mans exposed to CCP. Acute dermal
toxicity tests in rabbits were conducted
with 18 chemicals or mixtures. Each pos-
sessed an LD50 >2 g/kg. On the basis of
CPSC criteria, these materials are nega-
tive for acute dermal toxicity. Skin sen-
sitization tests in guinea pigs were
performed with 95 chemicals or mix-
tures. Eighty-seven were negative. Of
the eight positive tests, treatment-related
results ranged from very faint to faint er-
ythema reactions that cleared within 24
hr of the test material administration. Six
materials were tested as liquids—which
does not represent normal usage of CCP.
Therefore, Tardiff [1997] concludes that
these reactions would not occur in hu-
mans. The other two positive substances
were tested as powders. Because the ex-
posure is expected to be limited to “min-
ute” quantities produced as CCP is cut,
shredded, or torn, the doses encountered
were considered insufficient by the au-
thors to cause sensitization.
Acute inhalation toxicity testing in rats
was conducted with 44 chemical sub-
stances or mixtures. Forty-three were
negative according to CPSC criteria.
The only positive result came from a liq-
uid mixture with an LC50 between 2 and
200 mg/L. Treatment-related effects in-
cluded failure to gain expected body weight,
respiratory distress, increased secretory re-
sponses, other changes in hair coat, and
death. Since exposure conditions with nor-
mal use of CCP would not be in liquid
form, Graves and Tardiff [1999] concluded
that the test material was unlikely to be an
acute hazard to humans by inhalation.
All 22 chemicals or mixtures tested for
genotoxicity were negative for point
mutations and did not increase chromo-
somal aberrations. These toxicity tests
demonstrate that the tested CCP constit-
uents are not mutagenic.
4.3.3 Summary
After examining the toxicological animal stud-
ies submitted to the NIOSH docket, NIOSH
concludes that with a few exceptions, CCP
constituents are not acutely toxic by the oral,
dermal, or inhalation route. A number of CCP
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constituents were shown to be mild irritants to
the skin and eyes of experimental animals. One
study [Anderson 1992] stated that CCP from
an unspecified source acted as both a sensory
and pulmonary irritant in mice.
In summary, more than 300 substances and
various combinations of materials were in-
cluded in the animal studies. Of 238 tested for
skin irritation, 8 were positive. In addition,
some materials caused mild, transient irritation
(25.2%; 60/238) but did not satisfy FDA’s reg-
ulatory definition of an irritant. In 129 dermal
lethality tests, mild skin irritation was noted
(17.8%; 23/129); however, the regulatory defi-
nition is not based on this type of test. No pat-
tern was observed to identify the CCP
component responsible for the mild skin irrita-
tion reported in humans. A total of 271
substances were tested in the allergic contact
dermatitis animal model, and 13 were positive.
This result suggests that CCP infrequently
causes allergic contact dermatitis in animals.
Whether materials with positive toxicological
outcomes were actually marketed is unclear;
but the general rationale for toxicity testing is
to prevent the marketing of materials that may
harm users.
Most of the toxicological data submitted to the
NIOSH docket were coded by the manufactur-
ers for proprietary reasons. Thus it was not
possible to identify replicate tests or the nature
of the test materials or their means of prepara-
tion (dry, aqueous, neet, etc.). However, the
animal toxicology results indicate only mild
and transitory effects with liquids, and end us-
ers would not be exposed to the liquids.
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5 Summary and Conclusions
Overall, the toxicologic, epidemiologic,and experimental studies reviewed in this
document indicate that exposure to CCP has
been associated with the following adverse
health effects: irritation of the skin and mucous
membranes of the eyes and upper respiratory
tract, allergic contact dermatitis (rarely), and
some systemic reactions (rarely). The evidence
regarding each of these possible health effects
is summarized in this Chapter.
5.1 Irritation of the Skin, Eyes,
and Upper Respiratory Tract
Evidence in the scientific literature indicates
an association between exposure to some types
of CCP and symptoms consistent with irrita-
tion of the skin, eyes, and upper respiratory
tract. The primary evidence for an association
comes from human studies. Irritative symp-
toms of the skin, eyes, and upper respiratory
tract have been observed in numerous case re-
ports and case series. Associations between
irritative symptoms of the skin, eyes, and up-
per respiratory tract and CCP exposure have
also been generally observed in cross-sectional
epidemiologic studies of CCP-exposed work-
ers.
A potential source of bias in the epidemiologic
studies is overreporting of symptoms by work-
ers who are already aware of a possible associ-
ation between CCP exposure and irritative
symptoms of the skin, eyes, and upper respira-
tory tract. This form of bias is often referred to
as “recall bias” and is well recognized to be an
important factor in epidemiologic studies in
which symptoms or exposures are identified by
questionnaires administered to the study sub-
jects. The potential for recall bias may have
been exacerbated by the use of leading ques-
tions such as “Do you think the paper makes
you itch?” (e.g., Menné et al. [1981]).
A positive exposure-response relationship was
observed between increasing CCP exposure
and the prevalence of irritative symptoms of
the skin, eyes, and upper respiratory tract in all
of the studies that examined this issue; but the
strength and statistical significance of the ex-
posure-response relationship varied dramati-
cally from report to report. The studies that
examined an exposure-response are summa-
rized in Table 5–1. Less potential exists for
subjective report biases to influence a
dose-response relationship than for such biases
to influence an overall relationship with CCP.
For subjective report biases to be important,
study subjects with high CCP exposures would
need to report symptoms more often than those
with moderate or low CCP exposures. Though
such a scenario is possible, it is less likely than
for people with any CCP exposure to report
symptoms more often than people with no ex-
posure.
Selection bias is also a major concern in the
cross-sectional studies that had low participa-
tion rates, such as the study by Fristedt and
Pettersson [1980]. It is possible that in these
studies, subjects with symptoms would have
been more likely to return the questionnaires
than were subjects without symptoms.
Potential biases in the epidemiologic studies
could also have led to an underestimation of
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Table 5–1. Summary of studies that examined exposure-response
relationships between CCP handling and irritative symptoms































































































*Cases are individuals with irritation of the eyes, nose, upper respiratory tract, or skin.
†NR=not reported.
‡Based on repeated measure in group of 18.
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the health effects associated with CCP. In these
cross-sectional studies, workers who reacted to
CCP might have left the workforce and thus
would not have been included. In addition,
since many of the researchers did not classify
their subjects by exposure level, the overall ef-
fect could have been diluted by the mix of
workers with high and low potential for CCP
exposure.
The strongest evidence for an association be-
tween symptoms and CCP exposure comes
from the studies of indoor air quality [Skov et
al. 1989; Mendell 1991; Zweers 1992; Jaakola
and Jaakola 1999]. These studies report a posi-
tive (and in several cases a statistically
significant) association between CCP expo-
sure and symptoms of skin, eye, and upper
respiratory tract irritation (Table 5–2). These
are the least susceptible to recall bias because
they were not conducted in workplaces where
concerns about CCP or other indoor pollutants
played a role in their selection for study. Also,
none of the indoor air studies were designed
primarily to address the CCP question; hence
investigator bias is also less likely. These stud-
ies used the most rigorous epidemiologic study
designs, and the investigators were able to con-
trol for a number of potentially confounding
exposures when examining the association be-
tween symptoms and CCP exposure.
Determining whether associations observed in
epidemiologic studies are causal is frequently
difficult given the observational nature of these
studies and the possible influence of confound-
ers and other sources of bias. Such is certainly
the case with the epidemiologic CCP literature.
Hill [1977] has developed useful criteria for
evaluating causality using all of the available
data. Epidemiologists have widely adopted
these criteria for evaluating the evidence of
causality in the epidemiologic literature. The
criteria include (1) the strength of the associa-
tion, (2) the consistency of the association,
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Table 5–2. Elevated ORs for CCP exposure
and irritation of the skin, eyes, nose, or respiratory system
reported in the indoor air cross-sectional studies
Authors Health effect OR* 95% CI
Skov et al. 1989 Mucosal irritation 1.3 1.1–1.6
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*Abbreviations: CI=confidence interval; OR=odds ratio.
5 SUMMARY AND CONCLUSIONS
(3) specificity, (4) relationship in time (tempo-
rality), (5) biological gradient, (6) biological
plausibility, (7) coherence, (8) experimental
evidence, and (9) reasoning by analogy. The
following sections describe these criteria and
use them to evaluate the reported associations
between CCP exposure and irritation of the
skin, eyes, nose, and upper respiratory tract.
5.1.1 Strength of the Association
Associations that are large in magnitude are
considered more likely to be causal, since they
are less likely to be explained by confounding
or other forms of bias.
In the cross-sectional studies, weak to moder-
ate associations were observed between CCP
exposure and irritation of the skin, eyes, and
upper respiratory tract. The odds ratios (ORs)
reported in the cross-sectional studies summa-
rized in Table 5–2 were approximately be-
tween 1.1 (e.g., Zweers [1992]) and 2.3 (e.g.,
Mendell [1991]). The strength of association
for rate (or odds) ratios that are 1.2 to 1.5 and
1.5 to 3.0 has been interpreted as being weak
and moderate, respectively (see Monson
[1980], p. 94). It should be recognized that the
size of the odds ratios are limited by the rela-
tively high background rates of the symptoms
studied. Many of the other cross-sectional
studies (i.e., non-indoor air studies) did not in-
clude an unexposed population, and thus it is
difficult to judge the strength of association in
these studies. It is noteworthy that the preva-
lence of symptoms among workers with ex-
tremely high CCP exposures (i.e., 1,000
sheets/day) was between 92% and 100% in two
of the non-indoor air cross-sectional studies
(Table 5–1), which suggests a strong associa-
tion among highly exposed workers.
5.1.2 Consistency
Consistency refers to the repeated observation
of similar findings in numerous study settings.
The case studies and case series reports are
consistent insofar as they report similar
symptoms involving the skin and mucosal
membranes of the eyes and upper respiratory
tract. However, this apparent consistency
might be partly a reporting bias that occurs be-
cause investigators have read previous case re-
ports and are more likely to report findings that
are similar to those previous reports. Perhaps
more convincing is the fact that the
cross-sectional epidemiologic studies were
generally consistent (see Table 4–3) in associ-
ating skin, eye, and upper respiratory symp-
toms with exposure to CCP. Associations of
CCP with other symptoms such as headache
and fatigue have not been consistently ob-
served in these studies. Overall, the
epidemiologic studies are judged to be rela-
tively consistent in reporting irritative symp-
toms of the skin, eyes, and upper respiratory
tract.
5.1.3 Specificity
Specificity requires that an exposure be associ-
ated with a single specific effect. Furthermore,
if a disease has no other major risk factors (e.g.,
asbestos and mesothelioma), the association is
often very credible and the studies are the least
susceptible to recall bias.
The irritative symptoms of the eyes, skin, and
upper respiratory tract reported in CCP
studies are common effects with many risk
factors. Ocular and upper respiratory tract
irritative symptoms in particular can be trig-
gered by many exposures encountered in the
indoor environment and are quite prevalent in
many office buildings. Thus the irritative
symptoms of the eyes, skin, and upper respira-
tory tract that have been associated with CCP
exposure are not specific to CCP. On the other
hand, the studies have been relatively consis-
tent in reporting an association between CCP
exposure and irritative symptoms of the eyes,
skin, and upper respiratory tract. These symp-
toms commonly occur together with exposures
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to an irritant and thus should probably be
viewed as a single effect and consistent with
the specificity criterion.
5.1.4 Relationship in Time
(Temporality)
Temporality requires that the exposure precede
the disease and that the effects follow a course
in time that is physiologically plausible in rela-
tion to the exposure.
In the epidemiologic studies, it can be reason-
ably assumed that the CCP exposures preceded
the observed symptoms or signs. Furthermore,
several of the case reports describe symptoms
or signs of disease that subsided or disappeared
after the subject left work or after the CCP ex-
posure was removed. Thus these human stud-
ies meet the temporality criterion for the
irritative symptoms of the eyes, skin, and up-
per respiratory tract associated with CCP expo-
sure.
5.1.5 Biological Gradient
Biological gradient refers to evidence for a
dose-response (or exposure-response) rela-
tionship. A dose-response relationship is
viewed by most epidemiologists to be strong
evidence for causality. A dose-response rela-
tionship is less likely to be explained by report-
ing bias or confounding than is an overall
measure of association (i.e., a yes/no expo-
sure). However, it is possible that such a
dose-response relationship could be produced
by confounding.
A positive dose-response relationship between
the frequency of handling CCP and the preva-
lence of irritative symptoms of the eyes, skin,
and upper respiratory tract was reported in the
nine studies that examined this relationship
(Table 5–1). Recall bias might explain these
relationships in some studies. However, it is
unlikely to explain the relationships observed
in the study by Skov et al. [1989], which was
one of the indoor air quality studies that was
not conducted at a building with previous com-
plaints related to CCP.
Overall, these studies demonstrate a biological
gradient by providing consistent evidence for
an exposure-response relationship for irritative
symptoms of the eyes, skin, and upper respira-
tory tract associated with exposure to CCP.
5.1.6 Biological Plausibility
Biological plausibility exists when an associa-
tion is consistent with what is known about the
biology of the disease. The biological plausi-
bility of the symptoms associated with CCP
exposure is supported by the presence of sev-
eral well-known irritants in some formulations
of CCP (e.g., formaldehyde, isocyanates,
phthalates, acrylates, glutaraldehyde, amines,
and kerosene). For example, in seven studies of
CCP and formaldehyde, nearly all exposure
measurements exceeded the NIOSH REL (but
not the OSHA PEL) for formaldehyde
[Chrostek and Moshell 1982; Gockel et al.
1981; Hazelton Laboratories 1985; Apol and
Thoburn 1986; Chovil et al. 1986; Omland et
al. 1993; Zimmer and Hadwen 1993]. The bio-
logical plausibility of the irritative effects is
further supported by the similar effects ob-
served in animal studies. Irritation of the skin
or respiratory tract has been demonstrated in
several studies of animals exposed to CCP or
its components (e.g., see Certin and Zissu
[1983]; Wolkoff et al. [1988]; Anderson
[1992]). Irritation of the skin was reported in a
number of the industry-sponsored toxicologic
studies reported to the NIOSH docket, al-
though these reactions did not indicate primary
skin irritation according to the regulatory
criteria established by FDA. In addition, the
positive reactions observed in these studies
were generally due to exposures to CCP com-
ponents in liquid form. Users of CCP are not
exposed to these substances in liquid form, and
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it is therefore unlikely that they would experi-
ence such high levels of exposure.
Understanding the mechanism by which an ex-
posure causes a health effect adds credence to a
causal association. The mechanisms involved
in the irritative symptoms of the eyes, skin, and
upper respiratory tract associated with CCP ex-
posure have not been established. In fact, it is
unclear which of the CCP components might
be responsible for these symptoms, although
(as mentioned above) chemicals in some types
of CCP are known irritants. Few studies have
included ordinary bond paper as a control for
mechanical abrasion from handling paper or
for exposure to chemicals (such as formalde-
hyde) that are contained in ordinary paper.
However, in the few studies that compared
CCP with ordinary bond, the irritative effects
were clearly greater for CCP (i.e., Nilzen
[1975], Norbäck et al. [1983b], Morgan and
Camp [1988], and Koenig [1988]).
An understanding of the mechanism should not
be required for inferring causality. As Hill
[1977] suggested, “What is biologically plau-
sible depends upon the biological knowledge
of the day.” In numerous examples, causal as-
sociations have been identified well before the
underlying biological mechanisms were un-
derstood (e.g., smoking and lung cancer).
Overall, reasonably supportive evidence exists
for the biological plausibility of the association
between CCP exposure and the irritative symp-
toms of the eyes, skin, and upper respiratory
tract observed in the epidemiologic studies.
5.1.7 Coherence
Coherence requires that the observed associa-
tion not conflict with what is known about the
natural history and biology of the disease. The
distinction between this criterion and biologi-
cal plausibility is a fine one. An example given
by Hill [1977] is that the association between
lung cancer and smoking is coherent with the
temporal rise that has taken place in both vari-
ables over the last century.
The reports in the literature of an association
between exposure to CCP and irritative
symptoms of the eyes, skin, and upper respi-
ratory tract are not in conflict with current
knowlege of the biology of these health ef-
fects. One apparently contradictory fact is that
health-related inquiries to CCP manufacturers
have reportedly decreased from 1987 to 1996,
dropping from approximately 130 to 50 inqui-
ries per year [letter to the NIOSH docket from
Robert Tardiff, October 6, 1998]. This de-
crease has occurred despite increases in the
production of CCP from approximately 85,000
to 100,000 tons/year over the same period.
However, increases in production would not
necessarily lead to increased exposures in of-
fices and other situations where CCP is used.
Thus it is unclear whether the number of peo-
ple exposed and the level of exposure have
dropped or increased during this period.
Changes in the formulation of CCP during this
period could also explain the decrease in com-
plaints. Therefore, the coherence criterion con-
tributes little to determining causality for the
irritative symptoms of the eyes, skin, and up-
per respiratory tract associated with CCP expo-
sure.
5.1.8 Experimental Evidence
Experiments can provide the strongest evi-
dence for causality, but such information is
rarely available for toxic effects in workers. In
the case of CCP, a few experimental studies in
humans have demonstrated irritative symp-
toms and signs with exposure to some types or
components of CCP.
Nilzen [1975] reported weak to moderate signs
of skin irritation among atopic persons exposed
to CCP with skin-prick testing, but the same re-
actions were observed with exposure to
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ordinary bond paper. Nilzen [1975] also re-
ported symptoms consistent with nasal irritation
in subjects exposed to vapors from CCP or bond
paper, but the CCP caused a stronger reaction.
Another study measuring the effects of CCP on
nasal passages reported signs consistent with
nasal irritation and congestion [Morgan and
Camp 1986; Koenig 1988]. In an indus-
try-sponsored study, a high percentage of sub-
jects (40%) demonstrated irritation of the eyes,
skin, or nose when they used scissors to cut one
particular type of CCP (Hill Top Research, Inc.,
Report 83–0965–70), but not when they cut
bond paper. Signs of dermal irritation (e.g. Hill
Top Research, Inc., Report 79–0085–73) were
observed in some of the RIPT studies that were
submitted to the 1987 docket. However, the use
of the products tested in these studies has gener-
ally been discontinued. Only very mild signs of
skin irritation were observed among subjects in
the more recent RIPT studies that tested CCP
materials in current use and that were submitted
to the NIOSH docket in 1997. Generally less
than 2% of subjects demonstrated very mild
skin irritation in these studies, but higher per-
centages (e.g., >10%) were reported for some of
the materials tested in two of the more recent
studies submitted to the docket (Hill Top Re-
search, Inc., 1998 and 1999). However, these
two studies were not considered by the investi-
gators to be positive for irritation.
These experimental studies are not subject to
the potential recall bias of the epidemiologic
studies, since they used objective tests. Also, it
is very unlikely that the positive findings in
some of these studies could be explained by
other forms of biases or chance. The inconsis-
tency between the findings in these studies
may be explained by differences in the types of
CCP tested or other differences in study de-
sign. It is unclear how relevant these experi-
mental models are, since the exposure from
patch testing is quite different from exposures
among workers who use CCP in offices and
elsewhere. These studies also have the
potential for a negative selection bias, since
they generally involved healthy volunteers and
could thus have excluded sensitive persons.
5.1.9 Reasoning by Analogy
Reasoning by analogy refers to making an
analogy with the known health effects for a
similar exposure. For example, the fact that a
drug has characteristics similar to Thalidomide
(a known teratogen) provides support for a
causal relationship between this drug and birth
defects. No useful analogies exist for CCP;
thus this criterion is not useful for judging cau-
sality in this case.
5.1.10 Summary
In summary, the Hill criteria for consistency,
specificity, temporality, biological gradient
(dose-response), biological plausibility, and
experimental evidence support a casual associ-
ation between CCP exposure and irritative
symptoms of the skin, eyes, and upper respira-
tory tract. Because the associations observed
in the epidemiologic studies were generally
weak to moderate, the evidence does not fully
satisfy the criterion for the strength of associ-
ation. Although not all of the criteria are fully
met, Hill [1977] points out that none of the
criteria can provide absolute proof of a
cause-and-effect relationship, and none should
be used as an absolute requirement for proof of
a cause-and-effect relationship. Furthermore,
not all of these criteria are equally important.
The dose-response relationship observed and
the experimental evidence reported for some
CCP exposures and irritative symptoms of the
eyes, skin, and upper respiratory tract provide
the strongest evidence for a causal association.
5.2 Allergic Contact Dermatitis
Several authors have reported cases of allergic
contact dermatitis that appear to have been as-
sociated with CCP or its components [Marks
1981; Kannerva et al. 1990a,b, 1993; Shehade
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1987]. Development of sensitization to CCP or
its components was also reported in a few per-
sons in several industry-sponsored RIPT stud-
ies (Report 77–512–70 and Supplemental
Report 79–512b–70, Report 77–896–71, and
Report 79–0085–73, all from Hill Top Re-
search, Inc.; and Project SH–72–4, dated April
18, 1972, performed by the Shelanski Holding
Company, Conshohocken, Pennsylvania, for
Monsanto Co., St. Louis, Missouri). In 8 of 217
test materials shown in Table 4–12, study in-
vestigators indicated that skin sensitization oc-
curred in some human subjects. However,
these studies were mostly judged to be nega-
tive for irritation by the investigators. Thus in a
small proportion of the population, CCP or its
components appear capable of inducing
cell-mediated (type IV) immune response and
allergic contact dermatitis, particularly under
the intensive exposures associated with RIPT
protocols. Cases of allergic contact dermatitis
were reported only in RIPT studies from the
1970s that were submitted to the 1987 NIOSH
docket; no cases were reported in the studies
submitted to the 1997 docket. This fact indi-
cates that the CCP component(s) responsible
for the allergic contact dermatitis observed in
the early studies may have been removed from
the more recent formulations of CCP.
5.3 Systemic Reactions
Three patients with systemic reactions clini-
cally suggestive of mast cell and/or basophil
degranulation after cutaneous challenge with
CCP or its components have been reported in
two published case reports [Marks et al.1984;
LaMarte 1988]. One patient challenged by
CCP handling became symptomatic approxi-
mately 15 to 20 min after exposure and experi-
enced swelling of the exposed hand, hives on
the neck, changes in both the inspiratory and
expiratory limbs of the flow-volume loop (sug-
gesting upper airways obstruction), and ele-
vated circulating levels of several arachidonic
acid metabolites. Skin-prick testing with CCP
dust was reported to be negative [Marks et al.
1984]. One patient who was challenged by rub-
bing 1% alkylphenol novolac resin dispersion
onto the forearm became symptomatic approx-
imately 15 min after exposure and developed
hoarseness, wheezing, and angioedema of both
arms. A subsequent challenge with this mate-
rial was followed by hoarseness, wheezing,
and angioedema at the challenge site. Video
endoscopy of the larynx was interpreted as
showing diffuse swelling and marked edema of
the true vocal cords. Plasma histamine levels
obtained at the onset and peak of symptoms
were sixfold higher than the prechallenge level
[LaMarte 1988]. Finally, one patient who was
challenged by rubbing 1% alkylphenol
novolac resin onto one arm was reported to
have angioedema of the arm and hoarseness
30 min after challenge [LaMarte 1988].
These reports suggest that some CCPs or their
components can induce reactions clinically
compatible with those caused by mast cell
and/or basophil mediator release. Immuno-
logic sensitization was not adequately evalu-
ated in these studies, and thus it is unclear
whether an immunologic mechanism underlies
these reactions. However, no additional reports
were located in the peer-reviewed literature
over the last 12 years. Thus, even if the re-
ported reactions were referable to CCP expo-
sure, systemic reactions of this type appear to
be exceedingly rare. Furthermore, the rele-
vance of these reports to current CCP expo-
sures is uncertain.
5.4 Conclusions
On the basis of a NIOSH review of the scien-
tific literature and information submitted in re-
sponse to its 1987 and 1997 Federal Register
notices, NIOSH concludes the following:
 The weight of the evidence supports the
conclusion that exposure to certain types
of CCP or its components has, under
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some conditions, resulted in symptoms
of irritation of the skin and of the
mucosal membranes of the eyes and up-
per respiratory tract.
This conclusion is based primarily on in-
terpretation of the evidence from the
epidemiologic studies. Although the
magnitude of the effects observed in
these studies was only weak to moder-
ate, these studies were reasonably con-
sistent in reporting an association and
evidence of an exposure-response rela-
tionship between CCP exposure and
irritative symptoms of the eyes, skin,
and upper respiratory tract. The
plausibility of the epidemiologic evi-
dence is supported by the presence of
known irritants in some types of CCP,
toxicologic studies that demonstrate
mild irritation in laboratory animals ex-
posed to CCP, and the evidence for
respiratory and skin irritation in some of
the experimental laboratory studies in
humans. Some of the epidemiologic
studies may have been biased, particu-
larly by overreporting from study sub-
jects who were already concerned about
the potential effects of CCP exposure
(i.e., recall bias). However, it is unlikely
that recall bias could explain the associa-
tions observed between CCP exposure
and irritative symptoms of the eyes,
skin, and upper respiratory tract in the
indoor air quality studies, since these
studies were not conducted in an atmo-
sphere of concern regarding the health
effects of CCP.
 Exposure to CCP or its components may
rarely cause allergic contact dermatitis.
This conclusion is based on published
case reports of allergic contact sensitiza-
tion and results reported in several in-
dustry-sponsored RIPT studies. Cases of
allergic contact dermatitis were reported
only in RIPT studies from the 1970s that
were submitted to the 1987 NIOSH
docket; no cases were reported in the
studies submitted to the 1997 docket.
This fact may indicate that the CCP
component responsible for the allergic
contact dermatitis observed in the early
studies was removed from the more re-
cent formulations of CCP.
 Systemic reactions have occurred in a
few persons exposed to CCP.
This conclusion is based on the finding
that three such cases have been reported
in the peer-reviewed medical literature.
No cases have been reported in the last
7 years, and thus there is no evidence
that current exposures to CCP present a
risk for this health outcome.
 Data are insufficient to evaluate claims
of other adverse health effects (such as
neurologic effects and reports of MCS)
that have been suggested in some of the
clinical reports submitted to the NIOSH
docket.
In conclusion, although the weight of the evi-
dence indicates that exposure to CCP in the
past has resulted in adverse health effects, it is
uncertain whether current formulations of
CCP represent a significant risk to exposed
workers. Only a few cases of systemic reac-
tions and allergic contact dermatitis have been
reported in the United States or in Europe,
which suggests that the risk of these serious
outcomes is extremely low given the large
number of people who have been exposed to
CCP over a period of many years. Recently
conducted experimental studies in humans
(RIPT studies) suggest that the potential for
skin irritation from exposure to current formu-
lations of CCP is nonexistent, or at most slight.
However, it is unclear how well these experi-
mental studies simulate the exposures and
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potential responses of CCP users—particularly
heavy users. Data from industry reporting
systems suggest no widespread problem and in
fact indicate a decrease in health-related
complaints in recent years despite an increase
in CCP production. However, these passive
reporting systems are unlikely to capture all or
even most cases of CCP-related health ef-
fects, and changes in publicity about CCP may
have caused fluctuations in the reporting of
cases. Since the 1980s, no epidemiologic stud-
ies have been conducted to determine irritative
symptoms among U.S. Workers exposed to
CCP [Mendell et al. 1991]. A positive epi-
demiologic study was conducted in Finland in
1991 [Jaakkola and Jaakkola 1999]. However,
the relevance of these findings for U.S. work-
ers may be limited because of differences be-
tween the CCP products used in Europe and
the United States. Thus information is lacking
about the prevalence of irritation of the eyes,
skin, and upper respiratory tract among work-
ers currently handling CCP in the United
States.
116 Carbonless Copy Paper
5 SUMMARY AND CONCLUSIONS
6 Recommendations
6.1 Historical Recommendations
in the Scientific Literature
The earliest recommendations for eliminat-ing or reducing symptoms associated with
CCP exposures originated in Sweden from the
National Swedish Board of Occupational Safety
and Health [1976]. These recommendations
and those that were echoed or expanded by
various authors [Andanson et al. 1979; Messite
and Fannick 1980; Harris 1983; Messite and
Baker 1984], the Danish Branch Safety Coun-
cil for Offices and Administration [1988], the
Cornell University Chemical Hazard Informa-
tion Program [CHIP 1988], Wattendorf
[1988], and Öko-Test Magazin [1990] are enu-
merated below (not prioritized):
 Ensure adequate environmental condi-
tions (including ventilation, tempera-
ture, and humidity control) in office,
paper storage, and filing areas.
 Avoid ingesting CCP chemicals by min-
imizing hand-to-mouth contact.
 Do not rub eyes when handling CCP.
 If symptoms occur, select a CCP with a
different composition.
 Substitute a mechanical-type paper
(e.g., carbon paper) for a chemical-type
paper (i.e., CCP).
 Limit contact with CCP by spreading
CCP-related work over a longer period
or by reducing the amount used and/or
stored in the workspace.
 Employ proper housecleaning and good
hand-hygiene procedures (including, oc-
casionally, the use of protective gloves
and/or hand creams).
 Inform workers about the symptoms that
have been noted by workers who handle
CCP.
 If you are a CCP manufacturer or im-
porter, give exact data about the sub-
stances used and provide quality
certificates for auxiliary substances, ad-
ditives, and intermediate products used
for each lot of CCP.
The Danish Branch Safety Council for Offices
and Administration [1988] also recommended
use of the following checklist to evaluate com-
plaints received when working with CCP:
 Why do you think that the discomforts
can be traced to CCP work?
 How many persons suffer discomfort in
connection with work using this kind of
paper?
 Who suffers from the discomforts?
 Have there been complaints in connec-
tion with work with CCP?
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 Has the paper quality been recently
changed or has a new delivery of CCP
been made?
 Have any of the following discomforts
developed:
—Irritation of mouth, eyes, nose, or
throat
—Skin problems of the face, hands, or
arms
—Headache, vertigo, or exhaustion
 How long have the person(s) affected
suffered from the symptoms?
 Do the symptoms disappear during
weekends and/or vacations?
 Do the symptoms develop especially in
certain departments or at some special
function?
 How much CCP is handled, separately
or in total?
 Does the consumption of CCP vary dur-
ing the course of a month?
 Is there any connection between the
amounts of CCP and the complaints?
 How long have you worked with the
CCP that you believe to be the cause of
your symptoms?
 Have similar symptoms occurred among
fellow workers who do not work with
CCP?
 Is the indoor climate (temperature, rela-
tive humidity, quality of the air, etc.)
satisfactory?
 What is the extent of cleaning?
 Who produces the CCP?
 Who prints the CCP?
 Have the symptoms following work with
CCP been reported?
6.2 NIOSH Recommendations
NIOSH recognizes that it may occasionally be
necessary to limit CCP exposure in certain
workers through administrative controls
(such as job rotation). But in most cases, im-
plementing normal precautions and recom-
mendations for maintaining acceptable indoor
air quality should be adequate to reduce or
eliminate symptoms. Good industrial hygiene
and work practices are likely to prevent symp-
toms from potent irritants (such as formalde-
hyde) that may be emitted from CCP. These
include adequate ventilation, humidity, and
temperature controls; proper housekeeping;
minimal hand-to-mouth and hand-to-eye con-
tact; and periodic cleansing of hands.
In addition, NIOSH recommends the follow-
ing:
 CCP manufacturers and their suppliers
are encouraged to follow best practices,
such as the Product Stewardship Code
of Management Practices [American
Chemistry Council 2000]; they should
also consider enhancing their product
guidance to reflect that published studies
indicate that irritative symptoms appear
to increase with increasing exposure to
CCP.
 CCP manufacturers and their suppliers
should also consider how human test
procedures (e.g., RIPT) can be modified
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by the use of standardized protocols
that include proper controls (e.g., bond
paper), tests that mimic high-use situa-
tions, and meaningful criteria for scoring
and interpreting these tests to assess
safety from skin contact (e.g., ASTM
D 6355–98) [ASTM 1999]. Current best
practices in the field of product testing
may not be sensitive enough to identify
mild skin irritants.
 As part of ongoing surveillance, CCP
manufacturers and their suppliers may
want to evaluate the frequency and
severity of irritation in workers using
CCP.
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